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Abstract  
 
The discovery of new β-haematin inhibitors has become one focus for researches in response 
to the resistance of P. falciparum malaria parasites that emerged towards well-known 
antimalarials. While hundreds of new β-haematin inhibitors have been discovered using 
detergent mediated high-throughput screening methods, a crucial aspect is understanding 
exactly how these β-haematin inhibitors behave in the malaria parasite and inhibit the 
formation of haemozoin. What is known, is that well-known β-haematin inhibitors like 
chloroquine cause increased amounts of exchangeable haem in the parasite digestive vacuole 
and form a Fe(III)PPIX-inhibitor complex by accumulating at high concentrations which 
consequently inhibits parasite growth. Another important focus is on understanding the 
digestion of haemoglobin and its role in haemozoin formation. This research investigates the 
in vitro modelling of cellular haemozoin and inhibition by various β-haematin inhibitors across 
different scaffolds and the role of haemoglobin degradation in P. falciparum malaria parasites.  
The investigated β-haematin inhibitors resulted in micromolar IC50 (NF54) values and 
decreased parasite growth with increases in concentration. Using a pyridine-based parasite 
haem fractionation plate method, these β-haematin inhibitors were shown to target haemozoin 
formation by causing increased amounts of exchangeable haem that corresponded to 
decreasing amounts of haemozoin in chloroquine-sensitive parasites. The amounts of 
exchangeable haem were shown to be inversely proportional to the percentage of parasite 
growth in the presence of these β-haematin inhibitors. It was apparent that there was a tendency 
for parasite growth inhibition activity to decrease as the amount of exchangeable haem present 
in chloroquine sensitive parasites increased, although, the trend was not statistically significant. 
Moreover, it was observed that experimental cellular accumulation ratio values were low in 
comparison to chloroquine and amodiaquine. Based on the experimental cellular accumulation 
ratio values, it was deduced that the accumulation of these β-haematin inhibitors was not 
primarily due to pH trapping and more complex than previously proposed. Further 
investigations into the exchangeable haem amounts as a function of intracellular test compound 
amounts at the IC50 values of these β-haematin inhibitors highlighted that there was an apparent 
1:1 relationship with the amount of intracellular exchangeable haem, indicative of complex 
formation.  
 Transmission electron microscopy images were obtained for untreated parasites that 
showed intact parasites inside red blood cells with clearly visible haemozoin crystals dispersed 
throughout the parasite digestive vacuole, whilst, treated parasites showed less defined 
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haemozoin crystals as a result of inhibition. Moreover, electron energy-loss spectroscopy 
revealed that untreated parasites exhibited a strong iron signal which was associated with 
haemozoin in the parasite digestive vacuole with a weaker signal attributed to the red blood 
cell cytoplasm. Similarly, a strong iron signal was shown in the digestive vacuole of treated 
parasites which was associated with less defined haemozoin crystals. A halo around these 
haemozoin crystals was observed and was suggested to be indicative of the build-up of 
exchangeable haem. Additionally, a strong bromine signal attributed to a bromine-containing 
β-haematin inhibitor, test compound 1, was also observed in the same region as the haemozoin 
crystals. Overlaid signal distribution maps for iron and bromine showed direct evidence of 
Fe(III)PPIX and test compound 1, suggesting complexation. High-quality Raman spectra were 
obtained for the Fe(III)PPIX species in red blood cells, chloroquine sensitive parasites and 
synthetically prepared samples for the Fe(III)PPIX porphyrin dominated spectral region of 
1700-500 cm-1 at an excitation wavelength of 532 nm. From the spectra, a putative 
Fe(III)PPIX-test compound 1 complex was identified and shown to be similar to the 
synthetically prepared counterpart, haematin-test compound 1 mixture. It was highlighted that 
a unique peak at 1080 cm-1 indicated π- π interactions between the pyrrole-imidazole ring and 
thus confirming that the formation of this putative Fe(III)PPIX-inhibitor complex occurs. The 
confocal Raman true mapping technique proved to be efficient and reliable for imaging the 
signal distribution of haemozoin at the Raman peak of 754 cm-1 and 1080 cm-1 for the 
Fe(III)PPIX-test compound 1 complex which co-localized in the digestive vacuole of 
chloroquine sensitive parasites. Moreover, oxy- and deoxy-haemoglobin was observed to be 
localized to the red blood cell, where, deoxy-haemoglobin was located on the outer parts of the 
parasite. Principle component analysis, based on the Raman peak positions, exhibited 
significant differences in the spectra for Fe(III)PPIX species in red blood cells, chloroquine 
sensitive parasites and synthetic samples where clusters were observed to separate mainly 
along principle component 1. These data proved that the spectra of the Fe(III)PPIX-test 
compound 1 complex was the same as its synthetically prepared counterpart but different from 
the remaining Fe(III)PPIX species. In comparison to the Fe(III)PPIX-test compound 1 
complex, the cluster separations were observed to be significant, where, no significant 
separation was observed for the Fe(III)PPIX-test compound 1 complex and the haematin-test 
compound 1 mixture. Based on this, it was evident that a Fe(III)PPIX-test compound 1 complex 
existed in the digestive vacuole of treated chloroquine sensitive parasites. 
 To fully understand the inhibition of haemozoin, the development of a haem pathway 
model is necessary, but, requires certain prerequisites.  Bioinformatics data from PAXdb and 
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ExPASy revealed that chloroquine resistance (Dd2) parasites, containing 1337 previously 
identified proteins with an average abundance-weighted molecular weight of 40,483 ± 77 
g/mol. With this, the protein mass per cell for red blood cells, chloroquine-sensitive and -
resistant parasites were consistent across three protein quantification methods was measured 
and revealed that chloroquine resistant parasites had a significantly higher protein mass per 
cell than chloroquine sensitive parasites and in turn a higher total number of protein molecules 
per cell. Aspartic proteases are 4-fold higher in concentration than cysteine proteases with 
histo-aspartic protease having the highest concentration in chloroquine resistant parasites. 
Along with these data, a time point quantification for chloroquine sensitive parasites 
throughout the blood-stage showed that the amount of haemoglobin decreased in a sigmoidal 
manner and corresponded to a linear increase in the amount of haemozoin and relatively 
constant exchangeable haem amount. This was consistent with Giemsa smears that showed that 
for early time points, large initial decreases in the amount of haemoglobin were observed 
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1.1 Malaria overview  
 
Malaria is a human infectious disease that has infected hundreds of millions and claimed the 
lives of hundreds of thousands annually over the past decades, where, up to 90% of these deaths 
occur in Sub-Saharan Africa with children and pregnant women being the most vulnerable 1-2. 
Malaria is caused by the Plasmodium protozoan parasite that is transmitted to the human host 
through the bite of an infected female Anopheles mosquito. Currently, there are five reported 
Plasmodium species which are; P. vivax, P. ovale, P. knowlesi, P. malariae and P. falciparum 
1, 3-4. The P. falciparum species, specifically, has been reported to be responsible for threatening 
up to one third of the World’s population as it has been classified as the most frequently fatal 
malaria parasite to humans 5-7. Historically, for the treatment of P. falciparum associated 
malaria the most widely used antimalarial drug that was used is chloroquine (CQ). During this 
time, CQ had proven to be the most cost effective, efficient and reliable antimalarial drug which 
decreased the number of malaria related infections and deaths. However, within a period of ten 
years of its introduction, CQ-resistant P. falciparum parasites first emerged and then the drug 
gradually became less effective over the following three decades 8-9. Scientists even went on 
to develop CQ analogues that would possess the same advantages of being cheap to 
manufacture, reliable and show effectiveness against CQ-resistant P. falciparum 10-12. Since 
then, mortality rates have decreased and the spread of resistance has slowed down but still 
poses as a major threat to public health world-wide. To counteract this problem, the World 
Health Organization (WHO) introduced the use of artemisinin-based combination therapies 
(ACTs) over twenty years ago as the first-line treatment for P. falciparum. These ACTs 
included the use of previously discovered antimalarial drugs such as amodiaquine (AQ), 
mefloquine (MQ), piperaquine (PPQ) and various artemisinin’s (ART), where an example is 
artesunate (AS) 13-14. These ACTs have been very effective, contributing to reducing the 
number of malaria related deaths by 44% with reported cases of 99.7% in the African regions, 
62.8% in South-East Asia, 69% in Eastern Mediterranean and 71.9% in Western Africa. 
However, there have been reports of P. falciparum resistance towards artesunate-MQ, 
dihydroartemisinin-PQ and AS itself 15-21. Even though the effectiveness of certain ACTs have 
been compromised, WHO has reported 219 million cases of malaria and 435 000 deaths for 
the year, 2018, a large improvement over 2000 16. During this time, a non-profit organization 
Medicines for Malaria Venture (MMV) had been established and aims to develop new efficient 
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and cost-effective antimalarial drugs in the hopes to be able to completely eradicate malaria 
from at least 60 countries by 2030 (Figure 1-1) 22-23.  
 
 
Figure 1-1: Categorisation of countries as malaria-free, eliminating malaria, or controlling 
malaria, 2020 projection. Elimination date projections are based on current national and 
regional goals as well as epidemiological progress as documented in WHO’s annual World 
Malaria Report. For those countries that do not currently have clearly defined national or 
regional goals, elimination dates have been projected based on documented country-level 
efforts to reach pre-elimination status, recent epidemiological trends, geographical settings 
such as islands, and the necessary degree of ambition and optimism essential to achieve global 
eradication within a generation. Reprinted from: The Lancet, 387 (10029), Newby, G., Bennett, 
A., Larson, E., Cotter, C., Shretta, R., Phillips, A.A. and Feachem, R.G., The path to 
eradication: a progress report on the malaria-eliminating countries, pp.1775-1784., Copyright 
(2016), with permission from Elsevier 23. 
 
1.2 Life cycle of P. falciparum parasites 
 
The lifecycle of the P. falciparum parasite is divided into three different stages that can be 
defined as the hepatic stage, the intraerythrocytic asexual stage and the sexual mosquito stage 
24-27. The cycle starts with the malaria infected female Anopheles biting the human host and 
upon withdrawing blood through the capillaries of the host’s skin, injects sporozoites that are 
contained in their saliva.  For 2-3 hrs, these sporozoites can remain at the site of injection prior 
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to entering the blood stream via the dermal cell barrier and then traverse to the liver, where 
they proceed to enter hepatic cells 28-31. For a period of 6-7 days, these sporozoites multiply 
into roughly 30 000 merozoites each. By their own mechanism, these merozoites rupture from 
the hepatic cells in small merosomes and are released into the blood stream of the host 32. At 
this stage, they are temporarily exposed to the host’s antibodies before invading red blood cells 
(RBCs) 24. After the RBC invasion by one merozoite, the parasite begins to egress and 
transform into three distinct stages which include the ring, trophozoite and schizont stage which 
lasts for a period of 48 hrs. This is typically called the intraerythrocytic stage 7.  
 After 48 hrs, 16-20 merozoites are produced in one infected RBC through the cell 
division of the parasite. With this, the mature schizont ruptures and releases these merozoites 
as well as RBC debris. These merozoites are then able to then invade fresh non-infected RBCs. 
At this stage, the host begins to show visible symptoms that include fevers, fatigue, diarrhoea 
and nausea to name a few 24. Two examples of severe malaria are placental and cerebral, where 
the latter is the deadliest caused by P. falciparum 33-34.  
 The cycle of merozoites invading RBCs is repeated several times before the sexual 
lifecycle begins. This involves some of these blood stage parasites transforming into male and 
female gametocytes. These gametocytes further develop into gametes which are re-ingested by 
a non-infected female Anopheles when biting and withdrawing blood from the infected host. 
In the newly infected Anopheles, the gametes fuse together and form zygotes that have the 
ability to pass through the gut wall. In the gut, these zygotes mature into invasive ookinetes 
which pass through the midgut and develop into oocysts. Over a period of 10-22 days, these 
oocysts release migratory sporozoites that accumulate in the lobes of the salivary glands which 
are ready to be injected into another human host during its next blood meal (Figure 1-2) 7,33,35. 
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Figure 1-2: Life cycle of P. falciparum parasites in the human host. Reproduced from Duffy, 
P.E., Sahu, T., Akue, A., Milman, N. and Anderson, C., 2012. Pre-erythrocytic malaria 
vaccines: identifying the targets. Expert review of vaccines, 11(10), pp.1261-1280., Copyright 
(2012), with permission from Taylor & Francis Online 36. 
 
Throughout the stages of the life cycle, each stage is associated with different vaccine targets 
that can be targeted with various subunit vaccines. The aim of these vaccines is to induce 
antibody and T-cell responses 37. For instance, during the highly metabolically active hepatic 
stage subunit pre-erythrocyte vaccines, such as Hepatitis B-based ones, are commonly used 
36,38. These vaccines target sporozoites and liver stage parasites which have been seen to be 
important in eliminating the ability of the parasite to egress and develop into the 
intraerythrocytic stage. This is an important drug target for two main reasons. The first, being 
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that at this stage the number of infected hepatic cells range from dozens to hundreds. Second, 
the P. falciparum parasite is known to incubate in hepatic cells for a period of two weeks before 
infecting RBCs which offers ample time and opportunity to eliminate this disease 39-40. For the 
intraerythrocytic stage, subunit vaccines such as those targeting glutamate rich protein and 
merozoite surface protein-3 (MSP-3) as well as P. falciparum erythrocyte membrane protein-
1 (PfEMP-1) have been extensively assessed as potential vaccines for this stage. However, all 
these potential vaccines still require further investigations 37,41-42. More recently, studies into 
effective transmission blocking vaccines using improved gametocyte activity screening assays 
have also been carried out. These have proved to potentially reduce the chance of malaria 
transmission by targeting the sexual stage of the parasite, specifically the sexual gametocytes 
43-47.  
 
With that said, antimalarial drugs remain the only effective means to treat malaria infections. 
The mechanism of action of β-haematin inhibitors and their derivatives against the inhibition 
of haemozoin formation during the intraerythrocytic stage of the P. falciparum parasite is the 
focus of this literature review. 
 
1.3 Intraerythrocytic asexual cycle of P. falciparum parasite 
 
The intraerythrocytic asexual cycle is important for understanding how the parasite causes 
apparent symptomatic signs in the host, such as fevers. This cycle has also become the focal 
point for developing new antimalarial drugs in the efforts to kill the parasite. There are four 
distinct stages which occur; the merozoite stage, the ring stage, the trophozoite stage and the 




The cycle begins with the smallest stage, the merozoite stage, which involves invasive 
merozoites being released into the blood stream of the host which capture and invade RBCs. 
These invasive merozoites have a distinctive shape that has been previously described as 
“lemon-shaped” (Figure 1-3 a). This lemon-shape is attributed by the various membranous 
vesicles for contents secretion, ribosomes, nucleus, a mitochondrion and plastid contained in 
the merozoites 48-51. They are also coated in a thin merozoite surface protein-1 containing 
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filament which facilitates in the capturing of RBCs.  However, this thin filament is cleaved 
during the process of RBC invasion. They attach to RBCs with a random orientation, re-
orientate themselves to be in close proximity to the RBC membrane and start to invade the 
RBC. Whilst invading the RBC, an invasion pit is created whereby the merozoite becomes 
encapsulated in a membrane-lined cavity known as the parasitophorous vacuole (PV) 52-54. 
Upon entering the RBC, the merozoite forms dense knob-like features within its apical 
cytoplasm which increases its size. The main function of these dense knob-like features is to 
allow for contents to be transferred from the merozoite into the PV. This facilitates the 
transformation of the merozoite into flat thin discoidal cup shaped rings, known as the ring 




At this fairly low metabolically active ring stage, also referred to as the early trophozoite stage, 
a thick cytoplasmic rim containing various components forms while the center is quite void. 
This thick rim in the ring contains the nucleus, mitochondrion, plastid, ribosomes and 
endoplasmic renticulum which are necessary for the progressive growth of the parasite. At the 
surface of the parasite, small globules of the RBC cytosol are consumed through the parasites 
cytostome. With these RBC-containing globules, portions of the PV membrane and plasma 
membrane are digested within the parasite vacuoles 57-62. As the parasite develops, these small 
digesting vacuoles fuse together to form one single vacuole, known as the digestive vacuole 
(DV). During this fusing process, the PV membrane increases in size and the parasite 




While this highly metabolically active stage has the same functionality as the ring stage, it is 
distinctively different in terms of its shape and size (Figure 1-3 b). During this stage, the 
parasite continues to feed on the host RBC while changing the physiology of the host RBC. 
This occurs as a result of the parasite exporting an increased amount of proteins into the host 
RBC cytoplasm 51. Coincidentally, large amounts of haemoglobin from the cytosol of the host 
RBC are transported into the DV and are digested in an orderly manner by various proteases 
63. As a result of this haemoglobin digestion, toxic haematin and globin fragments are released, 
the latter being further digested into amino acids that are exported from the parasite. On the 
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other hand, the toxic haematin is converted into inert crystals called haemozoin. Subsequently, 
the size of the parasite enlarges and forms irregular bulges and deep tubular invaginations, seen 
as knobs and Maurer’s clefts at its surface 64-65. At this point there is an increase in the size of 
the endoplasmic reticulum, the number of free ribosomes and the complexity of the Golgi 
complex as a direct response to increased protein synthesis. With this increase in protein 
synthesis, proteins are exported to the surface of the host RBC by proceeding through the Golgi 
complex into cytoplasmic vesicles by means of an energy-dependent process into the PV 58,66-
67. Other proteins form into dense aggregates or in Maurer’s clefts that are able to penetrate 
through the PV membrane and bind to the surface of the RBC membrane 51. The parasite begins 




At the schizont stage, both the process of proteins being exported and haemozoin forming as a 
consequence of depleting RBC haemoglobin are continued (Figure 1-3 c-d). As a result of the 
continued export of proteins, the cytoskeleton and membrane of the host RBC becomes 
distorted and angular in shape, whereas the haemozoin crystals are densely compacted into a 
single mass 51. During this endomitotic process, the parasite nucleus divides and produces 
about 16-20 single nuclei containing chromosomes and mitotic spindles which move to the 
surface of the parasite 48,55,68-69. This is followed by the formation of the daughter merozoite 
centre, which in itself involves a number of stages that starts with the apical organelles 53,69-71. 
From here, a nucleus, mitochondrion and plastid is added from the schizont cytoplasm after 
which the merozoite coat forms. As a result of the secretion process of the apical organelle, the 
host RBC ruptures and releases the daughter merozoites into the host’s blood stream along with 
the haemozoin. The daughter merozoites are then able to invade new host RBCs. 
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Figure 1-3 a-d: Intraerythrocytic asexual cycle of P. falciparum parasite representing (a) 
merozoite and ring stage, (b) trophozoite stage, and (c-d) schizont stage. Reprinted from: 
Dluzewski, A.R., Ling, I.T., Hopkins, J.M., Grainger, M., Margos, G., Mitchell, G.H., Holder, 
A.A. and Bannister, L.H., 2008. Formation of the food vacuole in Plasmodium falciparum: a 
potential role for the 19 kDa fragment of merozoite surface protein 1 (MSP119). PLoS 
One, 3(8) 25. 
 
1.4 Haemoglobin degradation 
 
1.4.1 Haemoglobin digestion 
 
According to literature, haemoglobin being the main protein in RBCs, has a concentration of 5 
mM in the RBC which constitutes 95 % of the total cell protein. Thus haemoglobin, contained 
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in the RBCs cytoplasm, is the most important component needed for the survival of the malaria 
parasite, P. falciparum. During the intraerythrocytic life cycle of the parasite, haemoglobin is 
ingested via the parasite cytostome and transported into the DV by double-membrane vesicles 
72-73. Therefore, once inside the DV, digested haemoglobin provides a large number of amino 
acids which provide a source of nutrition utilized for self-generation of new proteins. At the 
same time the parasite has to maintain osmotic stability within the infected RBC (iRBC). It 
does this by exporting the amino acids from the iRBC 74-75. Research into the degradation 
process of haemoglobin, has become relevant for not only understanding the process of 
haemoglobin degradation within the DV, but also to design protease inhibitors as potential new 
drugs. Known protease inhibitors, such as pepstatin and E-64 inhibit the proteases which are 
responsible for this process, albeit non-selectively 76.  
The digestion process of haemoglobin by the parasite is complex. Haemoglobin 
undergoes a degradative catabolic reaction which occurs due to the presence of a series of 
proteinases within the DV 77. The proteinases, localized specifically to the DV, include; four 
main aspartic proteases, plasmepsin (Plm) I, II, IV and histo-aspartic protease (HAP), 
constituting the protein products of four of the ten main Plm genes 78; cysteine proteases 
(falcipains); a metalloprotease (falcilysin); a dipeptidyl aminopeptidase (PfDPAP1) and neutral 
amino peptidases 77,79-82. According to early studies by Francis et al, Gluzman et al & Goldberg 
et al, within the DV aspartic and cysteine proteases account for 60-80% of haemoglobin 
degradation as well as the degradation of globin fragments, while other enzymes account for 
only 20-40% 76, 83-84.  
From Figure 1-4, it can be seen that this catabolic degrading reaction is initiated by 
Plm I and II, such that these enzymes cleave native haemoglobin along the α-chain at the amino 
acid residues, specifically at αPhe33 and αLeu34 79. This is the cleaving point in native 
haemoglobin which is also referred to as “the α-helical hinge region” 76,79,85-86. But, according 
to Luker et al, the cleavage site at which these Plms cleave native haemoglobin is more specific 
such that Plm I tends to cleave haemoglobin at the αPhe33 whereas Plm II, cleaves at the αLeu34 
site both in the P1 position, which tends to be more hydrophobic in character 85. This cleavage 
not only causes the dissociation of the tetrameric structure of haemoglobin but also allows for 
the exposure of other possible cleavage sites. It has also been found that even though Plm I and 
Plm II are of the same group of proteases, they have different periods at which they appear in 
the intraerythrocytic stage of the malaria parasite 87. Plm I is first synthesized during the ring 
stage of the parasite and is continuous throughout the trophozoite stage. Francis et al has stated 
that this is an indication that the activity of Plm I activity is minimal in the haemoglobin 
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degradation process. On the other hand, Plm II, has been shown to be mainly active in the 
trophozoite stage, where it has been shown to be at its highest concentration 87. After this initial 
catabolic cleaving of haemoglobin, two main products, toxic haem and globin fragments are 
released 79. Concentrating on the resulting globin fragments, they are broken down to large 
globin fragments by a combination of enzymes which include mainly; falcipain II & III as well 
as Plm I, II, IV and HAP 75,88-90. Bjelic et al has mentioned that HAP, due to the 60% similarity 




Figure 1-4: Catabolic reaction process of haemoglobin degradation. RBC = red blood cell; PV 
= parasitophorous vacuole; Fe(II)PPIX = haem; Plm = plasmepsin; HAP = histo-aspartic 
protease; DV = digestive vacuole; Tv = transport vesicles 72,92. 
 
The third phase of haemoglobin degradation involves these large globin fragments, which are 
susceptible to further degradation, being cleaved by the hydrolysis of a metalloprotease 
falcilysin. The metalloprotease falcilysin mainly targets polar and charged smaller side chain 
residues within these large globin fragments therefore releasing small peptide fragments 92. In 
2004, Klemba et al reported that a dipeptidyl aminopeptidase (PfDPAP1) had also been 
identified in the DV of the P. falciparum parasite. PfDPAP1 is part of a set of homologous 
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gene sequences including, cathepsin C lysosomal exopeptidase. As indicated in Figure 1-4, it 
is known to be active in the fourth phase of the haemoglobin degradation process and is capable 
of digesting these smaller peptide fragments into dipeptide residues 93. According to Gavigan 
et al, these dipeptide residues are removed from the DV and digested in the cytoplasm of the 
parasite to amino acids by a group of neutral aminopeptidases 94. These neutral 
aminopeptidases include; M1-family alanyl aminopeptidase (PfM1AAP - transmembrane 
protein) and M17-family leucyl aminopeptidase (PfM1LAP) that are found in the P. falciparum 
genome 95-96.  The mechanism as to how this process occurs is still unknown, however, research 
done by Skinner-Adams et al, Grembecka et al and Gavigan et al, show that there is a direct 
correlation with the inhibition of these neutral aminopeptidases and the complete process of 
haemoglobin degradation for the survival of the parasite 94,97-98.  
 
1.4.2 Kinetics of aspartic and cysteine proteases 
 
In order to further understanding the process of haemoglobin degradation, research into the 
kinetics of each of these proteases has also been carried. These kinetic analyses have included 
looking at both native and recombinant forms of these proteases using various assays and 
equipment in order to obtain the Michealis-Menten (Km) and turnover (kcat) constants.  
The proteome of the P. falciparum parasite DV has been widely studied using techniques 
such as sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and liquid 
chromatography–mass spectrometry (LC-MS) 99. Experiments have also been done with 
recombinant Plm I, which were expressed in E. coli BL21 (DE3) cells at 37 °C and 
characterized using techniques including SDS-PAGE and Q-Sepharose column 
chromatography. Lolupiman et al, collected Km and kcat constants (Table 1-1) and tabulated 
them for different studies with recombinant Plm I 100. Unfortunately, they could not be directly 
compared as the methods by which the constants were obtained, differed in terms of the 
substrates and assay conditions that were used. The kinetics of the recombinant sample 1 
(Table 1-1) were analysed in the presence of a fluorogenic (FRET) peptide as a marker, 
(emitted fluorescence is based on the conformational change of the fluorogenic peptide), in this 
case DABCYL-Glu-Arg-Nle-Phe*Leu-Ser-Phe-Pro-EDANS specifically at pH 4.5. 
Recombinant samples 2-4 (Table 1-1) were analysed using another FRET peptide, DABCYL-
GABA-Glu-Arg-Met-Phe*Leu-Ser-Phe-Pro-GABA-EDANs at pH 5.0. However for samples 
2 and 4 purified, naturally occurring Plm I were used. The later samples (5-8) were analysed 
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in the presence of a chromogenic peptide (Leu-Glu-Arg-IIe-Phe*Nph-Ser-Phe), in which a 
change in the colour of the solution was observed when interacting with proteolytic enzymes 
such as Plm I. It was suggested that the lower Km values that were obtained (Table 1-1, samples 
1-3) could be due to the recombinant samples having a higher degree of interaction between 
the FRET peptides and the hydrophobic portions of Plm I. Lolupiman et al also stated that with 
the charge of the Glu residue being reduced in the FRET peptide at pH 4.5, this could have 
been the cause for lower Km values being obtained 100.  
 
Table 1-1: Comparison of kinetic parameters of recombinant Plm I from various studies 100. 
 
Additional studies by Moon et al, were carried out where the kinetics of recombinant Plm I 
and II were studied in the presence of two chromogenic peptide substrates with a sequence, 
Leu-Glu-Arg-Xaa-Phe*NPhe-Ser-Phe (NPhe = nitrophenylalanine), where Xaa is IIe and Val 
respectively. The kinetic analyses were done under pH conditions of 4.4 at 37 °C and are 
displayed in Table 1-2 104.  
 
Table 1-2: Kinetic analysis of recombinant Plm I and II in the presence of two chromogenic 
peptide substrates 104. 
Substrate Enzyme Km (µM) kcat (s-1) 
Xaa = IIe Plm I 10 1.3 
 Plm II 25 15.2 
Xaa = Val Plm I 30 1.6 
 Plm II 20 8.9 
 
 Km (µM) kcat (s-1) Reference 
1 0.092 ± 0.004 0.344 ± 0.050 100 
2 0.917 ± 0.144 0.473 ± 0.172 101 
3 0.49 ± 0.12 2.3 85 
4 13 ± 1 0.24 85 
5 8 16 102 
6 10 2.1 102 
7 8.6 ± 0.2 2.6 ± 0.1 103 
8 10 1.3 104 
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The values obtained in the study were comparable with those obtained in Dunn et al, where 
hydrolysis was carried out using proteases from various vertebrate and fungal species 105. The 
comparison with other aspartic proteases showed that Plm II gave observations that were in 
close agreement to these, whereas Plm I gave lower values. It was also noted that Plm II results 
in a much higher kcat values than Plm I for both substrates thus proving the efficiency of Plm 
II relative to Plm I 104-106 . According to Banerjee et al as well as studies mentioned above, 
immuno-electron microscopy showed that Plm II, IV and HAP were found in the same regions 
of the DV as haemozoin whereas Plm V, IX and X were located in the external parts of the DV 
80-81. Plm IV has been shown to result in higher affinity values (Km = 0.33 µM) than those 
reported for Plm I and II. HAP, on the other hand, has similarities with that of Plm I, II and IV 
as mentioned above, but when recombinant HAP studies were carried out in E.coli it was found 
that there was no significant haemoglobin cleavage. It was suggested that this could have been 
due to the fact that this protease lacks the ability to activate itself like the other proteases 81. 
But kinetic data has been published for HAP where a Km value 0.29 µM (Table 1-3) was 
obtained which corresponds to a higher affinity value than those of Plm I and II. It was also 
proved that even though a higher affinity was obtain for HAP the kcat proved to be much slower, 
0.05 s-1 (Table 1-3) showing that HAP may not play that much of a role in the cleaving of 
haemoglobin 85. When comparing Plm IV and HAP, Plm IV was observed to be more catalytic 
efficient as mentioned by Banerjee et al 81. Experiments, where Plm IV was incubated 
overnight, were carried out and proved that Plm IV digests globin residues much more in native 
haemoglobin, but is somewhat less efficient than Plm II when digesting globin fragments. 
However, the combination of these two enzymes resulted in much more efficient cleavage of 
haemoglobin 81.  
 
Table 1-3: Km and kcat values for PM I, II, HAP and PM IV 81. 
 Km (µM) kcat (s-1) Reference 
Plm I 0.49 ± 0.12 2.3 85 
Plm II 2.6 ± 0.9 11 85 
HAP 0.29 ± 0.04 0.05 ± 0.002 80 
Plm IV 0.33 ± 0.04 1.05 ± 0.03 80 
 
Studies by Francis et al and Rosenthal et al., have obtained kinetic data (Km and kcat) for both 
native and recombinant falcipain 83,106-107. In this study the native samples were obtained by 
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methods of haemoglobin denaturing assay whilst the recombinant samples were obtained from 
Francis et al and Rosenthal et al 83,106-108. The recombinant samples that were used were the 
forms VLR (Z-Val-Leu-Arg-AMC) and FR (Z-Phe-Arg-AMC) in order to obtain kinetic data 
for comparison (Table 1-4). 
 
Table 1-4: Kinetic analysis of falcipain 83. 
 Km (µM) kcat (s-1) 
Recombinant VLR 3.7 0.25 
FR 2.8 0.018 
Extracted VLR 4.0 0.017 
FR 15.7 0.43 
Native VLR 4.9 ± 1.2  0.011 ± 0.001 
FR 43 ± 16 0.086 ± 0.11 
 
According to Francis et al, the values that were obtained in Table 1-4 were similar to those 
obtained in previous studies which were done in whole trophozoite lysates as well as isolated 
DV 83. However, it was found that the values obtained using the baculoviral expressions system 
were substantially different to the results that were obtained by Salas et al, for the recombinant 
falcipain samples expressed in the ring stage 106,108. This was said to be due to the recombinant 
falcipain producing two major products that proved to have a different method of action to that 
of the native form. It was further proved by Rosenthal et al, that the recombinant form did not 
have the same conformation as the native form 106-107. 
Kinetic studies with dipeptide-digesting neutral aminopeptidases have also been carried 
out. Vander et al determined the Km for three soluble aminopeptidases in P. falciparum 
parasites which included L-Alanine-p-nitroanilide, L-Leucine-p-nitroanalide and L-Leucine-7-
amido-4-methylcoumarin, where L-Alanine-p-nitroanilide resulted in the highest Km 109. A 
more recent study by Teuscher et al determined that the aspartyl aminopeptidase, PfM18AAP, 
is localized to the parasite cytosol and trafficked out of the parasite to the parasite PV. With 
this, they measured the Km and kcat for the hydrolysis effect of the enzymes H-Asp-NHMec 
and H-Glu-NHMec by recombinant PfM18AAP in the absence and presence of cobalt (Co(II)). 
In the presence of 1 mM Co(II), the kcat/Km values were increased by 8- and 30-fold for H-Asp-
NHMec and H-Glu-NHMec respectively 110.  
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Nonetheless, the kinetics of both aspartic and cysteine proteases would be useful in developing 
a haem pathway model which may provide a better understanding of the P. falciparum parasite 




1.5.1 Structure of Haemozoin 
 
Early in the 18th century, haemozoin was first discovered and later led to the discovery of the 
malaria parasites life cycle in humans 111-113. While Brown et al identified that haemozoin 
contained haematin as the chromophore in 1911, very little attention was paid towards 
haemozoin 114, until 76 years later, when Fitch et al published a study which showed that 
haemozoin consists of the insoluble aggregated form of haem ferriprotoporphyrin IX 
(Fe(III)PPIX) 115-116. With this, it was shown that a haemozoin crystal contains roughly 80 000 
haem molecules where each crystal has a length of 100-200 nm 117. A few years later, Slater et 
al proved that while the chemical structure of haemozoin is related to haem, there are no 
proteins included in its structure. It was also reported that the spin state of the central iron (Fe) 
of haemozoin was different to that of the spin states of haematin and haemin which had high 
spin state ferric centers 118. This contradicted the observations of Ghosh and Nath whom 
showed that haemozoin was only comprised of Fe(III)PPIX which had an identical composition 
as haematin 119. Bremard et al agreed with this and showed that the Fe of haemozoin existed in 
the 3+ state which is characteristic of a high spin state, similar to haematin 120. In a related 
study, Slater and colleagues were able to show with the use of infrared and X-ray spectroscopy 
that the haemozoin crystal was characteristic of Fe(III)PPIX molecules that are bonded through 
an iron-carboxylate bond 115,118. In support of this, Pagola et al showed that there are two 
distinct bonds in the crystal structure of haemozoin, an iron-carboxylate bond which was 
thought to extend the Fe(III)PPIX chain and a hydrogen bonded carboxylic acid linkage 
between Fe(III)PPIX units of different chains through a propionate groups which provides 
rigidity to the structure by cross-linking 121-122. In haemozoin, this iron-carboxylate bond was 
estimated to be short with a distance of 1.92 Å. Later it was shown that haemozoin is in fact a 
dimer and is neutral in the form of Fe(III)PPIX which involves the ionization of one propionic 
acid group of each haematin molecule coordinated to the Fe centre of the other with hydrogen 
bonds between propionic acid groups of neighbouring dimers and strong π-π interactions in the 
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crystal 121. As illustrated in Figure 1-5, haemozoin crystals localize in the parasite DV and 
have a lath-like shape 123-126. 
 
 
Figure 1-5: Micrographs obtained by transmission electron and scanning electron microcopy 
of (a) P. falciparum iRBCs showing haemozoin crystals inside the DV (white arrow), and, (b) 
isolated haemozoin crystals. Reprinted from: Molecular and biochemical parasitology, 157 
(2), Egan, T.J., Haemozoin formation, pp.127-136., Copyright (2007), with permission from 
Elsevier 123. 
 
The structure of haemozoin is identical to its synthetic ferriprotoporphyrin counterpart, β-
haematin. This was originally recognized from observations that insoluble haemozoin formed 
in the parasite DV at a pH of 5 and under physiological conditions, both which are the favorable 
conditions for β-haematin formation 116,127-128. Bohle et al showed that β-haematin has a high 
spin ferric center similar to that of haemozoin 122. This was supported by earlier findings 
published by Koenig et al in 1965 129. The structure of β-haematin and haemozoin was at first 
proposed to be a polymer of Fe(III)PPIX units linked by coordination of the propionate group 
of one Fe(III)PPIX molecule to the Fe(III) center of the next as mentioned earlier 118. Slater et 
al was able to prove using X-ray adsorption spectroscopy that the composition and the ordered 
microcrystalline structure of haemozoin reported in the study by Fitch et al, in fact identical to 
β-haematin 115,118. At first, haemozoin/β-haematin was routinely referred to as a polymer until 
2000, when Pagola et al proved otherwise. Indeed, this incorrect description is still occasionally 
encountered in the literature. Having first established that the powder X-ray diffraction pattern 
of β-haematin was identical to that of whole dried iRBCs, the crystal structure of β-haematin 
was determined from the powder diffraction data obtained with synchrotron radiation using 
Rietveldt refinement. Haemozoin and β-haematin were determined to be made up of cyclic 
dimers of Fe(III)PPIX with the propionate of one Fe(III)PPIX coordinated to the Fe(III) center 
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of the other. Dimers are linked to each other by hydrogen bonding of propionic acid groups 
121,130. From the comparison of the single-phase microcrystalline powder of β-haematin and 
whole dried iRBCs, it was also shown that β-haematin and haemozoin have the same triclinic 
unit cell and are isostructural at an atomic level (Figure 1-6) 130-131.  
 
Figure 1-6: The dimer crystal structure of haemozoin/β-haematin formed through the Fe1-O41 
bond which are viewed along the fastest growing face (001). All hydrogen bonds have been 
omitted. Reprinted by permission from Macmillan Publishers Ltd: [Nature Publishing Group], 
Pagola, S., Stephens, P.W., Bohle, D.S., Kosar, A.D. and Madsen, S.K., 2000. The structure of 
malaria pigment β-haematin. Nature, 404(6775), p.307., Copyright (2000) 121.  
 
1.5.2 Intracellular Haemozoin formation 
 
Looking at the overall process, the parasite ingests up to 80 % of the host RBC haemoglobin 
in the DV. During this haemoglobin digestion, Fe(II)PPIX is released along with globin 
fragments. It has been presumed that in the presence of oxygen (O2), Fe(II)PPIX is oxidized 
into Fe(III)PPIX which is known to be toxic to the parasite. Indeed, superoxide has also been 
assumed to be produced as a result of the rapid oxidation process of oxy-haemoglobin at acidic 
pH values 123. The parasite is then able to convert this toxic Fe(III)PPIX to haemozoin ensuring 
that it does not damage the membrane of the parasite or cause lysis of the RBC host. The 
conversion of this toxic Fe(III)PPIX is in fact a rapid process that less than about 1 % of the 
total haem present in the parasite would be in the form of toxic Fe(III)PPIX 132. The parasite 
detoxifies this toxic haematin by producing the insoluble inert microcrystalline dimer 
haemozoin by a process of haem detoxification (Figure 1-7) 115,121,133-134. In line with this 
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theory, even though there has been extensive research into determining the exact pathway of 

















Figure 1-7: Haemozoin formation pathway 123. RBC = red blood cell; Tv = transport vesicle; 
N = nucleus; NLB = neutral lipid body; DV = digestive vacuole; PV = parasitophorous vacuole.  
 
There have been many theories that try to explain the mechanism by which haemozoin forms 
during the trophozoite stage. These theories include: the combination of Fe(III)PPIX molecules 
by a process of “haem polymerization” catalyzed by a haem polymerase 135; catalysis by 
histidine-rich protein II (HRP II) which is specific to the P. falciparum parasite and highly 
concentrated in the DV during the blood stage of the parasite 136-138; mediation by neutral lipid 
bodies 139 and more recently; by haem detoxification protein (HDP) 140-142. Initially, it was 
proposed by Slater et al that haemozoin was a polymer 118. This led to the second proposal by 
Slater and Cerami et al that haemozoin was formed due to the presence of a haemozoin forming 
enzyme. They termed this haemozoin forming enzyme, “haem polymerase” 135. Following this, 
Egan et al and Dorn et al disagreed with this theory of haemozoin formation and it was rather 
suggested by Dorn et al to be an autocatalytic process 143-145. In the same year, it was suggested 
that the haemozoin/β-haematin used in the process was contaminated with lipids and that this 
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A second theory for the mechanism by which haemozoin is formed involved the protein 
HRP II. HRP II is a 30 kDa protein which has previously been found to have 51 repeats of the 
tripeptide His-His-Ala 147-148. It was demonstrated with protein immunoblot analysis and 
indirect immunofluorescence with a monoclonal antibody that showed HRP II was localized 
in the DV of the parasite. In addition, it was shown that HRP II is able to bind to haem and 
promote β-haematin formation in a haem-binding titration experiment. However, it was 
uncertain whether the function of HRP involved a binding-releasing process or a nucleation 
role 136. In relation to the location of HRP II, Papalexis et al showed in more detail that the 
primary location of HRP II was in the RBC cytoplasm with a sub-population of this protein 
existing in the parasite DV 149. This findings agreed with that of Akompong et al, who reported 
that the parasite transports 97% of HRP II to the RBC, leaving only 3% that could facilitate 
haemozoin formation 150. In fact, parasite mutants lacking HRP II were shown to produce 
haemozoin normally. Later, this HRP II mediated haemozoin formation theory was proven not 
to be the sole cause but was facilitated by the presence of lipids in the parasite DV by Pandey 
et al 151. This agreed with later studies by Fitch et al 152.  
 Studies have also shown that the involvement of neutral lipid bodies in the DV of P. 
falciparum parasites could mediate the formation of haemozoin 153. It was first shown by 
Coppens and Vielemeyer that haemozoin was enclosed within neutral lipid bodies by using 
electron microscopy 154. These neutral lipids included mono-, di- and tri-acylglycerols, where 
tri-acylglycerol has been determined to accumulate in iRBCs but is difficult to detect 155-156.  In 
support of this, Pisciotta et al showed that in the parasite DV during the early trophozoite stage 
that the haemozoin crystals were entrapped within neutral lipid bodies using transmission 
electron microscopy (TEM). Furthermore, these lipid bodies were identified to have a specific 
composition that was made up of mono- and di-glycerols, monostearic, monopalmitic, 
dipalmitic, dioleic and dilinoleic glycerol in a 4:2:1:1:1 ratio 139. In a similar study with electron 
microscopy, it was also shown that these haemozoin crystals form within neutral lipid bodies 
in the parasites DV which facilitate the formation of haemozoin 154,157. It has been reported that 
lipids are sourced through the degradation of the inner membrane of haemoglobin transport 
vesicles by phospholipases once inside the parasite DV 61. Ambele and Egan supported the 
lipid mediated hypothesis by demonstrating that the neutral lipids associated with haemozoin 
formation mediate the formation of β-haematin under the same physiological conditions as 
those in the parasite 153. Hoang et al was also able to provide evidence of the partitioning of 
Fe(III)PPIX into neutral lipid bodies using a Nile red fluorescent probe, which is lipid specific 
158. With the use of the same fluorescent probe and TEM, Jackson et al showed that these 
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neutral lipid bodies were roughly 100 nm in size which was in the size range of the parasite 
DV 159. In a related study, it was shown that these neutral lipid bodies are surrounded by a 
monolayer comprised of a phospholipid, glycolipid or sterol 154. In support of this theory, 
Stiebler et al investigated the contribution of phospholipids in both chemical and biological 
haem crystallization. They demonstrated that unsaturated glycerophospholipids are true 
catalysts of fast and efficient synthetic haemozoin formation 160. In addition, Kapishnikov et al  
demonstrated the properties of these neutral lipid bodies that are required for the formation of 
haemozoin in the DV. They also provided evidence of the molecular interactions of these 
lipophilic bodies with haem that promote the nucleation and formation of synthetic haemozoin 
161. These studies were also in agreement with the findings of Stiebler et al and Oliveira et al, 
who also strongly indicated that neutral lipids and phospholipids are major catalysts of 
haemozoin formation but involved hydrophilic-hydrophobic interfaces 160,162. In 2012, 
Kapishnikov et al  used cryogenic soft x-ray tomography and three-dimensional electron 
microscopy to explore the nucleation process of haemozoin. They found no evidence that the 
nucleation of haemozoin occurred within neutral lipid bodies but rather that a thin layer of 
these lipid containing bodies may remain between adjacent crystal interfaces 161. However, it 
was then proposed that haemozoin crystals form on an acylglycerol lipid film rather than a lipid 
body which is absorbed onto the inner phospholipid membrane of the DV. In a relating study, 
they reported that the haemozoin crystals were orientated parallel along their needle c axes x-
ray diffraction patterns. This essentially allows for the {100} faces of haemozoin to be exposed 
to curved surfaces like the acylglycerol lipid surface 163. 
 More recently, haemozoin formation has been shown to be assisted by the presence of a 
HDP in P. falciparum parasites. Jani et al showed that HDP is found in the RBC cytosol from 
where it is co-transported with haemoglobin into the parasite DV. With its unique trafficking 
route and 2.7 Fe(III)PPIX binding sites, HDP was found more potent at converting haemozoin 
with concentrations of 1500-2000-fold lower than neutral lipids. From here, it was suggested 
that HDP is involved in the formation of haemozoin dimers and transports them into neutral 
lipid bodies which leads to the formation of haemozoin crystals 140. The observations by Chugh 
et al agreed with these findings and showed a multiprotein haemoglobin 
degradation/haemozoin formation complex in the DV of P. falciparum parasites. It was also 
shown that a cysteine protease, falcipain-2, was associated with HDP 141. This haemoglobin 
degradation and haemozoin formation was supported by the findings of Kapishnikov et al, who 
used correlative X-ray fluorescence microscopy and soft X-ray tomography to highlight that 
haemoglobin digestion and haem crystallization via the HDP are closely associated 142. 
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For decades, various antimalarial drugs have been discovered or synthesized for the treatment 
of malaria. One of the first naturally occurring antimalarial drugs that was discovered came 
from the bark of the Cinchona tree in South America, namely quinine (QN) 26,164-166. In the 
1800’s, QN was used to heal the intermittent fevers that were associated with malaria and this 
drug was highly effective during World War I. Following this, QN was considered to be the 
main treatment for P. falciparum malaria for many years 167. By the 1930’s, a group of German 
scientists at Bayer Chemicals discovered a 4-aminoquinoline antimalarial compound that was 
chemically somewhat similar to QN and was initially named Resochin. Later, this compound 
was renamed, CQ, which was used as a substitute for QN 168-171. It was eventually found that 
CQ exerted its antimalarial effect during the blood stage of the P. falciparum parasite by 
disrupting haemozoin formation, which at that time, was termed “haem polymerization” 135. In 
the 1950’s, CQ was announced as the first-line of treatment for P. falciparum by the newly 
established WHO, which not only saved millions around the world but cured many people 
suffering from this disease. However, with the frequent use of this antimalarial drug (in some 
countries CQ was even added to the salt supplies) the P. falciparum parasite developed a 
resistance to CQ which was first reported in the year of 1957 167. This resistance is now known 
to be associated with mutations in DV transport proteins lowering the concentration of CQ at 
its target site 172. Over time, CQ resistance became widespread which lead to the introduction 
of CQ analogues, like AQ. Being one of the first CQ analogues to be synthesized, AQ was 
assumed to behave similarly in terms of the mode of action of CQ 167. However, by 1980 some 
P. falciparum parasites were reported to be resistant towards AQ and led to the development 
of AQ analogues, isoquine (ISQ) and ferroquine (FQ). These AQ analogues showed an 
increased activity and proved to be effective against CQ-resistant parasites (CQR) 173-176. 
During the 1970’s and 1990’s, numerous other antimalarial drugs were developed and 
include; PPQ, MQ, halofantrine (HF), lumefantrine (LF) and primaquine (PQ), to name a few. 
PPQ, a bisquinoline antimalarial drug was first introduced in the 1960’s and synthesized with 
the intention to replace CQ. In China, this particular compound was used as the primary 
treatment for P. falciparum during 1970’s to 1980’s, but with its frequent use became 
ineffective due to resistance 177-181. Around the mid 1980’s, the US Military synthesized MQ 
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as a substitute antimalarial drug for QN in an effort to treat patients with CQR malaria. It was 
thought that MQ acted against the schizont stage of the P. falciparum parasite but its 
mechanism of action was still debatable. Although its mechanism of action was not apparent, 
an advantage to MQ was that it remained in the patient’s body for long periods of time. 
Ultimately, though, this was seen to be a disadvantage since the long half-life was thought to 
be the reason why parasites became resistant to it relatively quickly 167. Another antimalarial 
drug that was observed to be active against the intraerythrocytic stage of the P. falciparum 
parasite was, HF. HF is a phenanthrene-methanol compound that was developed for the 
purpose of aiding countries facing multi-drug resistant P. falciparum parasites. In spite of the 
fact that HF was highly effective it was observed to cause irregularities in patient heart beats, 
specifically for those who were suffering from heart diseases already 167,182. With a similar 
name, LF was developed by the Chinese Academy of Military Medical Sciences in the 1970’s. 
This compound was cleared for use as an antimalarial drug and proved to be quite effective 
against both CQ-sensitive (CQS) and –resistant P. falciparum parasites in vivo 183. 
Nevertheless, a drawback to using LF was that despite its half-life of 3-6 days, it was found 
not as fast acting when used on its own. Lastly, an 8-aminoquinoline, PQ, was also developed 
and used to eradicate P. vivax malaria in parts of the Southwest Pacific. It was most effective 
in Indonesia, Colombia and Papua New Guinea but presented adverse effects that included 
stomach pains and diarrhea (Figure 1-8) 167.   
 
 
Figure 1-8: Structures of past antimalarial drugs used to treat P. falciparum. 
 
Halofantrine (HF) Lumerfantrine (LF)
Chloroquine(CQ)
Primaquine (PQ)Piperaquine (PPQ)
Amodiaquine (AQ) Mefloquine (MQ)
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1.6.2 Present 
 
For the last few years, WHO has recommended the use of combinations of past antimalarial 
drugs with ART derivatives for the treatment of uncomplicated P. falciparum malaria 16. These 
Acts first came about after the discovery of ART in 1971 by Tu Youyou, who was recently 
awarded the Nobel Prize in 2015 184. This particular compound was found to be effective 
against multi-drug resistant P. falciparum parasites. Semi-synthetic derivatives of this 








Figure 1-9: The structure of some ART derivatives. 
 
There are limiting factors that are associated to the use of these derivatives, however, in that 
they rapidly breakdown and have high clearance rates from the hosts plasma 167,185. Therefore, 
ACTs entail using a previously discovered antimalarial drug, like AQ or MQ, with ART. 
However, these antimalarial drugs must have a different mode of action, suitable 
pharmacokinetic and pharmacodynamic properties, be effective against resistant parasites and 
have no undesirable or toxic effects 185. This results in the possible inhibition of two stages of 
the parasite simultaneously, therefore reducing the possibility of resistance emerging from the 
parasite. It has been theorized that ART exhibits its antimalarial effect by being activated by 
haem generated from haemoglobin digestion which results in free radicals that damage parasite 
proteins which are essential for its survival 186-188. Others have also reported that ARTs block 
the ring stage as well as the gametocyte stage 189. Additionally, various observations have been 
reported between 2013 and 2015 to try and understand the mode of action of ART, where it 
was shown that ART is first activated the iron centre in Fe(III)PPIX and then, subsequently, 
inhibits the function of the calcium pump PfATP6, leading to parasite death 190-192. Recently, 
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specifically in the regions of Southeast Asia, where the dihydroartemisinin-piperaquine 
(DHA/PPQ) combination has been used. This has been greatly concerning due to the fact that 
ACTs play a pivotal role in the treatment of P. falciparum malaria 193-194.  
 
1.7 P. falciparum chloroquine resistant transporter 
 
For many years, CQ was the most effective and reliable antimalarial drug used for the treatment 
of P. falciparum infections. CQ, a diprotic weak base compound 195, in its neutral form is 
known to be highly membrane permeable which makes it easier for CQ to cross parasite 
membranes. Moreover, CQ becomes protonated in the low pH environment of the DV, 
becoming membrane impermeable and accumulating at high concentrations 196-197. CQ is thus 
able to exert its antimalarial effect and inhibit the formation of haemozoin and cause 
subsequent death of P. falciparum parasites 198. CQ was used for almost two decades before 
CQ resistant P. falciparum emerged initially in South-east Asia and South America in the 
1950’s and 1960’s. After this, CQ resistant P. falciparum began to spread throughout the globe. 
By the 1970’s, CQ resistance was detected to have spread to Sub-Saharan Africa 199. To counter 
the effects of this resistance, antimalarial drugs such as sulfadoxine with pyrimethamine and 
MQ were introduced, however, as a result of the increased surge of P. falciparum resistance 
they have since become ineffective 200. Over the years, this not only caused the morbidity and 
mortality rates to increase but also brought about concerns of how to circumvent the resurgence 
of this life-threatening disease for the sake of the public health world-wide 201 (Figure 1-10). 
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Figure 1-10: World map showing the spread of CQ, sulfadoxine-pyrimethamine and MQ 
resistant P. falciparum parasites. Reproduced from: Okie, S., 2008. A new attack on 
malaria. New England Journal of Medicine, 358(23), pp.2425-2428 202. 
 
A striking observation with CQ resistant P. falciparum parasites was the decreased amount of 
accumulated CQ as a result of the reduced net uptake of CQ, compared to CQS parasites 203-
204. There have been several theories that have been reported in the efforts to understand the 
mechanism by which CQR parasites cause a reduction in the amount of accumulated CQ. Some 
of these theories include the efflux of CQ out of the parasites DV and increased detoxification 
of the CQ-haematin complexes which decreases the amount of CQ uptake and in turn decreases 
complex formation 205-208. In 2000, it was initially observed by Fidock and colleagues that CQ 
resistance was primarily caused by the mutation of a specific protein, called the Plasmodium 
falciparum Chloroquine Resistance Transporter (PfCRT). This specific transporter protein was 
identified to have ten α-helical predicted transmembrane domains (TMD) and localized in the 
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Figure 1-11: Arrangement of known polymorphic residues in PfCRT. PfCRT is predicted to 
contain 10 α-helical transmembrane domains (TMDs) and to be orientated in the DV membrane 
with the N- and C-termini extending into the parasite cytosol. The positions of the polymorphic 
residues are indicated with black circles. The key CQ resistance-associated mutation (K76T) 
is represented as a red square. The box attached to each polymorphic residue lists the (non-
wild-type) amino acid(s) known to occur at that position. The predicted roles of the TMDs are 
as follows: 4 and 9 (outlined in dark green) are implicated in the binding and translocation of 
substrates, TMDs 3 and 8 (boxed in light green) are thought to assist in the binding and 
translocation of the substrate and may also influence the substrate-specificity of the transporter, 
TMDs 1, 2, 6, and 7 (boxed in black) are involved in recognising and discriminating between 
substrates, and TMDs 5 and 10 (outlined in mid-green) play a role in the formation of homo-
dimers. Reproduced from: Cellular and Molecular Life Sciences, Know your enemy: 
understanding the role of PfCRT in drug resistance could lead to new antimalarial tactics, 69, 
2012, 1967 – 1995, Summers, Robert L., Megan N. Nash, and Rowena E. Martin, (Springer 
Basel AG 2012)., with permission of Springer 210-211. 
 
The mechanism by which PfCRT is able to reduce CQ accumulation and thus render it 
ineffective in killing the parasite has been extensively studied over the years. First, PfCRT was 
thought to reduce the ability of CQ to traverse parasite membranes and accumulate in the DV 
of parasites by altering the pH of the DV 199. With this, it was proposed by Yayon et al and 
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Ginsburg et al that the steady state reduction in CQ accumulation in CQR parasites could be 
as a result of CQR parasites maintaining a more acidic DV which was related to a much lower 
pH in comparison to CQS parasites 196,212. This was ostensibly confirmed by observations 
reported by Bennett et al, who reported that CQR parasites have a more acidic DV with a pH 
of 5.2 compared to CQS parasites with a DV pH of 5.7 213. In other attempts to confirm this 
theory, Dzekunov et al and Ursos et al. used a fluorescent dye acridine orange to monitor the 
changes in the intensity of fluorescence between CQR and CQS strains. They observed a much 
more intense fluorescence signal in CQR strains compared to CQS which they deduced to be 
as a result of a more acidic DV 214-215. However, these studies were later found to be incorrect 
by the independent studies carried out by Bray et al and Wissing et al, who proved that the use 
of acridine orange to monitor DV pH was unreliable and pH was found to be hardly changed 
199,216.  
An alternative theory is that PfCRT transports CQ out of the parasites DV in CQR strains 
in an efflux process which occurs in an energy independent manner 204,217. In related studies, it 
has been shown that this involves a polymorphic change in the transmembrane domain of 
PfCRT at position 76. At this position, the positively charged lysine residue is substituted for 
a threonine residue, K76T that is uncharged. This occurs in conjunction with a series of other 
mutations that evidently are required to preserve function. While the normal physiological 
function of PfCRT is unknown, but it has been suggested that it is used by the parasite to 
effectively transport peptides and amino acids out of the DV 218-219. It has been directly shown 
that the mutated PfCRT is able to transport CQ in its doubly protonated form down its 
electrochemical gradient in injected Xenopus laevis oocytes.  
Chemosensitizing agents have been investigated in an effort to reverse P. falciparum 
resistance. These include the calcium channel blocker verapamil and antidepressants and 
antihistamines such as imipramine, azatadine and chlorpromazine. These chemosensitizers are 
believed to interact with hydrophobic and negatively charged pockets within the protein 
sequence, inhibiting CQ transport 220. In this regard, Juge et al showed that verapamil could 
inhibit CQ transport in a PfCRT-liposome assembly 221. It has been suggested that these 
chemosensitizers have the ability to bind to PfCRT close to residues 72-76 which as previously  
stated is believed to be primarily responsible for CQ resistance 199. From this, it has been 
hypothesized that these chemosensitizers bind and compete with CQ. Indeed, Johnson et al 
have reported increased CQ accumulation in CQR strains upon treatment with amantadine 222. 
Combination studies have also been reported showing that the use of CQ combined with 
verapamil or chlorpromazine inhibits parasite growth. Specifically, it was observed that the 
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concentrations of CQ that are used to treat CQS parasites had a similar effective against CQR 
parasites 204,223-224. However, a drawback to using these chemosensitizers to substantially 
reverse CQ-resistance is that they all require high doses which are not clinically acceptable 225-
226.  
 
1.8 High-throughput screening for the identification of novel antimalarial 
drugs 
Over the last two decades, high-throughput screening (HTS) tools have been the forefront for 
identifying new and effective antimalarial drugs. These well-established HTS tools are 
frequently used as an approach for drug discovery in pharmaceutical and biotechnology 
industries world-wide including companies such as Novartis and GlaxoSmithKline (GSK) 227-
229. The HTS approached makes use of robotic automated systems to rapidly identify large 
numbers of potentially active compounds against a specific biomolecular pathway or whole 
cells, with success rates of up to 55% 230-231. This process uses miniaturized in vitro assays 
which require low volumes of samples being tested 232-233. Hit compound classes, also referred 
to as scaffolds, are identified from this process and are used as starting points for the 
development of new compounds. 
 In an early application of this approach, Kurosawa et al used a haematin 
“polymerization” assay which involved the use of radio-labeled haematin that incorporated 
into β-haematin under the pH conditions mimicking that of the parasite DV. They were able to 
screen more than 100 000 compounds from the Roche compound library, SPECS, NCC, 
microbial broths and chemical combinatorial chemistry libraries. Eight novel compound 
scaffolds were identified as active against haemozoin formation with 50% inhibitory 
concentrations (IC50) of less than 50 µM. The scaffolds that were identified included 
triarylcarbinols, piperazines, benzophenones, imides, hydrazides, indoles and isoxazoles, from 
which they found that the triarylcarbinol Ro 06-9075 and piperazine Ro 10-3428 showed 
consistent antimalarial activity after being administered orally in mouse models 234.  
 In 2009, Rush et al adapted a previously developed colorimetric pyridine 
ferrihemochrome (Phiβ) assay to a high-throughput screening method to screen 16 000 
compounds for possible β-haematin inhibitory activity. The assay utilized a robotic liquid 
handling system which was carried out in 384-well microtiter plates. From this, 600 hit 
compounds were identified, with 17 found to be active against both CQS and CQR strains, 3D7 
and Dd2 respectively 235. 
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Around the same time, Huy et al developed a fast, simple and reproducible HTS assay based 
on haem adsorption in β-haematin formation with the use of Tween 20 as a β-haematin inducer. 
A group of 9600 selected compounds were chosen from the chemical library of The Drug 
Discovery Initiative, Tokyo University (http://www.ddi.u-tokyo.ac.jp/en/#5) which contains 
more than 200 000 compounds. First, 394 compounds were identified from the HTS assay and 
showed activity, however, these were further refined using a dose-response assay to exclude 
false positives. From the dose-response assay, 224 HIT compounds were correctly identified 
having IC50 values not exceeding 5 µM 236.  
 Between 2008 and 2010, Novartis, GSK and a research group that was based at the St. 
Jude Children’s Research Hospital, performed HTS for potential antimalarials using a 
phenotypic screening approach. Novartis screened a total of 1.7 million compounds from which 
5973 compounds were identified as hit compounds 227, while the St. Jude Children’s Research 
Hospital group screened only 309 474 compounds. From the St. Jude Children’s Research 
Hospital group screening, only 561 hit compounds were identified 237. GSK screened the 
largest number of compounds (2 million) from their existing libraries against P. falciparum,  
identifying 13 533 hits that inhibited parasite growth at concentrations of up to 2 µM and were 
subsequently grouped and named the Tres Cantos Antimalarial set (TCAMS) 228. 
 More recently, Sandlin et al adapted a β-haematin formation assay to a 384-well HTS 
plate method, employing the lipophilic detergent, Nonidet P-40 (NP40) was used a surrogate 
lipid for in vitro β-haematin formation under physiological conditions. They were able to 
screen 38 400 small molecules at a concentration that was similar to the IC50 of AQ (19.3 µM). 
From this, they identified 161 compounds that were active against β-haematin formation with 
a reported 0.42% hit rate. After this prescreening process, they used a malaria SYBR green-I 
fluorescence (MSF) assay to determine the parasite growth inhibition activity of these hit 
compounds against a CQS (D6) and multi-drug resistant (C235) strain. Following this, they 
were able to identify 48 (D6) and 40 (C235) compounds that had parasite growth inhibition 
activity of more than 90%. Of these compounds, 25 resulted in IC50 values lower than 5 µM, 
and only 8 showed nanomolar parasite growth inhibition activity in the D6 strain 238-240.  
In a follow-on study, they used the same NP40 β-haematin formation was used to perform a 
target-specific screen on 144 330 compounds that were chosen from the Vanderbilt University 
Institute of Chemical Biology (VICB) library. The target-specific screen resulted in 729 
identified preliminary hit compounds which showed more than 80% inhibitory activity against 
β-haematin formation. Using a “cherry-picking” approach and a threshold of 27 µM, they were 
able to test for false positives from which they identified 530 of these compounds to be hits. 
Chapter 1: Literature review and Introduction 
Roxanne Openshaw-January 2020 31 
To further refine these hit compounds, they used a MSF assay to screen for parasite growth 
inhibition activity against D6 strain parasites. This resulted in the identification of 171 hit 
compounds that exhibited activity that resulted in more than 90% parasite growth inhibition, 
73 and 25 which showed micromolar and nanomolar activity, respectively. The latter 25 
nanomolar hits were subjected to further testing against the multi-drug resistant C235 strain 
and found 21 to be active against this strain 240-241. The mode of action of the hit compounds 
was confirmed in vivo using a haem fractionation assay developed by Combrinck et al which 
measures the amount of haemozoin and exchangeable haem as a function of increased dosage 
of a compound. All hits were shown to cause decreasing amounts of haemozoin with increasing 
amounts of exchangeable haem, indicating that they targeted haemozoin formation 241-242. 
 
1.9 Mechanism of action of antimalarials 
 
1.9.1 Haemozoin Inhibition 
Haemozoin formation is unique to the P. falciparum parasite and remains one of the most 
attractive targets for antimalarials even with P. falciparum resistance to known antimalarials 
emerging. The reason for this is that the Fe(III)PPIX concentration in parasites can reach up to 
200-500 mM if not detoxified into haemozoin. This is far above levels toxic to the parasite and, 
being a pathway unique to the parasite, makes it a viable target 26. The formation of haemozoin 
has also been shown to be unaffected by PfCRT and other membrane proteins which makes 
haemozoin inhibitors the key to possibly eradicating malaria 210. Researchers have made a 
considerable effort to understand the mechanism by which β-haematin inhibitors that have been 
discovered by HTS tools inhibit haemozoin formation within the parasite and subsequently 
cause parasite death. In 1970, CQ was known to target Fe(III)PPIX and showed only to be 
active during the intraerythrocytic stage of the parasite 243. Several other theories for the 
mechanism of action of CQ have also included inhibition of haemoglobin proteases and 
inhibition of glutathione dependent degradation of haem in the parasite cytosol 76,135,244-246. It 
has also been shown that CQ has the ability to bind to deoxyribonucleic acid (DNA) therefore 
inhibiting DNA replication and ribonucleic acid (RNA) synthesis in the parasite. This, 
however, only occurs at concentrations far higher than the IC50 against the parasite 247-249. In 
support of the haemozoin inhibition hypothesis, CQ has been shown to inhibit the formation 
of β-haematin in vitro. This has led to the many studies in which researchers have attempted to 
verify newly discovered β-haematin inhibitors as potential haemozoin inhibitors 135,143,145,250-
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255. While various investigations have been reported on the ability of quinoline-containing 
compounds to inhibit β-haeamtin formation, how they are able to achieve this in P. falciparum 
parasites and its relation to haemozoin inhibition is still inconclusive 256-259.  
Initially, Dorn et al investigated the β-haematin inhibition activity (termed haematin 
polymerization activity at the time) of a group of quinoline-containing compounds using a 
haem “polymerization” assay that incorporates the use of carbon-14 radio-labeled haemin. 
Their findings revealed that β-haematin inhibition activity (βHIA) was correlated to parasite 
growth inhibitory activity in CQS NF54 strain parasites. Included in this correlation was a 
compound that they synthesized, namely the bisquinoline Ro 48-6910, which showed the best 
βHIA and lowest IC50 value 144-145 (Figure 1-12). 
 
 
Figure 1-12: βHIA versus parasite growth inhibition activity in NF54 CQS strain P. falciparum 
parasites for various quinolone-containing compounds. Reprinted from Biochemical 
pharmacology, 55 (6), Dorn, A., Vippagunta, S.R., Matile, H., Jaquet, C., Vennerstrom, J.L. 
and Ridley, R.G., An assessment of drug-haematin binding as a mechanism for inhibition of 
haematin polymerisation by quinoline antimalarials., pp.727-736., Copyright (1998), with 
permission from Elsevier 144. 
 
In a related study, βHIA values were normalized with the association constants of these 
compounds and haem. From this, Vippagunta et al illustrated a better correlation between the 
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βHIA values and parasite growth inhibition activities in comparison to Dorn et al 144,260. It was 
also highlighted from this correlation that the parasite growth inhibition activity of CQ and its 
analogues was influenced by the binding strengths of these compounds to haem. On the other 
extreme, Kashula et al investigated the structure activity relationships (SARs) of CQ 
analogues, where it was observed that the chloro-group at the 7-position was important for β-
haematin inhibition and therefore haemozoin inhibition. No distinct correlation between βHIA 
and parasite growth inhibition activity values could be obtained unless the vacuole 
accumulation factor (α) was included (Figure 1-13) 261.  
 
 
Figure 1-13: Linear correlation between log IC50 × α plotted as function of log βHIA50. 
Reprinted with permission from Kaschula, C.H., Egan, T.J., Hunter, R., Basilico, N., Parapini, 
S., Taramelli, D., Pasini, E. and Monti, D., 2002. Structure− activity relationships in 4-
aminoquinoline antiplasmodials. The role of the group at the 7-position. Journal of medicinal 
chemistry, 45(16), pp.3531-3539. Copyright (2002) American Chemical Society 261. 
 
A similar trend was observed by Ncokazi and Egan, who developed a fast, cheap and reliable 
ferrichrome method that incorporates the use of pyridine to measure β-haematin inhibition to 
re-examine the βHIA of the same compounds as Kashula et al 261-262. In another study, 
Gligorijevic et al determined the effect of CQ on parasitized RBCs over a time period of 37 
hrs using spinning disk confocal microscopy. From the reconstructed z-stacked images they 
were able to show that CQ inhibits the formation of haemozoin during the time points 22-29 
hrs which was during the early trophozoite stage. The same was observed in both CQS and 
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CQR strains, however, was dependent on the concentration of CQ. Furthermore, a linear 
correlation between haemozoin inhibition and percentage parasite growth inhibition was 
observed for both CQS and CQR strain parasites. Verapamil- and CQ- treated parasites too 
conformed to the linear correlation (Figure 1-14) 205.  
 
 
Figure 1-14: Linear correlation of percentage haemozoin inhibition as a function of parasite 
growth inhibition for HB3 strain parasites (empty markers) with verapamil (triangle), without 
verapamil (squares), combination of verapamil and CQ (diamond) and Dd2 strain parasites 
(filled markers). Reprinted with permission from Gligorijevic, B., McAllister, R., Urbach, J.S. 
and Roepe, P.D., 2006. Spinning disk confocal microscopy of live, intraerythrocytic malarial 
parasites. 1. Quantification of hemozoin development for drug sensitive versus resistant 
malaria. Biochemistry, 45(41), pp.12400-12410. Copyright (2006) American Chemical 
Society 205. 
 
With this knowledge, Combrink et al went on to be the first to demonstrate direct evidence of 
haemozoin inhibition in P. falciparum parasites. Using a haem fractionation method, they were 
able to measure the individual haem species within D10 strain parasites as a function of 
increasing doses of CQ. From the data, it was observed that CQ caused a dose-dependent 
increase in the levels of haem and dose-dependent decrease in the levels of haemozoin. In 
addition, a direct correlation between increasing haem levels and decreasing percentage 
parasite growth was observed (Figure 1-15) 242.  
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Figure 1-15: Bar graphs showing (a) decreasing haemozoin levels and (b) the increasing “free” 
haem levels as a function of increasing CQ doses including the negative controls, 
pyrimethamine (P) and sulfadoxine (SP). Decreasing percentage parasite growth with 
increasing percentage “free” haem is represented in (c). Statistical significance was determined 
using a two-tailed t-test and is indicated, relative to the control (95% confidence interval (CI)), 
by the asterisks where; * p = <0.05; ** p = <0.01 and *** p = <0.001 etc. Reprinted with 
permission from Combrinck, J.M., Mabotha, T.E., Ncokazi, K.K., Ambele, M.A., Taylor, D., 
Smith, P.J., Hoppe, H.C. and Egan, T.J., 2012. Insights into the role of heme in the mechanism 
of action of antimalarials. ACS chemical biology, 8(1), pp.133-137. Copyright (2012) 
American Chemical Society 242. 
 
Following this, Combrinck et al optimized the method into a multi-well higher throughput 
colorimetric plate assay. This improved throughput colorimetric plate method was adapted to 
a 24-well plate which was faster by 6-fold and used less starting materials (24-fold). The study 
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showed that while AQ behaved similarly to CQ, the antifolate pyrimethamine and atovaquine 
(Atov) did not 263. 
 
1.9.2 Intracellular accumulation 
 
Historically, it has been assumed that haemozoin inhibitors like CQ have the ability to 
transverse into the parasite DV by permeating through the DV membrane, accumulating and 
exerting their antimalarial activity. For the weak diprotic base CQ, it has been shown that CQ 
selectively accumulates at high concentrations and is localized to the DV rather than normal 
tissue 264-266. The accumulation of CQ is also linked to its parasite growth inhibition activity 
127,133,139,267. There is strong evidence which has shown that the accumulation of CQ is 
dependent on two factors: (i) their physiochemical properties; and (ii) the pH-gradient between 
the external and internal compartments within the parasite 203,268.  
 As a weak base, CQ accumulation can be explained by the phenomenon of pH trapping. 
The pH-dependent accumulation of CQ involves both its neutral and protonated (CQH22+) 
forms. Neutral CQ, being highly membrane permeable, diffuses rapidly across parasite 
membranes 127,269-270. Once inside the parasite DV, neutral CQ becomes protonated at the pH 
of 4.8-5.2 of the DV and is not able to diffuse out in the protonated state 269,271. By equilibrium 
processes, neutral CQ continues to enter the DV until both the internal and external 
compartments within the parasite are equal. After some time, majority of the accumulated CQ 
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Figure 1-16: The pH-dependent process of accumulation of CQ from the external compartment 
(cytoplasm) of the parasite (blue) into the DV (red). Reproduced from: Wicht, K.J., 
2015. Discovery of benzamides and triarylimidazoles active against Plasmodium falciparum 
via haemozoin inhibition: high throughput screening, synthesis and structure-activity 
relationships (Doctoral dissertation, University of Cape Town) 273. 
 
Various studies have supported this hypothesis of pH trapping 128,274-278. Geary et al used [3H]-
CQ to determine the concentration of CQ that accumulated in the DV as a function of time in 
various P. falciparum strains. With the knowledge that CQS and CQR strains have varying pH 
values pertaining to their DV, they still concluded that the accumulated CQ was primary due 
to pH trapping which was driven by the simultaneous process of proton (H+) uptake and efflux 
across the membrane of the DV. Also, it was concluded that CQ accumulation was directly 
related to parasite growth inhibition activity 274. These data agreed with the conclusions drawn 
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Figure 1-17: Vacuole accumulation of CQ in various P. falciparum parasite strains. Reprinted 
from: Biochemical pharmacology, 35 (21), Geary, T.G., Jensen, J.B. and Ginsburg, H., Uptake 
of [3H] chloroquine by drug-sensitive and-resistant strains of the human malaria parasite 
Plasmodium falciparum. pp.3805-3812., Copyright (1986), with permission from Elsevier 274. 
 
Geary et al devised a model based on the weak base properties of CQ and its accumulation via 
pH trapping in the DV for CQS and CQR P. falciparum strains, where the inoculum size and 
medium pH were altered. From these data, it was observed that CQ does not raise the pH of 
the DV which showed that the weak base accumulation does not itself explain parasite growth 
inhibition activity as had been previously speculated 276. This contrasted with the study by 
Ginsburg et al that showed a protonophoric effect of various haemozoin inhibitors. MQ and 
QN were hypothesized to exert their antimalarial effect by transporting protons across the 
membrane of the DV whilst CQ was claimed to cause an increase in the DV pH which could 
inhibit parasite growth. They also found that these compounds concentrated at much larger 
amounts compared to their IC50 values 63. This agreed with the findings previously reported by 
Yayon et al, Krogstad et al and Fitch et al 61,128,281. Ginsburg et al, however, also emphasized 
that this depended not only on the DV buffering ability but also on the H+-gradient pump 
activity and the basal leak of protons out of the DV along the concentration gradient of these 
compounds 63.  
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Since then, a phenomenon that has been frequently used to experimentally determine the 
cellular accumulation ratio (CAR) of haemozoin inhibitors within P. falciparum parasites, is 
the inoculum effect. The inoculum effect is based on the fact that haemozoin inhibitors 
accumulate within the DV of the parasite via pH trapping and overall cellular accumulation 
can be experimentally determined by measuring the change in IC50 value as a function of the 
inoculum size. This inoculum size has been defined as the product of percentage parasitemia 
and haematocrit. The relative change in the IC50 value with changing inoculum sizes has been 
reported to be linearly correlated, where the absolute IC50 at inoculum size 0 can be determined 
by the extrapolation of the line to the y-intercept. From this linear correlation, the experimental 




Figure 1-18: An example of measuring the inoculum effect in 3D7 strain cultures that have 
been treated with an AQ analogue, where (a) represents the change in percentage parasite 
growth inhibition with increasing inoculum size, and (b) increasing IC50 values with increasing 
inoculum size. Reprinted from: Biochemical pharmacology, 52 (5), Hawley, S.R., Bray, P.G., 
O'Neill, P.M., Park, B.K. and Ward, S.A., The role of drug accumulation in 4-aminoquinoline 
antimalarial potency: the influence of structural substitution and physicochemical properties. 
pp.723-733., Copyright (1996), with permission from Elsevier 269. 
 
In relation to the inoculum effect, Hawley et al determined the CAR values for various AQ 
analogues, where they highlighted various structural features that influenced both 
accumulation and activity of quinoline-containing compounds like AQ. They deduced from 
their findings that this was due to the presence of specific binding sites for quinoline-containing 
compounds within the parasite. They showed that out of all the AQ analogues, a N-tertbutyl 
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substituted analogue of AQ (TBQ) had the highest CAR value of 79,456 compared to AQ with 
a CAR value of 8955 in 3D7 strain parasites 269. Similarly, Wicht et al used the inoculum effect 
with an antiplasmodial assay to determine the CAR values CQ and AQ of 105,343 and 98,024 
in D10 strain parasites, respectively (Figure 1-19) 273. 
 
Figure 1-19: Inoculum effect for CQ and AQ. Reproduced from: Wicht, K.J., 2015. Discovery 
of benzamides and triarylimidazoles active against Plasmodium falciparum via haemozoin 
inhibition: high throughput screening, synthesis and structure-activity relationships (Doctoral 
dissertation, University of Cape Town) 273. 
 
In 1998, Wünsch et al first provided evidence that the reduced uptake of CQ in CQR parasites 
could be accounted for by the alterations of the sodium-hydrogen (Na+/H+) exchanger which 
was thought to be responsible for the transport CQ through the parasite 282. This was later 
disproved by Bray et al, who showed that the specificity, accumulation and parasite growth 
inhibition activity are dependent on the saturable equilibrium binding of CQ and Fe(III)PPIX 
208. A year later, Bray et al used 3H-labelled CQ to measure the saturable uptake of CQ in P. 
falciparum parasites and the binding of CQ to Fe(III)PPIX. These data showed that CQ 
accumulation is in fact dependent on the binding of CQ to Fe(III)PPIX rather than the sodium-
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Figure 1-20: Cell-free system of CQ binding to Fe(III)PPIX. Republished with permission by 
the Journal of Cell Biology, from Bray, P.G., Janneh, O., Raynes, K.J., Mungthin, M., 
Ginsburg, H. and Ward, S.A., 1999. Cellular uptake of chloroquine is dependent on binding to 
ferriprotoporphyrin IX and is independent of NHE activity in Plasmodium falciparum. 145 (2), 
pp.363-376.; permission conveyed through Copyright Clearance Centre, Inc 283. 
 
Consequently, accurately determining whether a wide range of haemozoin inhibitors can 
accumulate might be beneficial to understanding the mechanism of these haemozoin inhibitors.  
 
1.10 Effects on Fe(III)PPIX distribution and localization of antimalarials 
 
With the knowledge that quinoline-containing compounds accumulate to high concentrations 
in the parasite DV, it is appropriate to discuss their effect on the distribution of Fe(III)PPIX 
within the parasite. Lipophilic Fe(III)PPIX, released as a consequence of the digestion of 
haemoglobin during the trophozoite stage, has been known to cause a number of toxic effects 
in the parasite at micromolar concentrations. These effects include increased osmotic stress in 
the DV which can lead to interrupted membrane function and destabilization. This further 
causes lysis of parasite membranes and in extreme cases even the host RBC, eventually causing 
the parasite to die 76,284-285. To avoid the toxic effect of haem, the parasite is able to sequester 
large amounts, more than 95%, of toxic Fe(III)PPIX into haemozoin which was proven in 2002 
In vitro modelling of cellular haemozoin and inhibition by β-haematin inhibitors and their derivatives 
Roxanne Openshaw-January 2020 42 
to be the primary fate of Fe(III)PPIX 286-287. From this, toxic Fe(III)PPIX has become of a 
considerable interest for not only understanding the chemical process that occur within the 
parasites DV and the effect of haemozoin targeting antimalarials, but also for the development 
of new haemozoin targeting antimalarials 287. The effect of haemozoin targeting antimalarials 
on the distribution of Fe(III)PPIX associated Fe and other major haem iron species within the 
parasite have been previously explored using various spectroscopic techniques that have 
proven to be useful in both identifying the distribution of Fe(III)PPIX associated iron with 
other haem iron species and its association with the localization of antimalarial compounds 
within parasites 72,242,251. 
 In 2002, Egan et al was the first to used electron spectroscopic imaging (ESI) with TEM 
to identify that the majority of the Fe(III)PPIX associated Fe signal within parasites was 
attributed to the haemozoin crystals whilst negligible Fe(III)PPIX associated Fe was observed 
in the rest of the parasite. Additionally, it was observed that small amounts Fe(III)PPIX 
associated Fe was observed in the RBC cytoplasm coinciding with haemoglobin. From these 
data, together with Mössbauer spectroscopy and wet chemical colorimetric Fe measurements, 
they were able to conclude that majority of the Fe(III)PPIX associated Fe (95%) was attributed 
to haemozoin with the remaining 5% suggested to be available for antimalarials to target 287. 
These data, however, disproved earlier reports by Ginsburg et al and Loria et al, who suggested 
that more than 70% of the Fe(III)PPIX associated Fe was located in either the parasite cytosol 
or the parasite DV 244-245. More recently, Combrinck et al used TEM and ESI coupled to 
electron energy-loss spectroscopy (EELS) to directly observe the effect of CQ on the 
distribution of haem as a consequence of haemozoin inhibition in CQS strain parasites that 
were prepared using a chemical fixation method. In accordance with the previous study 
mentioned above, TEM images revealed that in control parasites the haemozoin was localized 
to the parasite DV, where the EELS images showed that majority of the Fe signal was attributed 
to the haemozoin crystals. It was also shown that the rest of the parasite DV showed little or 
no Fe signal compared to the host RBC. In comparison to the control parasites, CQ treated 
parasites showed a similar TEM image with the haemozoin crystals inside the DV. However, 
the EELS revealed that upon treatment with 30 nM CQ the Fe signal increased in the parasite 
whilst the Fe signal associated with the haemozoin crystals was diminished (Figure 1-21) 242. 
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Figure 1-21: TEM images with corresponding EELS images measured with ESI for (a) 
untreated and (b) CQ-treated P. falciparum parasites. Reprinted with permission from 
Combrinck, J.M., Mabotha, T.E., Ncokazi, K.K., Ambele, M.A., Taylor, D., Smith, P.J., 
Hoppe, H.C. and Egan, T.J., 2012. Insights into the role of heme in the mechanism of action 
of antimalarials. ACS chemical biology, 8(1), pp.133-137. Copyright (2012) American 
Chemical Society 242. 
 
The localization of quinoline-containing compounds has also been explored. In 2012, 
Bohorquez et al used fluorescence microscopy to determine the localization of QN at a 
subcellular level in CQS and CQR strain parasites, 3D7 and Dd2 respectively. First, they 
observed with 2D-microscopy and DIC images that QN colocalized with haemozoin. In 
addition, the fluorescence attributed to QN was observed to appear in the DV as early as one 
hour into the experiment and was consistent for both parasite strains (Figure 1-22) 288. 
 
 
Figure 1-22: Fluorescent microscope images of QN-treated P. falciparum parasites over an 11 
hr period in both CQS and CQR strain parasites, 3D7 and Dd2 respectively. The haemozoin 
crystals in the parasite DV are indicated by the white arrows. All images have a scale bar of 5 
µm. Reproduced with permission by Malaria journal, from Bohórquez, E.B., Chua, M. and 
Meshnick, S.R., 2012. Quinine localizes to a non-acidic compartment within the food vacuole 
of the malaria parasite Plasmodium falciparum. , 11(1), p.350 288. 
In vitro modelling of cellular haemozoin and inhibition by β-haematin inhibitors and their derivatives 
Roxanne Openshaw-January 2020 44 
To further characterize this QN and haemozoin co-localization, they used a lysoTracker Red 
DND-99 fluorescent dye to stain the parasite DV and DRAQ5 fluorescent probe that is specific 
to DNA 289. From 3D reconstructed z-stacked fluorescent images, they observed that QN did 
not co-localize with DRAQ5 but rather in an adjacent but separate compartment to the 
lysoTracker Red. From this, they were not able to definitively state whether QN and haemozoin 
co-localize as a limitation to this method is that haemozoin cannot be viewed 288. In another 
study, Dubar et al, used the chlorine (Cl) atom as a tracer for label-free FQ and CQ in H3B 
strain parasites using ESI to determine their co-localization with haemozoin in the DV. From 
the results they observed that for untreated iRBCs the DV have a very low Cl signal and a high 
Cl signal in the rest of the iRBC. For FQ- and RQ-treated parasites, a very high Cl signal was 
observed in the DV of the parasite, where, they suggested this to be indicative of co-localization 
with haemozoin. On the other hand, for CQ, the Cl signal was distributed equally throughout 
the iRBC including the DV, thus giving inconclusive results as to whether it co-localized with 
haemozoin. From here, they concluded that Cl was not suitable for determining the co-
localization of CQ and haemozoin 290. However, from the distinctively different results that 
were observed for FQ and RQ compared to CQ, they did suggest that it could be related to the 
fact that FQ and RQ accumulate at a much faster rate than CQ 251,283. In a related study, 
Kapishnikov et al showed that bromine (Br) analogue of CQ accumulates at a sub-millimolar 
concentration and caps haemozoin crystals in the parasite DV using X-ray microscopy. From 
this, they measured that this bromoquine (BrQ) capping was sufficient enough to disrupt the 
detoxification process of Fe(III)PPIX and suggested that it could possibly bind to Fe(III)PPIX 
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Figure 1-23: X-ray fluorescence maps represented for (a) Fe and (b) Br in P. falciparum 
iRBCs. The BrQ coverage was calculated to be 7 ± 2%. The intensity scale factor IFe/IBr ~ 272 
with an estimated uncertainty factor of 15%. Reprinted from Kapishnikov, S., Staalsø, T., 
Yang, Y., Lee, J., Pérez-Berná, A.J., Pereiro, E., Werner, S., Guttmann, P., Leiserowitz, L. and 
Als-Nielsen, J., Mode of action of quinoline antimalarial drugs in red blood cells infected by 
Plasmodium falciparum revealed in vivo. Proceedings of the National Academy of 
Sciences, 116(46), pp.22946-22952. Copyright (2019) National Academy of Sciences 291.  
 
1.11 Fe(III)PPIX-inhibitor complexes 
 
One theory that has long been proposed for the mode of action of antimalarial compounds is 
their ability to bind with Fe(III)PPIX, forming a Fe(III)PPIX-inhibitor complex. This proposed 
theory stems from the fact that quinoline-containing antimalarials are able to accumulate in the 
parasite DV which is dependent on their ability to bind to monomeric or dimeric Fe(III)PPIX 
and form a Fe(III)PPIX-quinoline complex via π-π interactions 292-294. A hypothesis is that these 
complexes form immediately after the digestion of haemoglobin and release of toxic 
Fe(III)PPIX but before this toxic Fe(III)PPIX is partitioned into neutral lipid bodies and 
converted into haemozoin 295. Moreover, it is thought that these complexes are able to interfere 
with the function of parasite membranes and subsequently lead to parasite death by causing a 
build-up of toxic Fe(III)PPIX 145,283,296-297. In other cases, it has been found that both toxic 
Fe(III)PPIX and these complexes are able to cause potassium leaks in normal RBCs 298-299. 
Several spectroscopic studies have investigated the interaction between antimalarials and 
Fe(III)PPIX in solution. Blauer et al used circular dichroism (CD) and visible light-absorbance 
spectra to investigate the Fe(III)PPIX-QN complex at a temperature between 26 °C and 27 °C 
and pH values of 7.4 and 11.5, respectively. They observed from CD titrations that an optically 
A B
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active Fe(III)PPIX-QN complex was comprised of QN and Fe(III)PPIX in a 1:1 mole ratio at 
pH 7.4 300. A similar effect with CQ on parasite derived Fe(III)PPIX was observed by 
Balasubramanian et al 301. Fe-Mössbauer spectroscopy has also been used to study the 
association of CQ, QN, quinidine (QD) and AQ to Fe(III)PPIX as complexes 61,302-304.  
Presumably, one would also expect that if these complexes are responsible for parasite 
death, then they would be tightly bound to Fe(III)PPIX and soluble in order to result in the 
accumulation of Fe(III)PPIX. This then causes an increased DV osmotic pressure which in turn 
results in the rupturing of the parasite DV thus killing the parasite 305-307. In this regard, Dodean 
et al investigated the binding affinities with the assumption that these inhibitors bind in a 1:1 
ratio with Fe(III)PPIX. They used UV spectroscopy to monitor the effects of different 
concentrations of a fluorinated xanthone compound on the intensity and shifts of the Soret 
band. From this, the fluorine-containing xanthone compounds showed a higher binding affinity 
to Fe(III)PPIX, with larger Ka values than CQ and a non-fluorinated compound 308-309. Related 
to this, is the solubility of these complexes, where the formation of these complexes may be 
influenced by a pH–dependent solubility 209. However, up until 2008 no detailed structure of 
any of these complexes had been presented. It was only in 2008 that de Villiers et al used single 
crystal X-ray diffraction to determine the first crystal structure of a 1:1 complex of the 
antimalarial HF and Fe(III)PPIX. From the crystal structure, it was observed that HF was able 
to bind to Fe(III)PPIX by coordinating to the Fe(III) center by a Fe-O bond from its 
deprotonated alcohol group. In addition, HF was able to π-stack over the haem porphyrin 
through its phenanthrene ring 124. A few years later, de Villiers et al also published the 
structures for the Fe(III)PPIX complexes of QN and QD. From these complexes, it was 
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Figure 1-24: The asymmetrical complex structures of QN and QD with Fe(III)PPIX. Each 
atom has been colour coded; C, gray; H, white; N, blue; O, red; and Fe, cyan with hydrogen 
bonds indicated with broad dashed lines. Reprinted with permission from de Villiers, K.A., 
Gildenhuys, J. and le Roex, T., 2012. Iron (III) protoporphyrin IX complexes of the antimalarial 
cinchona alkaloids quinine and quinidine. ACS chemical biology, 7(4), pp.666-671. Copyright 
(2012) American Chemical Society 310. 
 
A method that has been well documented and used to investigate Fe(III)PPIX complexes, 
including Fe(III)PPIX-inhibitor complexes, in P. falciparum parasites, is Raman spectroscopy 
311-313. Raman spectroscopy, a fast, label-free and non-invasive technique, is both highly 
sensitive and selective which makes it suitable for the analysis of biological species such as 
Fe(III)PPIX complexes in parasites 313-315. Fe(III)PPIX complexes tend to cause strong 
Resonance Enhanced Raman Scattering (RERS) when excited at various excitation 
wavelengths. This results from the highly symmetrical and chromophoric structure of 
Fe(III)PPIX 316. RERS can be explained by two terms, type A and B. Type A is dependent on 
and can be explained by the Frank-Condon principle. This principle is based on the significant 
overlap of two vibrational wave functions which facilitates an electronic transition in totally 
symmetric systems. On the other hand, type B can be explained by the mixing of vibrations, 
where, one transition can be enhanced by the more intense neighboring transition 317-318.  
Initially, Ong et al used resonance Raman spectroscopy to show that haemozoin could 
be identified in P. Berghi infected parasites 319. In a similar study, Wood et al showed that 
haemozoin and haemoglobin could be identified in P. falciparum parasites using a Raman 
microscope with an excitation source of 632.8 nm. The spectrum of β-haematin was also 
recorded and observed to be similar to that of the spectrum for haemozoin, as illustrated in 
Figure 1-25 320.  
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Figure 1-25: Raman spectra recorded for haemozoin and haemoglobin at the late trophozoite 
stage shown in the inserted photomicrograph. The regions where the corresponding spectra 
were recorded are indicated by the grey arrows. For comparison, the spectrum of β-haematin 
was included. Image reprinted with permission from Wiley & Sons for Wood, B.R., Langford, 
S.J., Cooke, B.M., Glenister, F.K., Lim, J. and McNaughton, D., 2003. Raman imaging of 
hemozoin within the food vacuole of Plasmodium falciparum trophozoites. FEBS 
letters, 554(3), pp.247-252. Copyright (2003) 320. 
 
Later, Frosch et al used polarization-resolved resonance Raman spectroscopy with an 
excitation wavelength of 514 nm to investigate the interaction of haematin and CQ in solution. 
From the spectra, small wavenumber shifts of 2 cm-1 were observed and thought to be 
indicative of the formation of a non-covalent interaction between Fe(III)PPIX-CQ. With this 
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they also suggested that the spectra of both haematin and the Fe(III)PPIX-CQ complex were 
similar 311. Three years later, Frosch et al used UV resonance Raman spectroscopy to 
investigate CQ under conditions that resembled the parasite. With the recorded Raman spectra 
and density functional theory (DFT) calculations they concluded that CQ was capable of 
forming a π-π interaction with haemozoin 312. This agreed with earlier studies with Near IR 
surface enhanced Raman Spectroscopy measurements 321. A year later, Webster et al used near 
infrared Raman microscopy to investigate the effect of CQ on haemozoin in iRBCs using a 782 
nm excitation source. Initially, they recorded the spectra of the µ-oxo dimer of haematin, 
haematin and haemozoin from a bright-field image of P. falciparum iRBCs for the spectral 
region of 1700-500 cm-1. What is worth noting, was that the haemozoin spectrum had a poorer 
signal-to-noise ratio compared to the haemozoin spectrum reported by Wood et al at a lower 
excitation wavelength (Figure 1-26) 322. Then, they recorded the spectra of untreated iRBCs, 
CQ-treated iRBCs and CQ itself in the same spectral region as the previous samples. They 
observed a reduction in the intensity of certain bands in CQ-treated iRBCs compared to 
untreated iRBCs, which are illustrated in Figure 1-27 322.  
 
Figure 1-26: Raman spectra of dried samples of the µ-oxo dimer haematin, haematin and 
haemozoin in live P. falciparum iRBCs (inset) at an excitation of 782 nm. The Raman spectra 
for haemozoin was collected form the dark spot in the image. Reprinted from: FEBS letters, 
582 (7), Webster, G.T., Tilley, L., Deed, S., McNaughton, D. and Wood, B.R., Resonance 
Raman spectroscopy can detect structural changes in haemozoin (malaria pigment) following 
incubation with chloroquine in infected erythrocytes. pp.1087-1092. Copyright (2008), with 
permission from Elsevier 322. 
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Figure 1-27: Raman spectra of dried CQ samples in comparison to untreated and CQ-treated 
iRBC samples, analyzed with an excitation wavelength of 782 nm. Reprinted from: FEBS 
letters, 582 (7), Webster, G.T., Tilley, L., Deed, S., McNaughton, D. and Wood, B.R., 
Resonance Raman spectroscopy can detect structural changes in haemozoin (malaria pigment) 
following incubation with chloroquine in infected erythrocytes. pp.1087-1092. Copyright 
(2008), with permission from Elsevier 322. 
 
Small shifts in bands were also observed in this region which was thought to be indicative of 
molecular changes in the haemozoin environment from drug interaction. To validate these 
small wavenumber shifts they used a multivariate data analysis tool, namely principle 
component analysis (PCA). PCA is a commonly used in conjunction with Raman spectroscopy 
to identify variables or descriptors within Raman spectra. By plotting the individual repeat 
spectra for a sample, a PCA plot of a chosen number of principle component axes can be used 
to both reduce the noise factor and re-express the data in a more simplified but detailed manner 
323-324. For the spectral region of 500-1700 cm-1, a differential spectrum of the average spectra 
for untreated iRBCs and CQ-treated iRBCs (haemozoin) was constructed. From this spectrum, 
a second derivative function was applied along the principle component 1 (PC1) axis. A PCA 
plot was constructed and illustrated that there was a significant difference between the spectra 
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Figure 1-28: Graphs representing (a) differential spectrum of the averaged spectra for both 
untreated iRBCs and haemozoin in CQ-treated iRBCs, (b) second derivative PCA loadings plot 
for both untreated iRBCs and haemozoin in CQ-treated iRBCs, and, (c) PCA plot of untreated 
(open circles) versus CQ-treated iRBCs (squares) which were taken from the corresponding 
loadings plot along the PC1 axis. Majority of the variance in the data lies along PC1 which was 
applicable for this study. Reprinted from: FEBS letters, 582 (7), Webster, G.T., Tilley, L., 
Deed, S., McNaughton, D. and Wood, B.R., Resonance Raman spectroscopy can detect 
structural changes in haemozoin (malaria pigment) following incubation with chloroquine in 
infected erythrocytes. pp.1087-1092. Copyright (2008), with permission from Elsevier 322. 
 
More recently, Kozicki et al investigated the effect of CQ in iRBCs. From the resulting spectra, 
they observed reductions in the band intensities for the spectra regions of 3300-2600 cm-1 and 
1700-1300 cm-1 upon treatment with CQ (Figure 1-29). In addition, PCA plots identified that 
there was a significant difference in oxygenated (oxy) and deoxygenated (deoxy) haemoglobin 
in CQ treated and untreated parasites. However, they observed that there was no significant 
a b
c
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difference in the spectra of haemozoin in both CQ-treated and untreated parasites which 
disagreed with the findings by Webster et al 322,325.  
 
 
Figure 1-29: Recorded Raman spectra for both untreated and CQ-treated P. falciparum iRBCs 
using a 532 nm excitation wavelength. The insets show both untreated and CQ-treated iRBCs 
for the spectral ranges, 3300-2600 cm-1 and 1700-1300 cm-1. Reproduced with permission from 
Kozicki, M., Creek, D.J., Sexton, A., Morahan, B.J., Wesełucha-Birczyńska, A. and Wood, 
B.R., 2015. An attenuated total reflection (ATR) and Raman spectroscopic investigation into 
the effects of chloroquine on Plasmodium falciparum-infected red blood cells. Analyst, 140(7), 
pp.2236-2246. Copyright (2015) The Royal Society of Chemistry 325. 
 
1.12 Key remaining questions 
The morbidity and mortality rates associated to the virulent P. falciparum malaria have 
decreased dramatically over recent years including the effects on young children despite the 
wide-spread problem of P. falciparum resistant parasites. This has been achieved through the 
implementation of control measures such as insecticide-treated bed nets and ACTs. On-going 
HTS searches for new parasite growth inhibitors including β-haematin inhibitors could lead to 
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potentially new and effective antimalarial drugs, despite the remaining question of the 
mechanism of haemozoin inhibition of these β-haematin inhibitors in P. falciparum parasites.  
Recently, direct evidence of the behavior of CQ and related quinoline-containing compounds 
has been published in which these compounds were shown to inhibit haemozoin formation. 
This was evident from the decreasing haemozoin amounts and increasing exchangeable haem 
amounts that resulted in the simultaneous inhibition of parasite growth 263,242. Spectroscopic 
techniques have also been quite useful in determining the effect and localization of haemozoin 
inhibitors in relation to haem within the parasite. This haem distribution effect has been 
suggested to be as a result of the formation of possible Fe(III)PPIX-inhibitor complexes that 
could be responsible for oxidative stress, membrane damage and eventually parasite death 326-
327. However, this suggestion has not yet been conclusively identified within P. falciparum 
parasites. In that regard, the application of these previously described methods could not only 
help in understanding the exact mode of action of these β-haematin inhibitors but also provide 
the necessary determinants for the development of a mathematical haem-pathway model for 
future development of new antimalarials.  
 
1.13 Aims and objectives 
 
1.13.1 Aim  
 
To investigate the behavior of β-haematin inhibitors and their derivatives in the inhibition of 




The following objectives were used to achieve the above aim; 
- To investigate ten selected β-haematin inhibitors, measuring their inhibition of the 
formation of haemozoin, inhibition of parasite growth and accumulation within CQS 
P. falciparum parasites. 
- To use spectroscopic techniques to investigate the possible co-localization of 
Fe(III)PPIX and a β-haematin inhibitor in the parasite DV and further investigation of 
the possible formation of a Fe(III)PPIX-inhibitor complex. 
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- To investigate the concentrations of four major haemoglobin digesting proteases and 
the amount of haemoglobin, exchangeable haem and haemozoin throughout the blood 
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2.1 General Materials  
 
The materials that were commercially obtained (AR or higher purity grade) and corresponding 
suppliers are listed below in tables; Table 2-1 to Table 2-6. The materials were used without 
further purification or sterilization unless otherwise stated in the sample preparation. They are 
listed in order of the methods first performed where some of the materials were used in multiple 
methods and those that were purchased from different suppliers are listed separately. Lasec, 
Millipore, Merck and Becton Dickinson (BD) Science were specific suppliers for the sterile 
consumables used throughout this study.  
 
De-ionized MilliporeÒ Direct-Q water (d.H2O) was used to prepare all solvent solutions 
throughout this study. Test compounds that showed poor solubility in relevant solvents were 
sonicated and heated in 100% dimethyl sulfoxide (DMSO) for a fixed period of 5 min. Single-
channel micropipettes and multichannel micropipettes (Eppendorf) were used for sample 
dilutions, titrations and aliquoting. For all solutions pH was measured and adjusted using a 
calibrated Jenway 3510 benchtop pH meter fitted with a 924 007 glass electrode. Calibration 
of the pH meter was carried out with standard phosphate buffer solutions (PBS) of pH 4.00 and 
7.00 before performing measurements. 
 
Table 2-1: List of materials for the preparation of controls and β-haematin inhibiting test 
compounds 
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Table 2-2: List of materials for cell culturing of P. falciparum parasites. 
Cell culturing of P. falciparum parasites 
Material Supplier 
O+ Human Red Blood Cells (RBCs) Blood Bank (Groote Schuur Hospital) 
RPMI-1640 Culture medium powder (with 
glutamine but excluding sodium bicarbonate 
(R6504)) 
Sigma Life Science 
Phosphate buffer tablets Sigma Life Science 
D-sorbitol Sigma-Aldrich/Merck 
Hypoxanthine Sigma Life Science  
Albumax II Gibco 
Sodium bicarbonate (NaHCO3) Sigma Life Science 
Giemsa’s azur eosin methylene blue solution Sigma-Aldrich/Merck 
Methanol (MeOH) KIMIX 
Microscope immersion oil Sigma-Aldrich/Merck 
D -(+)- Glucose Sigma Life Science 
Gentamicin Sigma Life Science 
N-2-[hydroxyethyl]piperazine-N¢-2-
[ethanesulfonic acid] (HEPES) buffer 
Sigma Life Science 
Sodium L-lactate (³ 98%) Sigma Life Science 
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Table 2-3: List of materials used for parasite antiplasmodial p-LDH assay. 
Parasite antiplasmodial p-LDH Assay 
Material Supplier 
Triton X-100 Thermofisher 
Nitro blue tetrazolium chloride (NBT) Sigma-Aldrich/Merck 
Phenazine ethosulfate (³ 95%) Sigma-Aldrich/Merck 
3-Acetylpyridine adenine dinucleotide  
(³ 85% APAD) 
Sigma-Aldrich/Merck 
Tris (hydroxymethyl) aminomethane buffer 
(Trizma® base ³ 99%)   
Sigma-Aldrich/Merck 
Calcium L-lactate hydrate Sigma Life Science 
Hydrochloric acid (HCl) 32% wt. Sigma-Aldrich/Merck 
 
Table 2-4: Materials used for parasite isolation, fixation and cell counting. 
 






Parasite isolation, fixation and cell counting 
Material Supplier 
Saponin (1%) Sigma-Aldrich/Merck 
Glutaraldehyde (50%) Sigma-Aldrich/Merck 
BD TrucountTM beads BD and Company 
SYBR green ® I nucleic acid gel stain Sigma-Aldrich/Merck 
DNAse Sigma-Aldrich/Merck 
Solvent-mediated plate method for fractionation of parasite haem species 
Material Supplier 
Pyridine Sigma-Aldrich/Merck 
Dodecyl sulfate sodium salt (SDS) Sigma-Aldrich/Merck 
Sodium hydroxide (NaOH) KIMIX 
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Table 2-6: Materials used for ferrihaem standard curve 
Ferrihaem standard curve 
Material Supplier 
Porcine haematin Sigma Life Science 
 
2.2 General Instrumentation 
 
Detailed below is the instrumentation that was used throughout this study where specific 
instrumentation utilized for specific procedures is described.  
 
2.2.1 Centrifuge 
Centrifugation of solutions of 10 ml or more was carried out in plastic Greiner falcon tubes 
using an Eppendorf Centrifuge 5810R or 5804. Microlitre solutions in 24- and 96-well plates 
were suspended and separated using an Eppendorf deep well plate attachment (A-2-DWP).  
 
2.2.2 Incubator 
Both CQ-sensitive and -resistant strain P. falciparum cultures were cultured at 37 °C using a 
Labcon 508IU incubator. 
 
2.2.3 Light Microscope 
Synchronicity of cell expressions and parasitemia was viewed from thin films of malaria 
parasites on Giemsa stained glass microscope slides using a Laborlux 12 Leitz light 
microscope. The above microscope was also used to determine cell counts by viewing prepared 
cells on a Sigma bright-line haemocytometer (Z 353, 962-9).  
 
2.2.4 Sonicator 
In order to ensure complete dissolution of solid samples in the relevant solvents, a Banelin 
Sonorex RK100H sonicator was used.  
 
2.2.5 Vortex 
For all prepared solutions and samples, a homogenous solution was achieved by using a 
Scientific Industries Vortex Genie (G560E). 
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2.2.6 Water bath 
A GRANT digital Y6 or YIH DER BL-710 water bath was used for heating and maintaining 
relevant solutions for parasite culturing, assays, as well as b-haematin formation experiments 
at a physiological temperature of 37 °C. In order to confirm the required temperature, an 
external thermometer was used.  
 
2.2.7 Weighing balance 
The weighing balance was calibrated with mass standards before weighing of all materials 
using a Sartorius R200D balance (5 decimals). 
 
2.2.8 UV-Vis spectrophotometer 
Absorbance measurements were carried out using a Shimadzu UV1800 spectrophotometer, to 
quantify the binding constants for ferrihaem and various test compounds. All UV-visible 
spectra, conducted in a 1 cm pathlength HellmaÒ quartz cuvette and were monitored for 
changes in the characteristic Soret band as well as the weaker Q band and charge transfer band. 
For 96-well absorbance measurements, a SpectraMax 340PC plate reader was used.  
 
2.2.9 Haemocytometer cell counting chamber 
A bright-line haemocytometer cell counting chamber, from Sigma, was used to determine cell 
counts under a light microscope with cover glasses (22 x 26 mm) supplied by Superior 
Marienfield, Germany.  
 
2.2.10  Flow cytometry 
Cell viability, counts, stages and DNA content were determined using a BD FACSCaliburTM 




Analysis and calculations for all data and statistical significance was performed using 
GraphPad Prism (GraphPad Software Inc.) version (v) 8.2.1 (227) for MacOs 328. Referencing 
was carried out using Mendeley Ltd. 2008-2016 v1.16.1. Marvin Sketch v6.2.2 (Windows x86 
8.6.2) was used to manually generate molecular structures and calculated molecular weights 
for all β-haematin inhibiting test compounds in this study 329. Microsoft Office home and 
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student 2013 (v 15.0.5093.1001) Excel was used to formulate spreadsheets for the calculations 
of haem amounts, haemocytometer counts as well as flow cytometry counts 330. FlowJo LLC 
1997-2015 v10.1 331 was used to analyze flow cytometry data (gated cell counts) collected 
using BD CellQuest™ Pro analysis software v 5.1 332. An annual subscription of FlowJo 
software was donated by Tree Star Incorporated. SoftMax Pro v4 software was used to acquire 
absorbance data for 96-well plates 333.   
 
2.4 Preparation of solutions and samples 
 
2.4.1 β-haematin inhibiting test compounds and their derivatives 
 
Molecular structures for all β-haematin inhibiting test compounds that were investigated 
throughout this study, unless specified for a particular experiment, are shown in Figure 2-1. 
The quinoline-containing positive standard CQ was purchased from Sigma-Aldrich. 
Benzimidazole test compound derivatives 1-4 were synthesized and characterized by Dr F. 
L’abbate, quinazoline test compound derivatives 5-7 by Mr S. J. Benjamin, and a benzothiazole 
test compound 8 and benzoxazole test compound 9 by Miss L. Wainwright. A triarylimidazole 
test compound 10 and a benzamide test compound 11 were previously synthesized and 
characterized by Dr K. J. Wicht. For comparison with test compounds 1-9, previously 
published data by Dr K. J. Wicht for test compound 10, 11 and AQ were used throughout this 
study. All stock solutions for the investigated β-haematin inhibiting test compounds (1-9 
including CQ) were dissolved in 100% DMSO to a final concentration of 2 mg/ml and stored 
in sealed Eppendorf tubes at -20 °C until further use. The βHIA values that were determined 
using a NP-40 detergent mediated β-haematin inhibition assay for all β-haematin inhibiting test 
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Test compound 8 
MW: 397.42 g/mol 
βHIA IC50 (µM): 30 ± 2 
Test compound 7 
MW: 316.36 g/mol 
βHIA IC50 (µM): 23 ± 2 
Test compound 9 
MW: 381.35 g/mol 
βHIA IC50 (µM): 22 ± 1 
Test compound 1 
MW: 393.24 g/mol 
βHIA IC50 (µM): 32 ± 1  
Test compound 2 
MW: 392.25  g/mol 
βHIA IC50 (µM): 24 ± 4  
Test compound 3 
MW: 496.40 g/mol 
βHIA IC50 (µM): 80 ±  3 
Test compound 4 
MW: 347.80 g/mol 
βHIA IC50 (µM): 38 ± 1  
Test compound 5 
MW: 470.17 g/mol 
βHIA IC50 (µM): 20 ± 2 
Test compound 6 
MW: 318.42 g/mol 
βHIA IC50 (µM): 26 ± 2 
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Figure 2-1: Molecular structures for all β-haematin inhibiting test compounds used throughout 
this study. 
 
2.4.2 Cell culturing of CQS and CQR P. falciparum malaria parasites 
 
Incomplete Culture Medium 
Incomplete culture medium was prepared by dissolving RPMI 1640 with glutamine (10.4 g/L) 
but without NaHCO3, D-(+)-glucose (4 g/L), HEPES buffer (6 g/L), hypoxanthine (0.088 g/L), 
Albumax II (5 g/L) and gentamicin (0.05 g/L) in d.H2O. The solution was pre-filtered with a 
Test compound 10 
MW: 416.5 g/mol 
βHIA IC50 (µM): 14 ± 0.4 
AQ 
MW: 355. 86 g/mol 
βHIA IC50 (µM): 23 ± 3 
Test compound 11 
MW: 373.17 g/mol 
βHIA IC50 (µM): 7 ± 0.1 
CQ 
MW: 515.89 g/mol 
βHIA IC50 (µM): 39 ± 2 
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0.45 µm filter then filter sterilized using a 0.22 µm membrane filter. Autoclaved glass bottles 
were used to store the incomplete medium at 4 °C until further use.  
 
Sodium Bicarbonate 
A 0.6 M solution of NaHCO3 was prepared by dissolving 50 g NaHCO3 in 1 L of d.H2O. Before 
storing the solution at 4 ºC, the solution was prefiltered through a 0.22 µm membrane filter 
into autoclaved glass bottles. 
 
Complete Culture Medium 
Roughly 17.5 ml of NaHCO3 was added to 400 ml of incomplete culture medium to prepare 
complete medium. This solution was stored at 4 ºC under sterile conditions until further use. 
 
Prepared O+ Human RBCs 
In a sterile centrifuge tube, unwashed human blood was washed by adding 30 ml of complete 
medium to the centrifuge tube (1:1.5 ratio) and centrifuged at 1200 relative centrifugal force 
(rcf) for 5 min after which the supernatant was discarded.  Before storing the washed RBCs at 
4 ºC, this process was repeated for a second time.  
 
Sorbitol 
A 0.6 M solution of D-sorbitol was prepared by dissolving 50 g of D-sorbitol in 1 L of d.H2O. 
Before storing the solution at 4 ºC, the solution was prefiltered through a 0.22 µm membrane 
filter into autoclaved 250 ml glass bottles. 
 
Phosphate Buffer Solution (PBS) 
A stock solution of PBS (1 tablet = 0.01 M phosphate buffer, 0.0027 M KCl and 0.14 M NaCl) 
was prepared by dissolving 5 tablets in 1 L of d.H2O. The solution, pH 7.4, was stored at room 
temperature. For specific experiments, filtered PBS was prepared by filtering  the PBS solution 
with a 0.22 µm membrane filter. 
 
Giemsa Stain  
The stain was prepared by adding 1 ml Giemsa to 9 ml of PBS (1:10) before applying to culture 
smeared glass microscope slides.  
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2.4.3 Parasite antiplasmodial assay  
 
Malstat 
A 400 ml solution of Malstat was prepared by gently heating 400 µl of Triton X-100 with 8 g 
of L-lactate, 2.64 g of Tris buffer in d.H2O. The solution was stirred until dissolved before 
adding 0.044 g of APAD (pH 9) and stored at 4 ºC until further use.  
 
NBT 
A 100 ml solution of NBT was prepared by dissolving 0.16 g NBT salt and 0.008 g of 
phenazine ethosulphate in 100 ml of d.H2O and stored at 4 ºC until further use.  
 
2.4.4 Pyridine-based parasite haem fractionation plate method 
 
2.4.4.1 Parasite isolation, fixation and cell counting 
 
Mature trophozoite cultures were isolated using a saponin solution that was stored at 4 ºC and 
can be kept for a maximum of two weeks. The solution was prepared as a 1% solution (0.5 g) 
in 50 ml of d.H2O. Isolated parasites were fixed with a solution of glutaraldehyde that was 
prepared by vortexing 25 µl of a 50% solution of glutaraldehyde in 10 ml of 0.22 µm membrane 
filtered PBS. To prevent cells from aggregating, which is necessary for flow cytometry, 50 µl 
of DNAse was added to the 10 ml of 0.22 µm membrane filtered glutaraldehyde in PBS 
solution. In preparation of flow cytometry samples, a 10 ml diluted solution of SYBR green® 
I nucleic acid stain (1:10000) in 0.22 µm membrane filtered PBS was prepared and used as an 
indicator of cell growth and division. In addition, Trucount™ beads (5 ml) were diluted in a 
separate tube with 1 ml of 0.22 µm membrane filtered PBS. After thawing of samples and 
solutions, all were vortexed before each experiment (Table 2-4) 
 
2.4.4.2 Solvent-mediated plate method for fractionation of parasite haem species 
 
Various solutions were prepared for the solvent-mediated plate method for fractionation of 
parasite haem species which are listed in Table 2-5 and include: (i) a 0.2 M buffer solution 
which was prepared by dissolving 4.76 g of HEPES in 100 ml of d.H2O and brought to a pH 
of 7.5; (ii) a 4% anionic protein denaturing detergent solution prepared by dissolving 4 g of 
SDS in 100 ml of d.H2O; (iii) a 0.3 M solution of NaCl, by dissolving 1.75 g in 100 ml of 
d.H2O; (iv) a 0.3 M solution of NaOH prepared by dissolving 1.2 g in 100 ml of d.H2O; (v) a 
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0.3 M HCl solution prepared by dissolving 3 ml (v/v 32 %) in 100 ml of d.H2O; and (vi) a 25 
% pyridine in 0.2 M HEPES (v/v) solution prepared by adding 25 ml of aqueous pyridine to 
10 ml of 0.2 M HEPES (pH 7.5) diluting with 65 ml of d.H2O. 
 
2.4.4.3 Standard ferrihaem curve 
 
Haematin 
A 100 µg/ml solution of porcine haematin was freshly prepared by dissolving 0.01 g of 
haematin in 100 ml of 0.3 M NaOH for each experiment (Table 2-6). 
 
2.5 Experimental Methods 
 
Throughout this study, CQS (NF54) and CQR (Dd2 – clone of W2-MEF originating from 
Indochina 339-340 and K1- and pyrimethamine-resistant clones originally derived from Thailand 
341 P. falciparum parasite strains) were used. CQS strain, NF54 originally isolated from a 
patient near Schiphol Airport, Amsterdam 342 was used in the majority of the experimental 
methods described below, unless stated otherwise. 
 
2.5.1 Cell culturing of CQS and CQR P. falciparum parasites 
 
Parasites were cultured using a modified version of Trager and Jensen under a sterile laminar 
flow hood 343. Donated trophozoite cultures from a routine culturing laboratory at the Division 
of Pharmacology, UCT were decanted into sterile 50 ml centrifuge tubes and spun down at 750 
revolutions per minute (rpm) for 5 min. The supernatant was aspirated before aliquoting 1 µl 
of iRBCs onto a glass microscope slide. The droplet was smeared to create a thin film of iRBCs, 
methanol fixed and completely covered with a 10% Giemsa solution. The stained slide was left 
for 10 min before rinsing with tap water, air-dried and viewed with an oil immersion light 
microscope at 100 × magnification. The iRBCs were then checked for the correct stage, 
parasitaemia and confluency. The remaining iRBC pellet was diluted to 2% haematocrit and 
10% parasitaemia, in complete medium and washed O+ RBC in a sterile 250 ml flat bottom 
culture flask. For parasite growth, culture flasks were gassed for 1 min with O2 (3%), CO2 (4%) 
and N2 (4%) before being placed in a CO2 incubator (37 °C).  
After a duration of 24 hrs, the culture flasks (ring stage) were removed from the 
incubator and centrifuged at 750 rpm for 5 min in a sterile 50 ml falcon tube. The supernatant 
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was discarded and a Giemsa smear of the culture was prepared as previously mentioned. The 
ring stage parasites were checked before resuspending the remaining culture pellet in 15 ml of 
D-sorbitol and incubating in a water bath for 5 min. This was done to synchronize the culture. 
After 5 min in the water bath, the iRBC pellet was centrifuged at 750 rpm for 5 min, aspirated 
and diluted in complete medium and washed O+ RBCs to give 2% haematocrit and 10% 
parasitaemia. The culture flask was re-gassed (3% O2, 4% CO2 and 4% N2) for 1 min and 
placed back into a CO2 incubator. The culturing cycle was maintained at 10% parasitaemia 
until further use. 
 
2.5.2 Parasite antiplasmodial assay 
 
The parasite antiplasmodial assay, previously described by Makler et al., was modified to 
evaluate the IC50 of various antimalarial test compounds by measuring the amount of lactate 
dehydrogenase (LDH) present in parasites inoculated with a test compound 344. During the 
pathogenic blood stage of the malaria parasite, lactate synthesized through the glycolytic 
pathway can be converted back to pyruvate which is catalysed by parasite lactate 
dehydrogenase (p-LDH) and is easily distinguishable from human LDH isoforms. The reason 
is that p-LDH has the ability to use APAD more rapidly and effectively than host LDH isoforms 
(200-fold) (Figure 2-2) 345. 
 
 
Figure 2-2: The formation of pyruvate in the presence of the APAD coenzyme (Malstat™) 
produced in viable malaria parasites. APADH formation is colourimeterically observed from 
the reduction of NBT (yellow) to formazan (purple). The figure was adapted and modified from 
Combrinck et al 346. 
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Specifically, NAD analogue, APAD, is used during glycolysis instead of NAD in the assay due 
to its unique uptake by malaria parasites and not RBCs as well as its conversion rate of lactate 
to pyruvate. During plate development for spectroscopic analysis, iRBCs are suspended in a 
solution of Malstat™ (containing APAD) allowing the formation of reduced 3-acetylpyridine-
adenine dinucleotide (APADH) in viable cells. This rapid formation can be colourmeterically 
assayed, in the presence of NBT, by the disappearance of the yellow colour and formation of a 
deep purple solution of formazan salt as the process proceeds. The measured formazan 
absorbance, recorded at 620 nm, is equivalent to the percent parasite viability at a known 
concentration of test compound.  
Prior to each experiment, test compound solutions of 2 mg/ml were freshly prepared the 
night before in DMSO (100%) and stored at -20 °C overnight. When preparing for the assay, 
test compounds were thawed in a water bath at 37 °C and vortexed before diluting to a known 
starting concentration (1000 ng/ml) in complete medium. Briefly, in columns 3-12 of a 96-well 
plate, test compound samples were serially diluted further in complete medium, resulting in a 
DMSO concentration of less than 0.5% (1:2000 dilution). All test compounds were tested in 
triplicate adjacent to a control test compound (CQ). Column 1 (negative control), contained 
solely RBCs at a haematocrit of 2%. For the positive control (column 2), iRBCs in complete 
medium were diluted to 2% haematocrit and 2% parasitaemia where 100 µl was also added to 
columns 3-12. The plates were covered and sealed in a sterile gassing chamber and gassed with 
3% O2, 4% CO2 and N2 before placing in an incubator at 37 °C (Figure 2-3). 
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Figure 2-3: p-LDH assay scheme used to determine the IC50 of a test compound. 
 
After 48 hrs, the plate was frozen at -20 °C prior to thawing so as to lyse trophozoites for 
development of the plate. The plate was developed by resuspending 15 µl of lysed trophozoites 
in 100 µl of Malstat™ and left to stand for 30 min before adding 25 µl of NBT. The measured 
absorbance was recorded at 620 nm, using a Modulus™ Microplate Multimode Reader (Turner 
Biosystems), and plotted using sigmoidal dose-dependent curve analysis in GraphPad Prism 
v8.2.1 software. 
 
2.5.3 Pyridine-based parasite haem fractionation plate method 
 
The pyridine-based parasite haem fractionation method was developed from another method 
that was first established in 2005 and used as a cheap and reliable means of detecting the 
inhibition of β-haematin formation 262.  This method is based on the fact that pyridine forms a 
monomeric low-spin complex with haematin. Dissolved haematin in purely aqueous medium 
is characterized by a strongly absorbing band, commonly known as a Soret band (389 nm) 
which is broadened, indicative of an aggregated state of haematin, probably as a result of 
dimerization 347. At longer wavelengths, haematin also exhibits a weakly absorbing Q band 
and is somewhat more prominent charge transfer band (CT). In more detail, in accordance with 
the Gouterman four orbital model 348 these bands are a result of the transition of an electron 
between two closely spaced filled porphyrin π orbitals to a low-energy pair of unoccupied 
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porphyrin π* orbitals of haematin. The Soret band, which is broadened as a result of a 
vibrationally excited state in the unoccupied π* orbital of haematin is further broadened by 
aggregation owing to decreased symmetry of the system, which lifts the degeneracy of these 
orbitals. By forming a monomeric complex, pyridine sharpens the Soret band and gives a 
consistent extinction coefficient.  Nonetheless, upon exposure of haematin to aqueous pyridine, 
the resulting Soret band is sharpened and significantly increases in intensity along with a 
characteristic red shift to 405 nm. This increase in intensity is typically due to the presence of 
monomeric haematin. Simultaneously, a more prominent Q band at 527 nm is observed which 
is indicative of a low-spin Fe(III)PPIX-pyridine complex where two pyridine ligands are 
coordinated to the central Fe(III) centre of the haematin porphyrin. The resulting coordination 
causes the axial water from the haematin Fe(III) centre to be displaced by means of a ligand 
substitution reaction 262.  
Briefly, the colorimeteric multi-well pyridine-based parasite haem fractionation method, 
previously described by Combrinck et al, is a method that involves quantifying haem species 
present in P. falciparum parasites which can be spectroscopically assayed as a low-spin 
Fe(III)PPIX-pyridine complex 263. In this chapter, this method was used to determine the effect 
of nine selected β-haematin inhibitors and their derivatives, including CQ, on the inhibition of 
haemozoin formation in P. falciparum parasites. Resulting haem species; undigested 
haemoglobin, exchangeable haem and haemozoin present in isolated trophozoites were solvent 
fractionated and spectroscopically assayed at 405 nm in the presence of aqueous pyridine at 
pH 7.5 (5% v/v). All absorbance measurements were carried out on a SpectraMax 340PC plate 
reader. 
 
2.5.3.1 Parasite inoculation plate method (24-well plate) 
 
CQS NF54 strain parasites were cultured according to methods described in Section 2.5.1. 
Starting with highly synchronous ring stage cultures, iRBCs were confirmed by viewing 
Giemsa stained smears using an oil immersion objective lens (100×). The ring parasitaemia 
was determined by calculating the percentage of ring iRBCs in the total number of RBCs and 
iRBCs (average of 1000 cells counted). The calculated parasitaemia was used to dilute the ring 
cultures (5% parasitaemia; 2% haematocrit) in 49 ml of complete medium and washed O+ 
RBCs. Treated cultures were inoculated, in a 24-well plate (Greiner Bio-One), with increasing 
multiples of the individual test compound 50% inhibitory concentrations values (0.5, 1.0, 2.0, 
2.5, 3.0 × IC50) where the highest volume of test compound used in a single well was 20 µl 
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(Figure 2-4). All dilutions of β-haematin inhibiting test compounds (≤ 0.5% DMSO v/v) in 
complete medium were prepared prior to inoculation of iRBC cultures, where individual 
experiments were carried out in quadruplicate. Before incubation at 37 °C for 30-32 hrs, all 













Figure 2-4: 24-well plate setup for CQS strain P. falciparum parasite (NF54) inoculation assay. 
 
2.5.3.2 Parasite isolation and fixation  
 
Before removing the plates from the incubator, Giemsa stained “scrape” slides were prepared 
to assess the maturity of the trophozoite culture due to variations in the maturation of P. 
falciparum cultures in the presence of test compounds. In order to attain reliable results, plates 
were removed from the incubator (37 °C) after roughly 32 hrs and well contents were 
transferred, under sterile conditions, to the corresponding wells in a 2.5 ml deep well plate. The 
settled pellet was analysed as a Giemsa stained smear under a light microscope oil immersion 
lens to view the parasitaemia of trophozoite iRBCs. After the confirmation of trophozoite 
iRBCs, supernatants were aspirated and parasites isolated by saponin lysis of RBCs by adding 
100 µl of 1% saponin in 1.8 ml of PBS (pH 7.5) to 300 µl of iRBC pellet (Figure 2-5). The 
iRBC pellets were resuspended to promote lysis and centrifuged at 1200 rpm for 5 min. After 
centrifugation, supernatants were aspirated before washing the isolated pellet with 2 ml of PBS. 
This process was repeated until a clear supernatant was observed in order to remove excess 
traces of RBCs (undigested haemoglobin), cell debris and associated haemozoin from previous 
cycles 263. A 100 µl aliquot of PBS was added to the washed pellet and vortexed to ensure a 
Column: 
1. Control-No inhibitor 
2. 0.5 x IC
50
 
3. 1.0 x IC
50
 
4. 2.0 x IC
50
 
5. 2.5 x IC
50
 
6. 3 x IC
50
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homogenous mixture. For cell counting, 10 µl of the resuspended mixture was aliquoted into a 













Figure 2-5: Saponin lysis of mature trophozoite cultures from red blood cells. 
 
2.5.3.3 Glutaraldehyde-fixation and cell counting 
 
Cell counting plates were prepared by adding a 10 µl aliquot of isolated trophozoites to 190 µl 
of 25% glutaraldehyde in PBS (1:20 dilution) and were stored at 4 °C overnight. A bright-line 
haemocytometer was used to determine the cell count per ml by pipetting 10 µl of 
glutaraldehyde-fixed trophozoites at room temperature (rt.) onto the counting grid and allowing 












Saponin Lysis, PBS 
centrifugation and 
aspiration 
Inoculated iRBCs  
(after 30-32 hrs incubation) 
5 % parasitaemia and 2% 
haematocrit 
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Figure 2-6: Haemocytometer counting grid containing glutaraldehyde-fixed isolated 
trophozoites (red box). 
 
A minimum of 5 blocks were counted to calculate the number of viable cells per ml in each 









(') = haemocytometer cell counts per ml in a single well 
TCC = total cells counted 
TBC = total blocks counted 
DF = dilution factor (10000) 
 
Multiples of the test compound IC50 values were individually counted and calculated in order 
of increasing dosage including the control (no inhibitor present).  
 
For confirmation of haemocytometer counts, cell viability and number of cells per ml in each 
well were analysed with flow cytometry using a method previously described by Combrinck 
et al 263. In 5 ml Trucount™ tubes, 100 µl of the glutaraldehyde-fixed trophozoite solution was 
pipetted into an 800 µl solution of 0.22 µm filtered PBS containing 0.01% SYBR green® I 
(DNA binding fluorescent dye) spiked with 100 µl of fluorescent trucount beads. Samples were 
analyzed further on a BD FACSCalibur™ with CellQuestPro software (Figure 2-7). 
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Figure 2-7: A dot plot of side scatter (complexity of cells, SSC) versus the SYBR green® I 
fluorescent intensity detected on the FL1 detector. Displayed are the predetermined gates for 
the populations of; a) trucount beads, b) isolated stained trophozoite population fixed with 
glutaraldehyde after staining with DNA binding fluorescent dye, SYBR green® I and c) ring 
and PBS debris. 
 
The cell count, relative to fluorescent trucount beads, was used to calculate the concentration 
of cells per ml in a single well from the number of gated stained trophozoites, gated fluorescent 
beads and concentration of fluorescent beads per ml provided by the supplier on each package 





	× CFB                                  Eq. 2 
 
Where: 
Cc = cell concentration per ml 
GST = number of gated stained trophozoites 
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CFB = concentration of fluorescent beads per ml 
 
2.5.3.4 Solvent-mediated plate method for fractionation of haem species 
 
Fraction 1: Undigested haemoglobin fraction 
 
After 24 hrs, the 96-well round bottom stock plate was removed from the freezer (-80 °C) and 
left to thaw for 30 min at rt. To the stock solutions, 50 µl of d.H2O was added and sonicated 
for 5 min. An additional 50 µl of d.H2O was added with 50 µl of 0.2 M HEPES (pH 7.5) and 
centrifuged for 30 min at 3600 rpm. The resulting supernatant was carefully pipetted, on the 
same plate, into the corresponding adjacent empty wells. To the supernatant, 50 µl of 4% SDS 
was added and the plate was sonicated for 5 min. Before adding 50 µl of 0.3M NaCl, 25% 
pyridine and 100 µl of d.H2O, the plate was left to incubate at room temperature for 30 min. 
The fraction 1 solution was transferred to a flat bottom 96-well plate (200 µl) where the 
solutions were re-sonicated before recording the absorbance for the range 350-800 nm 
(SpectraMax 340PC plate reader) (Figure 2-8 a). The absorbance was used to determine the 
fraction of haemoglobin in a cell 263.  
 
Fraction 2: Exchangeable haem 
 
To the remaining pellet in the stock plate, 50 µl of d.H2O and 4% SDS was added and mixed 
well by sonicating the plate for 5 min to ensure complete dissolution of exchangeable haem. 
For 30 min the solution was incubated at 37 °C prior to adding 50 µl of 0.2 M HEPES (pH 
7.5), 0.3 M NaCl and 25% pyridine. The solution was centrifuged at 3600 rpm for 30 min. To 
the resulting supernatant, 150 µl of d.H2O was added and mixed using a micro-multichannel 
pipette. The diluted solution was aliquoted into a 96-well flat bottom plate and 
spectroscopically assayed, using a SpectraMax 340PC plate reader (350-800 nm), to determine 
the fraction of exchangeable haem (Figure 2-8 b) 263.  
 
Fraction 3: Haemozoin fraction 
 
To the final pellet, 50 µl of d.H2O and 0.3 M NaOH, to dissolve the haemozoin fraction, was 
added followed by 30 min of sonication. A colour change was observed from a clear to green 
solution showing the dissolution of haemozoin crystals present in the isolated pellet. To the 
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green solution, 50 µl of 0.2 M HEPES (pH 7.5), 0.3 M HCl to neutralize the solution and 25% 
pyridine was added before diluting with 150 µl of d.H2O. Aliquots of 200 µl were transferred 
into a 96-well flat bottom plate and the absorbance was recorded from 350-800 nm 
(SpectraMax 340PC plate reader) to determine the fraction of the Fe(III)PPIX-pyridine 


















Figure 2-8: Solvent-mediated plate method for fractionation of haem species where 
Fe(III)PPIX-pyridine complex absorbance spectra represent a) fraction 1: undigested 
haemoglobin (methaemoglobin), b) fraction 2: exchangeable haem and c) fraction 3: 
haemozoin, present in P. falciparum isolated trophozoites (in the case shown, untreated). This 
was adapted and modified from Combrinck et al 263. 
 
2.5.3.5 Standard ferrihaem curve 
 
A haem standard curve was constructed to determine the total amount of haem in fractionated 
samples using a 30 µM prepared solution of porcine haematin in 0.3 M NaOH. Briefly, in a 
96-well plate, 80 µl of 0.3 M NaOH was added to column 1 as a blank. In the next 6 wells, 80 
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following solvent; 0.2 M HEPES (pH 7.5), 4% SDS, 0.3 M NaCl, 0.3 M HCl and 25% pyridine 
in HEPES and diluting each well to a final well volume of 400 µl with d.H2O. All wells were 
mixed using a micro-multichannel pipette before spectroscopically assaying the plate at 405 
nm (1 cm pathlength). GraphPad Prism v8.2.1 was used to plot the absorbance of haematin 
versus haematin concentration to determine the molar extinction coefficient of haematin as a 
Fe(III)PPIX-pyridine complex (Figure 2-9) 263. The molar extinction coefficient determined 
(93,726 ± 2221 M-1 cm-1) was in close agreement with the value previously reported by 
Asakura et al. This value was used as a reference when calculating the amount of haem per cell 
expressed as femtograms (fg) of Fe in each fractionated sample (untreated or treated samples) 
which was determined by dividing the total haem (expressed as Fe mass) by the total 













Figure 2-9: The standard curve for the absorbance of haematin at 405 nm at increasing 
concentrations of haematin, analysed as a Fe(III)PPIX-pyridine complex. The standard curve 
represents a fit to the mean ± SD for data points obtained from four different experiments. A 
linear regression analysis was performed using GraphPad Prism v8.2.1 to yield a correlation 
coefficient, R2 = 0.9979. 
 
2.5.4 Inoculum effect analysis 
 
The inoculum effect analysis was carried out using a modified p-LDH method previously 
described by Makler et al 344. When preparing for the experiment, test compound stock 
solutions were thawed in a 37 °C water bath before diluting to a known starting concentration 
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in complete medium. In brief, test compound solutions were serially diluted in columns 3-12 
in complete medium, resulting in a DMSO concentration of less than 0.5% (1:2 dilution). All 
test compounds were tested in triplicate, adjacent to the positive control CQ. Column 1 
(negative control), contained solely RBCs that were diluted to a final haematocrit of 2%. The 
positive control (column 2) contained iRBCs in complete medium that were diluted to a 2% 
haematocrit and varying parasitaemia (1 - 5%). 100 µl of the same solution was then transferred 
to columns 3-12 on the same plate. The parasitaemia was varied according to the inoculum size 
which ranged from 1-10 which is equivalent to 0.0001-0.001 fractional volume of an iRBC. 
The plates were covered and sealed in a sterile gassing chamber before gassing with 3% O2, 
4% CO2 and N2. Plates were incubated in a 37 °C incubator for 48 hrs.  
After 48 hrs, the plates were frozen at -20 °C prior to thawing the lysed trophozoite 
containing plate to facilitate the rupturing of parasite membranes. The plates were developed 
by resuspending 15 µl of the lysed trophozoite pellet in 100 µl of Malstat™ and left to stand 
for 30 min at rt. before adding 25 µl of NBT. The measured absorbance (Modulus™ Microplate 
Multimode Reader, Turner Biosystems), was recorded at 620 nm and the varying IC50 (NF54) 
values were calculated from the sigmoidal dose-dependent curves plotted using GraphPad 
Prism v8.2.1 software. 
Thereafter, individual experimental CAR values were calculated from a linear plot of 
IC50(NF54) concentrations plotted as a function of their corresponding inoculum size. Based 
on the IC50 value at each inoculum size, absolute IC50 and fractional volume of an iRBC 
(FViRBC) the experimental CAR values were calculated using a modified equation adapted from 




                                Eq. 5 
 
Which can be rearranged to: 
  
ICKY(NF54) = 	 {ICKY	(absolute) × Experimental	CAR} ×	FVqr2! + ICKY	(absolute) 
Where a plot of IC50 values versus FViRBC is a straight line with; 
 
Slope = 	 ICKY	(absolute) × Experimental	CAR 
 
And, 
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Intercept	(y	axis) = 	 ICKY	(absolute) 
 
From which the experimental CAR value can be directly calculated from the linear plot as 
follows (Eq. 6); 
 
Experimental	CAR	value = 	 /#Px"
qyR"z{"xR
	× 	10000                                        Eq. 6 
                                                                 








                              Eq. 7 
 
2.5.5 Total intracellular test compound amounts 
 
The total intracellular test compound amounts per cell were based on the product of 
experimental CAR values, volume of a RBC and IC50(NF54) values for each individual test 




		         Eq. 8 
 
Where:  
CAR = experimental CAR value 
VRBC = volume of a RBC (84.3 ± 5.7 fL) 350 
IC50 (NF54) = 50% inhibitory concentration (µM) at inoculum size 4 
 
2.5.6 Propagation of errors 
 
The standard deviation for all calculations were calculated using the propagation of error 
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3.1 Introduction 
 
Well-known β-haematin inhibitors, CQ and AQ to name two, are known to target and inhibit 
the formation of haemozoin which was evident from decreasing haemozoin amounts, variable 
increases in exchangeable haem amounts which have been shown to be detrimental to parasite 
growth 263,296,334-338,351. With the recent emergence of CQ resistance, as discussed in Chapter 1, 
a HTS search for new hit compounds uncovered hundreds of new successful β-haematin 
inhibitors that may inhibit haemozoin formation have been discovered from the HTS approach 
method. However, the exact understanding as to how they achieve this in P. falciparum 
parasites is still unclear 143-144,238,262,352-353.  
Various investigations have been carried out in the efforts to better understand the 
mechanism by which CQ and other potential β-haematin inhibitors inhibit parasite growth and 
haemozoin formation. Ncokazi and Egan developed a simplified method to determine β-
haematin inhibition which was cheap, reliable and fast. This method, based on a well-known 
method commonly known as the ferrihemochrome method (Phiβ), had, however, hardly been 
used in the study of β-haematin and haemozoin. Limitations to this method included the use of 
β-haematin inhibitors with poor water solubility. Nevertheless, they were able to show a 
correlation between β-haematin inhibition and parasite growth inhibition 262. This was in 
agreement with the findings of Kashula et al, whose studies had investigated SARs for 
quinoline-containing compounds. With specific reference to CQ, they were able to show that 
the 4-aminoquinoline nucleus and 7-chloro group were important for β-haematin inhibition as 
well as parasite growth inhibition 261. Recently, it has also been shown that a group of 
benzimidazole-containing β-haematin inhibitors inhibit haemozoin formation and this was 
suggested to be vital for parasite growth inhibition activity. For these β-haematin inhibitors, 
their parasite growth inhibition activity was observed to be influenced by the β-haematin 
inhibition activity and number of hydrogen bond donors 335. 
Recently, studies have shown that CQ and other β-haematin inhibitors also target 
membrane-associated haem, causing a build-up of toxic exchangeable haem inside the 
parasite’s DV, resulting in significant reductions in parasite growth 242,293,354.  Studies by 
Combrinck et al and Fong et al have both shown direct evidence of decreasing haemozoin Fe 
percentages which coincided with increasing exchangeable Fe percentages which have been 
thought to be the cause of subsequent parasite death for various β-haematin inhibitors 263,354. 
In the end, these studies showed that the reliability of using percentage haem values was 
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questionable and emphasized the importance of utilizing haem amounts conveniently 
expressed as haem Fe mass per cell values instead. It has also been shown for other β-haematin 
inhibitors, a group of benzamides and triarylimidazole β-haematin inhibitors, that haemozoin 
formation was inhibited in a dose-dependent manner causing increasing amounts of 
exchangeable haem that coincided with decreasing parasite growth 334,338. 
Reports have also suggested that the mechanism by which these β-haematin inhibitors 
inhibit the formation of haemozoin is dependent on their ability to accumulate in the parasite. 
Fitch et al suggested that the selective mechanism for accumulation of CQ to accumulate in 
iRBCs more than RBCs was due to the binding of CQ to a certain receptor that was unique to 
the parasite which they later claimed to be haem from the digestion of haemoglobin 203,279,355. 
It was also suggested to be as a result of a CQ readily forming a complex with haematin 
251,296,356. To quantify this accumulation, Yayon et al and Krogstad et al showed with the use 
of fluorescent probes and labelling procedures that CQ tends to accumulate in the parasite and 
inhibit parasite growth by raising the pH of the parasite DV 127,128,196,204. In addition, Yayon et 
al specifically provided evidence that transmembrane proton gradients play a role in the 
accumulation of β-haematin inhibitors in the parasite DV 196. Alternatively, the cellular 
accumulation ratio for a group of β-haematin-inhibiting benzamides known to inhibit the 
formation of haemozoin were determined by Wicht et al. An inoculum effect analysis was used 
to show that a linear relationship between IC50 values and inoculum sizes exists 334. With close 
agreement with Hawley et al and Warhurst et al, the cellular accumulation ratios of these β-
haematin inhibitors were suggested to be influenced by their basicity which facilitated their 
ability to accumulate by the process of pH trapping 269,357-358.  
In this chapter, ten selected β-haematin inhibiting compounds were selected for 
investigation from five different structural scaffolds and their derivatives, for which the 
synthesis and parasite growth inhibition activity of which have been previously reported 263,334-
338. This was to ascertain their effectiveness in inhibiting P. falciparum CQS NF54 strain 
parasite growth and subsequent ability to interfere with the haemozoin formation pathway from 
accumulating in iRBCs.  
Firstly, a modified antiplasmodial assay, described in Chapter 2, was applied to these test 
compounds, as well as CQ (as a positive control for comparative reasons) 344. Decreasing 
parasite growth at micromolar concentrations was observed and was in agreement with 
previously reported data 263,334-335,354. 
Secondly, a pyridine-based parasite haem fractionation plate method that was modified from a 
previously established method, was used to quantitatively determine the effects of these test 
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compounds on haemozoin formation in parasites. In P. falciparum CQS parasites, this 
colorimetric measurement of haem species involved isolating trophozoites treated with 
increasing parasite growth inhibitory concentrations (0.5, 1.0, 2.0, 2.5 and 3.0 × IC50) for each 
test compound. Next, the resulting fractionated haem species (undigested haemoglobin, 
exchangeable haem and haemozoin) were further analysed as Fe(III)PPIX-pyridine complexes, 
formed as a result of haem complexation with aqueous pyridine (5% v/v pH 7.5) to produce a 
low-spin state complex, which can be spectroscopically measured at 405 nm 263. The resulting 
observations provided insight into the behaviour of these test compounds and clearly showed 
similar effects on haem species in the parasite to other test compounds; AQ, benzamides and 
triarylimidazoles 263,334,338. Sigmoidal profiles of parasite growth inhibition activity and 
exchangeable haem amounts as a function of increasing concentrations for each test compound 
proved to be inversely correlated. Specifically, decreasing percentage parasite growth 
corresponded to increasing exchangeable haem amounts present in the parasite. In spite of this, 
the relationship does not explain how parasite growth inhibition activity is related to the amount 
of exchangeable haem which varies between different test compounds. Consequently, the 
relationship between varying exchangeable haem amounts with parasite growth inhibition 
activities was explored by constructing a bar plot of the parasite growth inhibition activity with 
exchangeable haem amounts for all test compounds investigated in this chapter. Additionally, 
test compounds (10, 11 and AQ) investigated in D10 strain parasites were also included for 
comparison 263,334-338. Observations provided evidence that parasite growth inhibition activities 
generally corresponded to equivalent amounts of exchangeable haem present in the parasites 
for all test compounds. 
To better understand the mechanism by which these test compounds in this study result 
in the inhibition of parasite growth and haemozoin formation, investigations into their ability 
to accumulate in P. falciparum parasites were experimentally determined in CQS (NF54) 
parasites using a modified inoculum effect analysis 268-269,357,359-360. Briefly, a modified p-LDH 
assay was used to determine the IC50 (NF54) values of these test compounds at increasing 
inoculum sizes. This was done by focusing on their accumulation in iRBCs, where, the 
parasitaemia was varied between 1-5% for the individual inoculum size of 1-10 while the 
haematocrit was kept at a constant of 2%. A linear correlation analysis was performed where 
the IC50 (NF54) values were plotted as a function of increasing inoculum sizes. From the 
extrapolation of this linear correlation, the absolute IC50 (y-intercept). From this linear 
correlation, the experimental CAR values, using a modified version of a previously reported 
equation, were calculated from the slope and y-intercept which takes into account the IC50 
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(NF54) values at each inoculum size, absolute IC50 values and fractional volume of an iRBC 
as described in Chapter 2. 
Further investigations were carried out to explore the relationship between experimental 
CAR values and exchangeable haem amounts as a result of these test compounds, at their IC50 
value. A linear correlation plot was constructed by firstly converting the experimental CAR 
values into their total intracellular test compound amounts for all test compounds which was 
based on the product of the experimental CAR values, IC50 (NF54) values at an inoculum size 
of 4 and volume of a RBC under standard test conditions. From this, the individual total 
intracellular test compound amounts, expressed in fmols per cell, was plotted as a function of 
exchangeable haem amounts at each test compound IC50 value. Intriguingly, this plot showed 
a 1:1 relationship between the total intracellular test compound amounts and exchangeable 
haem amounts which provided further evidence for understanding the behaviour of these test 
compounds.  
Therefore, this chapter provides effective and reliable methods that contribute to the 
understanding of the mechanism of action of various β-haematin inhibiting test compounds in 
P. falciparum parasites. Included, is a clear outline that the investigated test compounds inhibit 
parasite growth and haemozoin formation by causing variable exchangeable haem amounts 
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Throughout this chapter, all commercially purchased materials were of AR grade or higher and 
used without further purification unless specified below. All general materials that were used 
throughout this study are detailed in Chapter 2. Haem-containing glassware was cleaned by 








The software used to analyse and constructing of graphs for parasite growth inhibition 
activities, fractionated haem species profiles, experimental CAR values and total intracellular 
test compound amounts is described in detail in Chapter 2.  
 
3.2.4 Preparation of samples and solutions 
 














Chapter 3: Measuring intracellular haemozoin inhibition in P. falciparum parasites in the presence of 
accumulating β-haematin inhibiting test compounds 
Roxanne Openshaw-January 2020 87 
3.3 Results and Discussion 
 
3.3.1 Parasite growth inhibition of P. falciparum cultures 
 
A modified antiplasmodial assay (p-LDH), described previously in Chapter 2 (see Section 
2.5.2), was used to determine the parasite growth inhibition activity in CQS NF54 cultures for 
ten selected test compounds including CQ. Test compound 11 and AQ were included for 













Figure 3-1: Parasite growth inhibition curves (mean ± SD) for test compound 1 (blue) and CQ 
(green) in NF54 strain cultures, generated using GraphPad Prism v8.2.1. All sigmoidal dose 
response curves were plotted using a non-linear regression function. The dotted line indicates 
the crossing point at which 50% of parasites are viable. 
 
A typical sigmoidal dose response curve is shown in Figure 3-1 for test compound 1, showing 
a decrease in the percentage parasite growth at increasing concentrations of test compound 1 
(blue). From this sigmoidal dose response curve, the resulting mean IC50 (NF54) value for test 
compound 1 was calculated to be 0.620 ± 0.005 µM. A parasite growth inhibition curve is also 
shown for CQ (green) at a lower starting concentration than test compound 1 with a mean IC50 
(NF54) value of 0.0170 ± 0.0009 µM. This IC50 value was in the laboratory reference range 
and in close agreement with Combrinck et al and L’abbate et al who previously reported IC50 
values of 0.019 ± 0.003 µM and 0.016 ± 0.006 µM for CQ, in CQS D10 and NF54 cultures 
respectively 263,335. Dose response curves were plotted for the remaining test compounds (2-
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10), see Figure 3-2 for the structures, and showed a range of IC50 values with a benzimidazole-
containing test compound (4) having the lowest parasite growth inhibition activity (8.5 ± 3 
µM). For comparison, test compound 11 and AQ were included and had previously reported 
IC50 values of 0.6 ± 0.1 µM and 0.022 ± 0.003 µM respectively 334. Test compound 11 resulted 
in an IC50 value that was in the micromolar range, close to the IC50 value for test compound 1 
whereas, AQ resulted in a similar IC50 value to CQ in the nanomolar range. The observed mean 
























Figure 3-2: The molecular structures, as presented in Chapter 2, for the test compounds (1-10) 
investigated in this study along with previously reported test compounds 11 and AQ. 
 
1 2 3 4 
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Table 3-1: The mean IC50 (NF54) values and SD for parasite growth inhibition of ten β-
haematin inhibiting test compounds and CQ including test compound 11 and AQ, were 
determined using the p-LDH assay previously described by Makler et al 344. All test compound 

















A drawback when performing parasite growth inhibition measurements with test compounds 
that show low water solubility is the large error values in both parasite growth inhibition curves 
and corresponding IC50 values. Low solubility was observed for low parasite growth inhibition 
activity test compounds (4 and 9) where experimental conditions had to be modified. The 
modified experimental conditions involved maintaining all sample and assay solutions at 
physiological temperature (37 °C) to ensure complete dissolution prior to performing the 
experiment.  
Parasite growth inhibition activities for the individual test compounds, listed in Table 3-
1, were required for subsequent use in the pyridine-based parasite haem fractionation plate 
method. These IC50 (NF54) values were used to determine different multiples of the inhibitory 
concentrations (0.5, 1.0, 2.0, 2.5 and 3.0 × IC50) for each test compounds needed to inoculate 
CQS P. falciparum cultures. The results for the inhibition of haemozoin formation in the 
presence of these test compounds are discussed in detail in the section that follows. 
 
Test compound Mean IC50 value (NF54) ± SD (µM) 
1 0.620 ± 0.005 
2 1.3 ± 0.09 
3 1.7 ± 0.3 
4 8.5 ± 3 
5 0.19 ± 0.002 
6 0.23 ± 0.008 
7 0.26 ± 0.003 
8 1.4 ± 0.04 
9 7.4 ± 0.07 
10 1.6 ± 0.0002 
11 7 0.6 ± 0.1 
AQ 7 0.022 ± 0.003 
CQ 0.017 ± 0.0009 
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3.3.2. Effects of β-haematin inhibiting test compounds on parasite haem species 
 
To determine the effect of individual test compounds on the haem amounts per cell (expressed 
as fg Fe per cell) for undigested haemoglobin, exchangeable haem and haemozoin in P. 
falciparum cultures, a pyridine-based parasite haem fractionation plate method, previously 
described in Chapter 2 (see Section 2.5.3), was used 263. Briefly, test compounds were tested 
in highly synchronous CQS NF54 strain cultures that were diluted to a 2% haematocrit and 5% 
parasitemia. Cultures were inoculated at the immature ring stage and incubated for a period of 
30-32 hrs. After the incubation period, saponin lysis of mature trophozoites was carried out 
before exposing the isolated trophozoites to a number of solvent mediated fractionation steps. 
The resulting fractionated haem species were spectroscopically assayed further as a 
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Figure 3-3: Fractionated haem species profiles for i) test compound 1 (blue) and ii) positive 
control, CQ (green), in synchronous CQS P. falciparum cultures. The above profiles represent 
the mass of haem Fe per cell (fg) that is attributed to (a) and (d) exchangeable haem, and (b) 
and (e) haemozoin. The percentage parasite growth inhibition curve (red) and exchangeable 
haem (fmol per cell) (black) profiles overlaid at increasing concentration for (c) test compound 
1 and (f) CQ are shown above. Statistical significance was determined using a two-tailed t-test 
and is indicated by the asterisks, relative to the control (red) at the 95% CI, where; * p = <0.05; 
** p = <0.01 and *** p = <0.001 etc. 
 
The effect of a benzimidazole β-haematin inhibiting test compound (1), in comparison to CQ, 
was investigated at increasing multiples of the IC50 values. In each case, a control (red) was 
included, which comprised of untreated iRBCs for determination of statistical significance. In 
Figure 3-3 a and d, both test compound 1 and CQ showed a dose-dependent increase in 
a.  b.  
i. Test compound 1 
c.  
ii. CQ 
d.  e.  f.  
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exchangeable haem which was significant from 0.5 × IC50 to 3.0 × IC50. Test compound 1 
showed a 7-fold increase in the amount of haem Fe attributed to exchangeable haem with 51 
fg per cell at 3.0 × IC50, in comparison to a 2-fold increase for CQ. An accompanying decrease 
in the amount of haemozoin haem Fe per cell (Figure 3-3 b and e), was observed at increasing 
concentrations of test compound 1 or CQ, but with a 4-fold greater decrease for test compound 
1 compared to CQ. The highest concentration at which parasites could be inoculated was 
observed to be 3.0 × IC50 due to difficulties experienced when fractionating the haem species. 
This was due to a reduction in the number of cells at a concentration above 3.0 × IC50 which 
also decreased the reliability of the total haem Fe per cell readings and, especially for 
exchangeable haem and haemozoin.  
Figure 3-3 c and f show an inversely proportional relationship between the percentage 
parasite growth inhibition and the amount of haem Fe per cell associated to exchangeable haem 
(fmol) when plotted as a function of increasing concentrations of test compound 1 and CQ 
respectively. Thus, a decrease in the percentage parasite growth corresponded to an increase in 
the exchangeable haem amounts in the presence of test compound 1 and CQ. In more detail, at 
the IC50 value for test compound 1 or CQ exchangeable haem amounts of 0.23 fmol and 0.15 
fmol per cell respectively corresponded to 50% of parasite still viable showing a clear inversely 
proportional relationship. This was in close agreement with previous reports 263. 
These results showed a clear relationship between percentage decreased parasite growth 
and exchangeable haem amounts. Finally, the results for test compound 1 strongly suggest that 
this benzimidazole-containing test compound acts by inhibiting the formation of haemozoin 
which is similar to that observed for CQ.  
 
Next, the pyridine-based parasite haem fractionation plate method was applied to eight other 
test compounds (2-9) to determine if they act similarly to test compound 1 by inhibiting the 
formation of haemozoin. These are listed in Table 3-1. All remaining test compounds, 
excluding test compound 10, were measured at increasing multiples of their individually 
determined IC50 values (0.5, 1.0, 2.0, 2.5, 3.0 × IC50). Test compound 10 was excluded as the 
pyridine-based parasite haem fractionation data has been previously reported by Wicht et al 
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i. Test compound 2 
a. b. c. 
ii. Test compound 3 
d. e. f. 
iii. Test compound 4 
g. h. i. 
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iv. Test compound 5 
j. k. l. 
v. Test compound 6 
m. n. o. 
vi. Test compound 7 
p. q. r. 
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Figure 3-4: Profiles for fractionated haem species for test compounds 2-9 in synchronous CQS 
P. falciparum cultures. The profiles a, d, g, j, m, p, s and v) represent the mass of haem Fe per 
cell (fg) that is attributed to exchangeable haem and b, e, h, k, n, q, t and w) haemozoin haem 
Fe per cell relative a control (red). The overlaid sigmoidal profiles c, f, i, l, o, r, u and x) 
represent percentage parasite growth inhibition (red) and exchangeable haem (fmol per cell) 
(black) at increasing concentration for test compounds 2-9. Statistical significance was 
determined using a two-tailed t-test and is indicated by the asterisks, relative to the control 
(95% CI), where; * p = <0.05; ** p = <0.01 and *** p = <0.001 etc. 
vii. Test compound 8 
s. t. u. 
viii. Test compound 9 
w. x. 
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A dose-dependent increase in the amount of exchangeable haem (Figure 3-4 a, d, g, j, m, p, s 
and v) for all test compounds (2-9), relative to the control was observed and similar to that 
observed for test compound 1. More specifically, test compounds 2, 3 and 4 showed significant 
increases from 0.5 to 3.0 × IC50 relative to the control which were similar but lower than test 
compound 1. Test compounds 5, 6 and 7 showed relatively small increases in exchangeable 
haem amounts compared to the remaining test compounds, demonstrating increases 
comparable to that of CQ. One specific test compound, test compound 7 showed significant 
increases from 0.5 to 3.0 × IC50 but resulted in the lowest amount of exchangeable haem 
compared to the remaining test compounds.  
The haemozoin haem Fe profiles (Figure 3-4 b, e, h, k, n, q, t and w) for most of the test 
compounds showed greater dose-dependent decreases in the amount of haemozoin than test 
compound 1 with the exception of test compounds 5 and 7. Test compound 4 showed a 
significant decrease in haemozoin from 0.5 to 3.0 × IC50, however, at concentrations higher 
than 3.0 × IC50, solubility difficulties were experienced, making it difficult to obtain reliable 
results. In the case of test compounds 5 and 7, small decreases in haemozoin from 91 fg per 
cell in the control to an average of 60 fg per cell at 3 × IC50 for both were observed. These 
results resembled decreases in the amount of observed for CQ. This could possibly suggest that 
test compounds 5 and 7 could have more than one mode of action. There is a widely accepted 
theory that quinoline-containing compounds like CQ inhibit the formation of haemozoin but 
could also result in the inhibition of protein synthesis and the activity of proteases inside the 
parasite DV which could explain the observed modest decreases in haemozoin amounts for test 
compound 5 and 7 361-362.  
Unexpectedly for the second least active test compound (9), 60 fg per cell of 
exchangeable haem was observed at the 1.0 × IC50 dosage and the most significant decrease in 
haemozoin (68 fg per cell) was observed. Despite the results observed for test compound 9, 
solubility difficulties were encountered which made it difficult to obtain reliable results. Along 
with these observations, Giemsa smear microscope images were obtained for both untreated 
iRBCs (Figure 3-5 a) and test compound 9-treated iRBCs (Figure 3-5 b). In Figure 3-5 b, 
evidence of an unprecedented total absence of haemozoin crystals in the parasites DV 
compared to untreated iRBCs was observed. This was not the case for test compounds 1-8 and 
CQ. At this point, test compound 9 could be considered to be more of an effective haemozoin 
inhibitor than the remaining test compounds including test compound 1. 
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Figure 3-5: Giemsa stained microscope images of treated CQS NF54 parasites, showing a) 
untreated iRBCs (red arrows) and b) test compound 9-treated iRBCs at the IC50 value. Empty 
parasite DVs are indicated by the red arrows in b.  
 
The parasite growth inhibition curves overlaid with the exchangeable haem (fmol Fe per cell) 
as a function of increasing concentrations for the individual test compounds, in Figure 3-4 c, 
f, i, l, o, r, u and x  showed that with increasing amounts of exchangeable haem Fe present in 
the parasites there is a corresponding decrease in the percentage parasite growth. Similar to test 
compound 1, exchangeable haem amounts at the IC50 value for each test compound (2-9) ,with 
the exception of test compounds 5, 6 and 7, corresponded to 50% parasites still viable. For test 
compounds 5, 6 and 7, exchangeable haem amounts at the IC50 value was observed to cross the 
percentage parasite growth inhibition at a much lower percentage of parasites still viable. 
This pyridine-based parasite haem fractionation plate method proved to be a reliable and 
efficient method for determining whether these β-haematin inhibiting test compounds, like CQ, 
inhibit the formation of haemozoin. These results strongly suggest that these test compounds, 
from a range of scaffolds, act by inhibiting the formation of haemozoin. What is also clear, is 
that parasite growth inhibition activity does not occur at a single given amount of exchangeable 
haem in the parasite. Indeed the observations with test compound 9, emphasize this.  
 
3.3.3 Relationship between parasite growth inhibition activity and exchangeable haem 
amounts. 
 
Given the observations in Section 3.3.2, a key question was whether parasite growth inhibition 
activity is related to the amount of exchangeable haem in the parasite. For this reason, the mean 
IC50 value of each test compound (1-9) was plotted next to the amount of exchangeable haem 
expressed in fmol Fe per cell at its IC50 value. Previously reported haem species data for test 
a. b. 
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compounds 10, 11 and AQ was included in the plot below for comparison to the test compounds 
investigated in this study.  
 
Figure 3-6: Bar plot of mean IC50 value (red) and corresponding amount of exchangeable haem 
in fmol per cell (black) present in treated CQS P. falciparum isolated trophozoites for all 
compounds (1-9) tested including test compound 10, 11, AQ and CQ in order of increasing 
IC50 values.  
 
A bar plot for the full series of test compounds (1-9) investigated in order of increasing IC50 
values in this chapter, including CQ and comparative test compounds 10, 11 and AQ is shown 
in Figure 3-6. A rough trend of increasing IC50 values (decreasing parasite growth inhibition 
activity) with corresponding increased amounts of exchangeable haem at the individual IC50 
value for all test compounds was observed.  
In more detail, test compounds with lower IC50 values, like test compound 5, resulted in 
smaller amounts of exchangeable haem whereas test compounds with higher IC50 values, like 
test compound 4, resulted in higher amounts of exchangeable haem. On the other hand, test 
compounds 5, 6 and 7 showed higher IC50 values that corresponded to lower amounts of 
exchangeable haem, opposite to similar quinoline-containing test compounds CQ and AQ in 
which lower IC50 values corresponding to significantly higher amounts of exchangeable haem 
present in the parasite. 
Lastly, previously published test compounds (10, 11 and AQ) that were investigated in 
other CQS P. falciparum strains (D10 and NF54 respectively) were included for comparative 
reasons (Figure 3-6) 334,338. These test compounds too conformed to this trend of increasing 
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IC50 value with corresponding increasing amounts of exchangeable haem present in parasites, 
therefore further suggesting that this trend is genuine, even if not statistically significant. 
 
3.3.4 Inoculum effect analysis 
 
From the observed results in Section 3.3.1-3.3.3 above, the ability of these test compounds to 
accumulate in iRBCs was investigated, excluding test compound 4 and 9 due to previously 
mentioned solubility difficulties with the solubility of these test compounds. This was carried 
out by measuring the experimental CAR values in CQS NF54 strain parasites using the 
inoculum effect analysis. As discussed in Chapter 1, cellular accumulation can be determined 
from the linear relationship of decreasing parasite growth inhibition activity (increasing IC50 
values) with increasing numbers of inoculated parasites 269,361. According to previous reports 
by Hawley et al, Bray et al and Brook et al, this linear relationship of increasing IC50 values 
can be further explained by the decreasing concentration of test compound in the extracellular 
complete medium as an increasing concentration of test compound is taken up by parasites 
269,283,359. This increasing number of inoculated parasites can be defined by what is known to 
be an inoculum size, where each inoculum size is a product of the varying percentages of 
parasitaemia and haematocrit. As outlined in Chapter 2 (see Section 2.5.4), to ensure that the 
optimal amount of these test compounds is taken up solely by iRBCs, the parasitaemia was 
varied (1-5%) at a constant haematocrit (2%) throughout this study. 
Secondly, the experimental CAR values were determined from this linear relationship 
using a modified equation, shown in Section 2.5.4 (Eq. 6), which takes into account the IC50 
values at each inoculum size, absolute IC50 values and the fractional volume of an iRBC 269,363. 
In more detail, the absolute IC50 value (test compound IC50 value at the limit of infinite dilution 
of iRBCs) was predicted from the extrapolation of this linear relationship to an inoculum size 
of zero (y-intercept). The fractional volume of an iRBC can be calculated from the division of 
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Figure 3-7: Linear relationship plots for the inoculum effect analysis in CQS (NF54) strain 
parasites for (a). test compound 1 (blue), (b) test compound 5 (orange), (c) test compound 8 
(pink) and (d) test compound 10 (red) that resulted in experimental CAR values of  5305 ± 
1079, 1757 ± 242, 1599 ± 552 and 479 ± 223 respectively. A linear regression function, using 
GraphPad Prism v8.2.1, was used to fit the above curves resulting in correlation coefficients, 
R2 = 0.9466 ,R2 = 0.9524 ,R2 = 0.6974 and R2 = 0.4489 respectively. Each inoculum size was 
tested in triplicate. 
 
Figure 3-7 a-d illustrates the linear relationship plots for the inoculum effect analysis for four 
test compounds (1, 5, 8 and 10). For all these test compounds,  a general trend of increasing 
inoculum size corresponded to increasing IC50 values. This agreed with previous observations 
by Hawley et al, Wicht et al and O’Neill et al with similarly behaving test compounds 269,334,363.  
Test compound 1 showed a more significant increase in IC50 value of 3-fold (R2 = 0.9466) in 
the micromolar range (Figure 3-7 a) over the range measured compared to a 2-fold increase 
for test compound 5, 8 and 10. It was also observed, specifically for test compound 8 and 10 
that there were much lower increases in IC50 values (R2 = 0.6974 and R2 = 0.4489 respectively). 
a. b. 
c. d. 
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The remaining test compounds (test compound 2-3 and 6-7) showed similar increases in IC50 
values with increasing inoculum size where, test compound 3 specifically showed a 3-fold 
increase in IC50 value which was comparable to that of test compound 1.  
Certain limitations were noticed when using the p-LDH method to carry out the inoculum 
effect analysis which included: (1) unreliable IC50 values were found for the inoculum size 1 
and 10, where, for an inoculum size 1 there were too few parasites to give a strong enough 
reading. The opposite was observed for inoculum size 10, where a much reduced effect on the 
parasite growth due to the number of parasites being too low for the amount of test compound 
being too high which resulted in complications in obtaining reliable IC50 values; (2) the 
absolute IC50 values were observed to be highly dependent on how close the intercept was to 
zero, therefore, resulting in extremely high errors and experimental CAR values tending to 
infinity where the intercept was too low; (3) solubility difficulties were also encountered when 
performing this experiment, especially at the inoculum size 10, where test compounds would 
precipitate out of solution even after maintaining all solutions at physiological temperature (37 
°C). This is the reason why all test compounds that were investigated in this study, except for 
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Table 3-2: Experimental CAR values (mean ± SD) for all test compounds in CQS NF54 
trophozoite cultures, including previously reported test compounds 11, AQ and CQ. 
 
Test compound Experimental CAR value 
1 5305 ± 1079 
2 1912 ± 276 
3 2039 ± 757 
4 N/A 
5 1757 ± 242 
6 1823 ± 381 
7 1746 ± 206 
8 1599 ± 552 
9 N/A 
10 479 ± 223 
11 7 5934 ± 945 
AQ 7 98024 ± 15296 
CQ 7 105342 ± 3365 
                                              * N/A, could not be determined 
 
Illustrated in Table 3-2 are the experimental CAR values which were determined using the 
individual slope and y-intercept values (Eq. 6) from the inoculum effect analysis plot for each 
test compound (1-10), excluding test compounds 4 and 9. Previously reported test compounds 
(11, AQ and CQ) determined in CQS NF54 cultures were also included 334. Of the series of test 
compounds investigated, test compound 1 was observed to be about 5305 times more 
concentrated in iRBCs compared to the external at its IC50 value, the highest experimental CAR 
value of the test compounds measured in this study.  
Varying experimental CAR values for the remaining test compounds were observed, 
albeit, much lower than test compound 1. Indeed, a 3-fold decrease in the experimental CAR 
values was observed for the remaining test compounds, indicating that these test compounds 
would be expected to be much less concentrated in iRBCs. Test compound 10, a 
triarylimidazole derivative resulted in the lowest experimental CAR value of the series. This 
could be due to suggestions that have been previously published where, for triarylimidazole-
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containing test compounds like test compound 10, certain groups that allow for the 
coordination or hydrogen bonding with haem are lacking 338. 
On the other hand, comparing these test compounds to previously published test 
compounds 11, AQ and CQ, much lower experimental CAR values were observed, except for, 
the benzamide-containing test compound (11) which was similar to test compound 1. It was 
also assumed that quinoline derivatives (test compound 5, 6 and 7) would have experimental 
CAR values close to that of AQ and CQ, but this was not the case. AQ is known to accumulate 
more than CQ in parasites and this was not observed. The experimental CAR for AQ (98,024 
± 15,296) was lower than the experimental CAR value for CQ which was 105,342 ± 3,365 
which did not agree with results published by Hawley et al 269. However, Wicht et al and 
Krogstad et al have previously suggested that varying experimental CAR values could be as a 
result of differences in the pH ranges (4.8-5.0) of the parasite DV across different P. falciparum 
strains which could affect the experimental CAR values when considering the accumulation of 
these test compounds to be as a direct result of the mechanism of pH trapping 128,334. It has also 
been suggested that binding of quinolines, like CQ, to haem across different parasite strains 
may also be the reason for varying experimental CAR values as seen for CQ and AQ and the 
test compounds investigated here 208,356,364. 
Hence, with the variations observed in the experimental CAR values, it could be 
concluded that the mechanism by which these test compounds accumulate could be driven by 
pH trapping, even if pH trapping is a small contribution to this equilibrium process of 
accumulation in parasites 269. However, this lack of correlation could also suggest that the 
accumulation process of these test compound in CQS NF54 parasites is more complex than 
only pH trapping and would need further investigations. This was in agreement with the 
observations reported by Wicht et al 334. A leading candidate for accumulation could be that 
haem binding may be the primary cause for the amount to which these test compounds 
accumulate in the parasite, which is in agreement with previous reports 128,208,269,283,334.  
Therefore, the experimental CAR values for all test compounds, including test compound 
11, AQ and CQ, were converted into their individual total intracellular test compound amounts 
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3.3.5 Relationship of total intracellular test compound and exchangeable haem amounts 
present in CQS iRBCs. 
 
The total intracellular test compound amounts for all test compounds (1-10), excluding test 
compounds 4 and 9 were investigated. In brief, the intracellular test compound amounts (fmol 
per cell) were calculated based on the product of their experimental CAR values, IC50 values 
and the volume of an iRBC (see Section 2.5.5, Eq. 8). The values are listed in Table 3-3 where 
test compound 11, AQ and CQ were also included for comparative reasons.  
 
Table 3-3: Total intracellular test compound amounts per cell (mean ± SD) for all test 
compounds in NF54 cultures.  
 
Test compound Total intracellular test compound amount 
(fmol per cell) 
1 0.27 ± 0.06 
2 0.21 ± 0.04 
3 0.4 ± 0.2 
4 N/A 
5 0.028 ± 0.004 
6 0.037 ± 0.008 
7 0.042 ± 0.006 
8 0.20 ± 0.07 
9 N/A 
10 0.07 ± 0.03 
11 0.30 ± 0.07 
AQ 0.18 ± 0.03 
CQ 0.17 ± 0.01 
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Figure 3-8: Linear correlation plots of total intracellular test compound amount (fmol per cell) 
plotted as a function of the amount of exchangeable haem at the IC50 (fmol per cell) present in 
treated P. falciparum CQS (NF54) isolated trophozoites for (a) all test compounds excluding 
test compound 4 and 9, and (b) including comparative test compounds 11, AQ and CQ.  A 
linear regression analysis, using GraphPad Prism v8.2.1, was performed to fit the above curve 
resulting in a correlation coefficients (95% CI) of R2 = 0.7884 and R2 = 0.7055 respectively. 
 
Linear correlation plots were constructed where the individual exchangeable haem amounts 
were plotted as a function of total intracellular test compound amounts at the mean IC50 value 
for all test compounds excluding 4 and 9 (Figure 3-8 a) and including comparative test 
compounds 11, AQ and CQ (Figure 3-9 b).  
In Figure 3-8 a, an apparent 1:1 relationship was observed where for example test 
compound 1 (red square) was shown to have a moderate total intracellular test compound 
amount which corresponded to a moderate amount of exchangeable haem at its IC50 value 
present in each parasite and is indicated in the red square. This was true for the remaining test 
compounds and resulted in a correlation coefficient of R2 = 0.7884 (p = 0.0032). Interestingly, 
test compound 3, a relatively active test compound with a mean IC50 value of 1.7 ± 0.3 µM, 
showed the second highest amount of exchangeable haem in the parasite which related to the 
highest total intracellular test compound amount (blue). On the other extreme, more active test 
compounds like test compounds 5-7 (orange) resulted in very small amounts of exchangeable 
haem that corresponded to small total intracellular test compound amounts present in parasites.  
b. a. 
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Finally, in an effort to establish whether or not this trend was applicable to different test 
compounds determined elsewhere, test compounds 11, AQ and CQ were included in this linear 
correlation plot (Figure 3-8 b). Observations showed that these test compounds too followed 
this apparent linear correlation and still resulted in a statistically significant plot with a 
correlation coefficient of R2 = 0.7055 (p = <0.0012). 
The findings from these linear correlation plots further explains how these test 
compounds are able to inhibit the formation of haemozoin, causing a build-up of exchangeable 
haem by accumulating at a 1:1 equivalence in the parasite. The equivalence in amount strongly 
suggests that these test compounds could accumulate via Fe(III)PPIX-binding which in turn 
allows for the formation of Fe(III)PPIX-inhibitor complexes in CQS NF54 parasites. Lastly, it 
was suggested from these data that pH trapping, to a certain extent, plays a role in the ability 
of these test compounds to accumulate in the parasite, specifically for quinoline-containing test 
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3.4 Summary and conclusions 
 
In summary, the inhibition of parasite growth, haemozoin formation and cellular accumulation 
of ten chosen β-haematin inhibiting test compounds (1-10 and CQ) to accumulate in P. 
falciparum CQS cultures was successfully investigated and compared to previously published 
test compounds (11 and AQ) in this study.  
Most of the test compounds were observed to decrease parasite growth in a dose-
dependent manner, similar to CQ, but had micromolar IC50 values. It was also observed that 
when performing p-LDH experiments for test compounds showing low water solubility, certain 
modifications were required. 
Use of a pyridine-based parasite haem fractionation plate method to determine the mass 
of haem Fe per cell profiles in CQS NF54 trophozoite cultures treated with test compound 1 
showed a 4-fold increase in exchangeable haem amounts and 3-fold decreases in the amounts 
of haemozoin compared to CQ. This meant that test compound 1, at a higher IC50 value, could 
be equivalent to that of CQ at inhibiting the formation of haemozoin. Similarly, the remaining 
test compounds (test compound 2-9) that were investigated proved to behave like test 
compound 1, excluding two of the quinazoline-containing test compounds (test compounds 5 
and 7). Interestingly, one of the least active test compound (test compound 9) resulted in the 
most significant decrease in haemozoin amounts at the IC50 value with evidence of empty 
parasite DVs with no observable haemozoin crystals. These results confirmed that like a well-
known β-haematin inhibiting test compound CQ, the mode of action for all compounds tested 
in this study was to inhibit the formation of haemozoin, with the exception that quinazoline-
containing test compounds may have more than one mode of action. Besides, overlaying plots 
of decreasing percentage parasite growth and increasing exchangeable haem amounts as a 
function of dose-dependent increasing test compound IC50 multiples further confirmed their 
target of action to be the formation of haemozoin.   
A bar plot of parasite growth inhibition activity and exchangeable haem amounts as a 
function of individual test compounds exhibited a trend in which amounts of exchangeable 
haem tended to increase with the mean IC50 values observed for all test compounds (1-9) 
including test compounds (10, 11 and AQ) that were determined elsewhere. However, this 
trend was not definitive and is counterintuitive given that higher levels of exchangeable haem 
would be expected to be more toxic. It thus does not reveal how the parasite growth inhibition 
activity relates to the observed amount of exchangeable haem present in the parasite. 
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With the knowledge of haemozoin formation being the major pathway within the parasites DV 
and evidence of these test compounds being involved in its inhibition, they were considered to 
be efficient haemozoin inhibitors. It has long been suggested that the cellular accumulation of 
haemozoin inhibitors, like CQ, within the parasites DV is vital in their ability to inhibit the 
formation of haemozoin and this may involve haem-binding 265,270,355-356,366.  
This led to further investigations to determine the cellular accumulation of these 
haemozoin inhibiting test compounds in CQS P. falciparum parasites. Experimental CAR 
values were determined using a previously published inoculum effect analysis for all test 
compounds. Linear correlation plots were observed whereby increasing IC50 values as a 
function of increasing inoculum size was used to quantitatively determine the experimental 
CAR values. The experimental CAR values were much lower for most of these test compounds 
relative to the test compounds 11, AQ and CQ, which were previously determined by Wicht et 
al using a similar procedure 334. Less basic test compounds do not accumulate primarily due to 
pH trapping which suggests that other influencing factors, like haem-binding, may play a 
primary role which then leads to the suggestion that accumulation of these compounds in CQS 
NF54 strain parasites may be more complex than initially believed, probably involving both 
pH trapping and haem-binding.  
Further calculations were carried out to determine the total intracellular test compound 
amounts for these compounds as well as, test compounds 11, AQ and CQ. A linear correlation 
plot of the exchangeable haem amounts plotted as a function of total intracellular test 
compound amount present in parasites at the IC50 values of these test compounds was 
constructed. Observations showed an apparent 1:1 relationship, and addition of test compound 
11, AQ and CQ to the plot maintained the linear correlation showing that these test compounds 
too conformed to this relationship.  
In conclusion, it could not be clearly explained from the above data if parasite growth 
inhibition activities are dependent on either the total intracellular test compound amount, 
amount of exchangeable haem present in parasites or both. Although, it was apparent that the 
ability of these test compounds to accumulate in iRBCs is vital for the build-up of exchangeable 
haem and thus inhibiting the formation of haemozoin. It has, however, been previously 
suggested that haem-binding by the co-localization of haem and test compound in the DV of 
the parasite allows for the interaction between test compounds and haem. This co-localization 
has been suggested to be from a possible haem-inhibitor complex forming inside the parasite 
and could be responsible for the ability of these compounds to accumulate at the site of action 
thus inhibiting the formation of haemozoin 279,355. This is investigated further in Chapter 4.
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4.1 Introduction 
 
A widely suggested theory for understanding the behavior of haemozoin inhibiting 
antimalarials is centered around their association with Fe(III)PPIX in P. falciparum parasites. 
According to this hypothesis, the method which they achieve this is by membrane impermeable 
accumulation of the protonated form in the DV, which concentrates the drug, driving 
equilibrium binding of these haemozoin inhibitors to Fe(III)PPIX. In turn, the build-up of 
Fe(III)PPIX or Fe(III)PPIX-inhibitor complex inside the parasite interrupts parasite membrane 
function, causing subsequent parasite death 283,293,297,367-370. 
 Researches have used spectroscopic techniques and diagnostics tools to detect the 
distribution of Fe(III)PPIX and to attempt to provide evidence of a Fe(III)PPIX-inhibitor 
complex that has been suggested to exist in parasites 311,325,371. In 2002, Egan et al used electron 
microscopy with electron spectroscopic imagining techniques together with chemical 
measurements of the Fe content of cellular fractions to show that > 90% of the total Fe present 
in untreated parasites is presented as Fe(III)PPIX that was attributed to haemozoin. This study 
also used, Fe-Mössbauer spectroscopy of freeze-dried isolated trophozoites to confirm that 
more than 95% of Fe was haemozoin that was located in the parasites DV 287. Related studies 
detected, with the use of TEM and ESI, that the Fe associated Fe(III)PPIX signal in untreated 
parasites was mainly attributed to haemozoin with evidence of negligible Fe in the parasites’ 
cytoplasm 242,287. In addition, parasites treated with CQ were observed to result in a substantial 
amount of Fe in the form of Fe(III)PPIX in the parasites’ cytoplasm which was suggested to 
be as a direct result of haem partitioning into lipid environments 287,372. This was also in 
agreement with the previous findings that were reported by Schmitt et al and Bendrat et al in 
1993 and 1995 respectively 146,284. 
 Another non-destructive technique that has long been used to identify structural and 
chemical variations in the speciation of Fe in Fe(III)PPIX complexes is Raman spectroscopy 
315,373. In 2008, Tarcea et al studied the spectra of haematin and parasite extracted haemozoin, 
where for haemozoin, certain peaks were observed to be enhanced using varying excitation 
wavelengths. They concluded that the most suitable excitation wavelength was 647 nm for the 
study of the structures of Fe(III)PPIX complexes 374. Wood et al had previously reported 
spectra consistent with high-spin Fe(III) electronic structures of both β-haematin and 
haemozoin at the excitation wavelengths of 780 nm and 830 nm. From this, they inferred that 
the enhancement of certain Raman peaks, specifically the electron density marker band at 1374 
cm-1, could be attributed to excitonic coupling in covalently bonded porphyrins that were 
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aggregated 320. They also showed that the spectrum of β-haematin appeared to be similar to 
that of the spectrum for haemozoin and agreed with the findings of Bohle et al 375. Other studies 
have also shown that distinctions between oxy- and deoxy-haemoglobin, can be observed using 
Raman spectroscopy. To explore the variability in the Raman spectra for oxy- and deoxy-
haemoglobin, they used a well-known chemometric analysis method, namely PCA. Here, they 
showed that the scores from the PCA plot exhibited a sigmoidal curve that coincided with the 
oxygen saturation curve observed in live cells 313. In 2015, Tempera et al explored the 
interaction of CQ and haemozoin-like crystals and showed increased intensities in parts of the 
spectra. This was suggested to be indicative of π-π interactions between the pyrrole ring of 
Fe(III)PPIX and the quinoline ring of CQ. They also showed spectra of haemin, β-haematin 
and haemozoin where similarities were observed for β-haematin and haemozoin which 
supported previously published findings by Wood et al and Bohle et al 313,320,375-376. Studies by 
Kozicki et al also reported observed increases in intensities of the Raman peaks in the 
Fe(III)PPIX core and pyrrole-ring stretching regions for CQ-treated iRBCs on a single cell 
level with an excitation of 532 nm. From this, they were also able distinguish between untreated 
and CQ-treated parasites using K-mean clustering analysis and PCA, however, they suggested 
that further investigations were required 325. Thus, direct evidence of a Fe(III)PPIX-inhibitor 
complex has remained elusive. 
In this chapter, evidence of the localization as well as the Raman spectra of Fe(III)PPIX 
and a Br-containing haemozoin inhibitor were investigated in an effort to look for evidence for 
the formation of a Fe(III)PPIX-inhibitor complex.  
First, CQS P. falciparum cultures (NF54) were treated with a benzimidazole haemozoin 
inhibitor containing a Br atom (test compound 1). Briefly, test compound 1-treated cultures, 
after 30-32 hrs of incubation, were enriched using a Percoll® density gradient enrichment 
method 245. Prior to performing cryofixation, enriched cultures were encapsulated using a 
polysaccharide gel encapsulation method with agarose 377. Agarose encapsulated cultures were 
prepared via cryofixation using a high-pressure freezing, freeze substitution and low 
temperature embedding protocol 378-380. From this, the Fe and Br distribution images for both 
untreated and treated iRBCs were obtained using TEM with ESI that is coupled with EELS. 
The resulting data showed that the Fe signal associated with Fe(III)PPIX and Br signal 
associated with test compound 1 co-localized within the DV of treated iRBCs. 
 Second, Confocal Raman microscopy was used to identify chemical and molecular 
changes in various Fe(III)PPIX complexes in the presence of test compound 1. This was carried 
out in an effort to provide evidence that this co-localization was as a result of the formation of 
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a Fe(III)PPIX-inhibitor complex. Using aluminium foil covered glass microscope slides, the 
spectra for different Fe(III)PPIX complexes both in cells (RBC and parasites) and synthetic 
were successfully recorded for the Fe(III)PPIX porphyrin dominated spectral region of 1700-
500 cm-1. The spectrum of a putative Fe(III)PPIX-inhibitor complex was observed and 
indicated the presence of π-π interactions. Confocal Raman true component mapping images 
were obtained for untreated and test compound 1-treated iRBCs, which, revealed that the signal 
distribution of haemozoin and the Fe(III)PPIX-test compound 1 complex could be imaged at 
the Raman peaks at 754 cm-1 and 1080 cm-1. From this, it was apparent that the signal 
distributions for both haemzoin and the Fe(III)PPIX-test compound 1 complex co-localized in 
the parasites DV, where the Raman peak at 1080 cm-1 was unique to the Fe(III)PPIX-test 
compound 1 complex and considered to be a marker band for this complex 
 With small variations in the position and intensities of peaks observed in comparison to 
the remaining Fe(III)PPIX complexes, it was difficult to make definite conclusions by direct 
inspection of spectra. Therefore, PCA was used to assess the variability in the Raman spectra 
of all Fe(III)PPIX complexes based on their peak positions. The resulting PCA plots 
demonstrated separations along PC1 for all Fe(III)PPIX complexes being compared including 
comparisons to the Fe(III)PPIX-inhibitor complex. With this, the significance of these 
separations was further analyzed statistically using a Welch’s t-test. These data showed that 
the proposed Fe(III)PPIX-inhibitor complex in the parasite was significantly different to all 
other Fe(III)PPIX complexes analyzed except its synthetically prepared counterpart. This 
analysis was also applied to oxy-haemoglobin and haemozoin in treated iRBCs in order to test 
the reliability of these data. These data proved that this analysis was reliable and could be used 
for future investigations. 
 Thus, this chapter provides insights into the location and distribution of Fe associated 
Fe(III)PPIX in the presence of a haemozoin inhibitor as well as strongly supporting evidence 
for the existence of a Fe(III)PPIX-inhibitor complex in CQS P. falciparum parasites. It also 
supports the theory that haemozoin inhibitors, like test compound 1, accumulate within the 
parasite causing variable exchangeable haem amounts via co-localization with Fe(III)PPIX that 
is facilitated by the formation of a Fe(III)PPIX-inhibitor complex which inhibits the formation 
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General cell culturing and fixation materials are listed in Table 2-2 in Chapter 2. Materials and 
their suppliers, that were specific to this particular chapter, are listed below (Table 4-1 to 4-3). 
All the materials were of AR grade or higher and used without further purification, unless 
specified. A haemozoin inhibiting test compound, 1, was used throughout this study. Its 
synthesis and characterization have been previously reported 335. Haem-containing glassware 
was cleaned by using 0.2 M NaOH, 1 M HNO3, with d.H2O and acetone rinsing in between.  
 
Table 4-1: Materials used for the preparation of TEM and EELS samples 
TEM and EELS samples 
Material Supplier 
PercollÒ Sigma-Aldrich/Merck 
Low melting point agarose Sigma-Aldrich/Merck 
1-Hexadecane Sigma-Aldrich/Merck 
Liquid Nitrogen Afrox 
Spurr’s epoxy resin (low viscosity) Agar Scientific 
Osmium tetraoxide Agar Scientific 
 
Table 4-2: Materials used for the preparation of samples for Confocal Raman 
microspectroscopy  
Confocal Raman microspectroscopy 
Material Supplier 
Heavy-duty aluminium foil (commercial 
grade) 
Aro 
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Table 4-3: Materials used to for β-haematin formation 
β-haematin formation 
Material Supplier 
Haemin (³ 97% Fluka) Sigma Life Science 
Glacial Acetic acid (AcOH) Sigma-Aldrich/Merck 
Sodium acetate trihydrate (C2H9NaO5) Sigma-Aldrich/Merck 
 
4.2.2 Instrumentation  
 
The instrumentation at the University of Cape Town Aaron Klug Centre for imaging and 
analysis was used throughout this study  
 
Microcentrifuge 
An Eppendorf microcentrifuge 5420 with an aerosol-tight rotor was used for the centrifugation 
of samples (500-1000 µl) at rpm ranging from 13000-21300.  
 
Microwave 
A LG Neochef stainless steel microwave (42 l) was used to prepare agarose gel solution for 
imaging microscopy and spectroscopy experiments. 
 
Leica electron microscopy high-pressure microsystem (EM HPM) 100 and Leica EM 
automatic freeze-substitution (AFS) UC7 unit 
A Leica EM HPM 100 was used to rapidly freeze agarose-encapsulated samples at a high-
pressure of 2100 bar to prevent ice crystal formation in TEM samples.  Freeze substitution and 
low temperature embedding of samples was carried out using a Leica EM AFS UC7 unit. 
 
TEM and ESI coupled with EELS 
TEM is a high-resolution electron microscopy technique used to capture images of samples 
that are minuscule. Coupled to the TEM microscope is an energy filter for ESI which measures 
the energy-loss of an electron. This is used for the determination of the location and distribution 
of elements which is achieved by the excitation of core electrons within a sample. All imaging 
and elemental distribution analysis was performed on a FEI Tecnai 20 transmission electron 
microscope (200 kV) and Gatan Tridiem 863 UHS.  All TEM images were collected using a 
Gatan charge-coupled-device camera (CCD) (2048 x 2048 pixels) with a slit width of 18 eV 
Chapter 4: Spectroscopic evidence of a Fe(III)PPIX-inhibitor complex in P. falciparum parasites 
Roxanne Openshaw-January 2020 115 
and processed using soft imaging system software. For EELS analysis, the software specifically 
uses a two-window difference method for calculating the elemental distribution images for 
each element analyzed.  For the Fe distribution images, a slit width of 30 eV and energy offset 
of 723 eV was used which corresponds to the L2-absorption edge. For the Br distribution 
images, slit widths of 10 eV or 40 eV with corresponding energy offsets of 72 eV or 1570 eV 
were used. These energy offsets correspond to the M4,5-absorption edge and L2-absorption edge 
respectively. 
 
Confocal Raman microspectrometer 
The Confocal Raman imaging and scanning electron microspectrometer (RISE) is a 
combination of a Scanning Electron Microscope (SEM) coupled to a standalone confocal 
Raman imaging microspectrometer. Raman spectra were collected using the confocal Raman 
microspectrometer alpha300 R (WITec GmbH, Germany) that is equipped with a CCD camera 
that was cooled to -60 °C and three air-calibrated objective lenses (10×, 50× and 100×). For 
this particular study, all spectra were collected using the 100× objective lens. This Raman 
microspectrometer uses a Nd:YAG laser (green) which has an excitation wavelength of 532 
nm and a laser spot of 1-2 µm with a resolution of 1-2 cm-1 that was set at a default grating of 
2050. The Raman microspectrometer was controlled using WITec Control FIVE v5.0.0 





Throughout this chapter, the software that was used to analyse the TEM and EELS images 
were: Microsoft® PowerPoint version 16.16.11(190609) and ImageJ bundled with Java 
v1.8.0_172 381. Raman spectra were collected and analyzed using Control FIVE copyright © 
2017 v5.0.0 and Project FIVE copyright © 2017 v5.0.0.40 supplied by WITec GmbH in 
Germany for Windows 10 (64-bit) 382-383. All Raman spectra, PCA plots and Welch’s t-test 
calculations were carried using Microsoft® Excel v16.16.11(190609) and GraphPad Prism 
v8.2.1 (227). Molegro Data Modeller executive v3.0 (Win 32 bit) version MDM 2013.3.0.0, 
supplied by a bioinformatics software company CLC bio (www.clcbio.com), was used to 
determine the eigenvalues and eigenvectors for all PCA plots 384. 
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4.2.4 Preparation of solutions and samples 
 
4.2.4.1 TEM and EELS samples 
 
5 x RPMI-1640: 25% D-sorbitol 
The solution was prepared by dissolving 1.05 g RPMI-1640 and 5 g D-sorbitol in 20 ml of 
d.H2O (pH 7.4). Before using or storing at 4 ºC, the solution was sterile filtered using a 0.22 
µm membrane filter. The solution was stored at 4 ºC until further use. 
 
Percoll® (60%) 
A 60% Percoll® solution was prepared in a 6:2:2 (v/v/v) ratio of Percoll®, 5 x RPMI-
1640:25% D-sorbitol and complete medium. The solution was stored at 4 ºC. 
 
Percoll® (90%) 
A 90% Percoll® solution was prepared by adding 1 ml 5 x RPMI-1640:25% D-sorbitol to 9 ml 
of Percoll®. The solution was stored at 4 ºC.  
 
2 × PBS 
The 2 × PBS solution was prepared by dissolving 1 tablet of PBS in 100 ml of d.H2O.  
 
1 × PBS 
The 2 × PBS solution was further diluted (1:2) with d.H2O for a 1 × PBS solution.  
 
Glutaraldehyde (5%) 
A 5% solution of glutaraldehyde was prepared by adding 1 ml of 50% glutaraldehyde in 9 ml 
of 1 × PBS 
 
Glutaraldehyde (2.5%) 
A 2.5% solution of glutaraldehyde was prepared by adding 0.5 ml of 50% glutaraldehyde to 
make up to 10 ml in 1 × PBS.  
 
Agarose (4%) 
A 4% slurry of agarose was prepared by gently heating 0.04 g of agarose in 1 ml d.H2O. 
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4.2.4.2 Confocal Raman microspectroscopy  
 
Test compound 1 
A 1 mM solution of test compound 1 was prepared by dissolving 1.97 mg of test compound 1 
in 5 ml of 14.1 M DMSO. The solution was stored at -20 ºC. 
 
Haematin  
A 1 mM solution of porcine haematin was prepared by dissolving 6.35 mg of haematin in 100 
ml of 14.1 M DMSO. The solution was stored at 4 ºC. 
 
Haemin 
A 1 mM solution of haemin was prepared by dissolving 6.52 mg of haemin in 100 ml of 14.1 
M DMSO. The solution was stored at 4 ºC. 
 
4.2.4.3 Formation of β-haematin in sodium acetate buffer 
 
NaOH  
A 0.1 M solution of NaOH was prepared by dissolving 0.399 g in 100 ml of d.H2O. 
 
NaOH 
A 5 M solution of NaOH was prepared by dissolving 19.95 g in 100 ml of d.H2O. 
 
HCl 
A 1 M solution of HCl was prepared by adding 4.91 ml of 32% HCl in 95.09 ml of d.H2O.  
 
Sodium acetate buffer 
A 9.7 M solution of C2H9NaO5 (pH 4.8) was prepared by gently heating 23.75 g C2H9NaO5 in 
10 ml of d.H2O. After total dissolution, 17.75 ml of acetic acid was added and topped up with 
5 ml of d.H2O.  The solution was parafilmed and stored at 4 ºC. 
 
Haemin 
A 9.2 mM solution of haemin was prepared by dissolving 30 mg of haemin in 5 ml of 0.1 M 
NaOH and sonicating for 5 min. The solution was stored at 4 ºC. 
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4.2.5 Methods 
 
4.2.5.1 TEM and EELS 
 
Untreated and treated CQS NF54 cultures were taken through various preparation procedures 
prior to cryofixation in order to perform TEM and ESI coupled with EELS (Table 4-1). This 
was carried out for imaging purposes as well as to determine the location and distribution of 
both Fe(III)PPIX associated Fe and Br attributed to a benzimidazole haemozoin inhibitor 
containing a Br atom (test compound 1). A modified version of the method described by Egan 
et al was used throughout this study and is described in what follows 287; 
 
Enrichment and fixation of untreated and treated iRBCs 
 
Sorbitol synchronized NF54 iRBCs (ring stage) were inoculated with test compound 1 at a 
known concentration that was equivalent to 1 × IC50 and incubated at physiological temperature 
(37 °C) for 30-32 hrs. After incubation, the trophozoite culture was centrifuged (750 rpm for 5 
min) and the supernatant was discarded by aspiration. Percoll® density gradient centrifugation, 
using a modified method reported by Ginsburg et al, was used to enrich the trophozoite iRBC 
sample 245. This was carried out by gently layering 500 µl of 60% Percoll® on top of 500 µl of 
90% Percoll® in a 1.5 ml Eppendorf tube. Roughly 300 µl of the trophozoite pellet was 
carefully layered on top of the 60% Percoll® layer (Figure 4-1 a). Samples were prepared in 
triplicate by centrifugation for 30 min at 13 000 rpm using a microcentrifuge. After 
centrifugation, 3 distinct layers were observed as depicted in Figure 4-1 b. Enriched 
trophozoite pellets were then transferred into 10 ml of complete medium in a 15 ml centrifuge 
tube and incubated for 15 min at 37 °C. Samples were further centrifuged at 750 rpm for 5 min. 
The supernatant was removed by aspiration before washing the remaining pellet with 5 ml of 
complete medium. This washing process was repeated three times to ensure complete removal 
of Percoll®. The separated black pellet was resuspended in 100 µl of 5% glutaraldehyde and 1 
ml of PBS (pH 7.5) for 10 min. After centrifugation (3000 rpm for 1 min), the pellet was 
resuspended in 1 ml of 2.5% glutaraldehyde in PBS and left to stand at rt. for 10 min. The fixed 
pellet was stored at 4 °C overnight for polysaccharide gel encapsulation. This method was 
repeated for untreated CQS NF54 cultures. 
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Figure 4-1 a-b: Percoll® density gradient centrifugation method for enrichment of samples, 
(a) iRBC trophozoite culture before centrifugation, and (b) three distinct layers post-
centrifugation. 
 
Polysaccharide gel encapsulation 
 
A 4% agarose gel solution was prepared using a modified microwave method that has been 
previously described by Koontz 377. In a 50 ml glass beaker, 4 g of low melting point agarose 
was dissolved in 10 ml of d.H2O, using a microwave. To avoid aggregation, the agarose was 
slowly sprinkled into a stirring solution of d.H2O. The solution, in a parafilmed glass beaker, 
was brought to a boil and left to boil for 10 min until the agarose was completely dissolved. A 
small piercing in the parafilm was made to avoid the parafilm from rupturing within the 
microwave and reduce the evaporation of d.H2O. After 10 min of boiling, the solution was 
allowed to cool to rt. before weighing. Warm d.H2O was added to bring the solution back to its 
initial weight. The fixed iRBCs were washed twice with 1 ml PBS before the samples were 
suspended in 50 µl of the 4% agarose slurry (1:1 v/v). The suspension was allowed to solidify 
before adding 10 µl of PBS to avoid sample dehydration. 
 
High-pressure freezing, freeze-substitution and low temperature embedding 
 
In order to preserve the native state of the agarose-encapsulated untreated and treated iRBCs, 
a process of cryofixation by rapid freezing at extremely low temperatures was used. This was 
performed using a modified high-pressure freezing, freeze-substitution and low temperature 
embedding method previously described by Yamada et al 378-380. Briefly, agarose-encapsulated 
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encapsulated iRBCs were removed from the Eppendorf tubes using a wooden spatula and 
placed on a clean microscope glass slide. Under a light microscope, samples were cut into thin 
sections (80-100 nm) using a diamond knife. Thin sections were transferred into the first single-
holed copper grid that was placed in the carrier plate of the lower cylinder of a Leica sample 
carrier (6 mm diameter). The sample was immersed under a small volume of hexane to remove 
any air bubbles. Using the Leica EM HPM100, the upper cylinder of same Leica sample carrier 
was placed on top of the lower cylinder and inserted into the system. Samples were rapidly 
frozen with liquid nitrogen at a pressure of 2100 bar to a temperature of -80 °C within 2 min. 
High-pressure frozen samples were transferred to a Leica EM AFS embedding system after 
removing the copper grids from the Leica sample carrier. Samples were embedded at a low 
temperature of -80 °C in acetone for 24 hrs. After 24 hrs, the acetone was replaced with osmium 
tetraoxide to maintain lipids and proteins within the sample for an additional 24 hrs. Samples 
were then left in the Leica EM AFS UC7 embedding system in low viscosity Spurr’s resin for 
an additional 5-7 days, over which the temperature was gradually increased to rt., after which 
they were analyzed further using TEM and ESI with EELS. 
 
4.2.5.2 Confocal Raman microspectroscopy 
 
Aluminium foil covered glass microscope slides 
 
For these experiments, aluminium was used because of its reduced cost and absence of 
background fluorescence with minimal interference when recording Raman spectra (Table 4-
2) 385-390. Aluminium foil covered glass microscope slides were prepared by adding a drop of 
clear nail polish onto a clean glass microscope slide and evenly smearing the nail polish to 
create a thin film. Pre-cut aluminium foil strips (1.5 x 3.5 cm) were carefully placed on the thin 
nail polish film using thin tipped tweezers. The aluminium foil strips were then carefully 




Packed RBCs were smeared (2 µl) onto an aluminium foil covered glass microscope slide and 
left to dry at rt. for 15 min before analysis. 
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Untreated and treated iRBC cultures 
 
The parasite cultures were maintained in continuous culture as described in Chapter 2 (see 
Section 2.5.1) . In brief, CQS NF54 cultures were inoculated with test compound 1 at 1 × IC50 
in 50 ml culture flask and incubated at 37 °C for 30-32 hrs. Thereafter, trophozoite cultures 
were removed from the incubator and centrifuged at 750 rpm for 5 min, after which, the 
supernatant was aspirated. Trophozoite cultures were mixed and decanted into four 15 ml 
centrifuge tubes (250 µl). The decanted trophozoite cultures were left to stand for 10 min at rt. 
before mixing and gently smearing 2 µl onto an aluminium foil covered glass microscope slide. 
The sample slide was left to air dry at rt. for 15 min before analysis. The same was applied for 




Solid crystals were crushed in a glass beaker before placing on an aluminium foil covered glass 
microscope slide for analysis. 
 
Test compound 1 
 
A 2 µl drop of 1 mM test compound 1 in DMSO was dried onto an aluminium foil covered 
glass microscope slide using an incandescent lamp at rt. before further analysis. 
 
Haematin and Haemin 
 
A 2 µl drop of 1 mM solutions of haematin or haemin were dried onto separate aluminium foil 
covered glass microscope slides using an incandescent lamp at rt. before further analysis.  
 
Haematin-test compound 1 mixture 
 
A 1:10 (v/v) mixture was prepared by titrating 5 ml of a 1 mM solution of haematin into 50 ml 
solution of 1 mM of test compound 1 in a 100 ml glass beaker. In order to correct for dilution, 
DMSO was added to a final volume of 100 ml. The parafilmed solution was gently heated in a 
water bath (60 °C) for 30 min and cooled to rt. Roughly 2 µl of the mixture was dried, using 
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an incandescent light lamp, onto an aluminium foil covered glass microscope slide for further 
analysis. 
 
4.2.5.2 Formation of β-haematin in sodium acetate buffer 
 
The formation of β-haematin in sodium acetate buffer was carried out using a method 
previously described by Egan et al 143. Briefly, 30 mg of haemin was dissolved in 5 ml of 0.1 
M NaOH in a glass beaker and sonicated for 5 min (stock solution). In a glass vessel, 2.5 ml of 
the stock solution was added to 0.25 ml of 1 M HCl and 2.31 ml of 9.7 M sodium acetate 
buffer. The solution was adjusted to pH 4.8 with 5 M NaOH. The glass vessel was then 
parafilmed and placed on a magnetic stirrer before stirring the solution in a glass titration vessel 
with a thermostat jacket that was connected to a 60 °C water bath. The solution was allowed 
to stir for 1 hr. After 1 hr, the solution was removed from the hot plate, quenched with d.H2O 
and placed on ice. Once precipitation had occurred, the precipitate was filtered through 8 µm 
cellulose acetate/nitrate Millipore filter paper using a Buchner funnel. Then, the precipitate was 
washed multiple time with d.H2O until a clear filtrate was observed. The precipitate was further 
dried between two pieces of filter paper before placing the filter paper containing the precipitate 
in a 15 ml centrifuge tube and into a phosphorous pentoxide desiccator. The β-haematin 
precipitate was left to dry for 48 hrs until further analysis. 
 
4.3 Data analysis 
 
4.3.1 Confocal Raman microspectroscopy 
 
The Raman spectra for all Fe(III)PPIX complexes were processed using the WITec Control 
FIVE software. For this study, the Fe(III)PPIX porphyrin dominated spectral region of 1700-
500 cm-1 was chosen. The excitation wavelength was 532 nm.  
 To obtain the single scan Raman spectra for the different Fe(III)PPIX complexes, a large 
area scan (LAS) image Raman spectra was initially performed to determine the particular 
regions within the sample that are associated with the different Fe(III)PPIX complexes in 
RBCs, parasites and synthetic Fe(III)PPIX complexes. Every LAS Raman spectrum has a 
corresponding residual image that is produced where each pixel pertains to a single spectrum. 
An average of 15 lines per image and 15 points per line for each LAS residual image was 
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recorded for an average collection time of about 35 min. It was difficult to avoid photo-damage 
to the cells with this laser exposure time, which has been previously reported to be a common 
problem when recording images for longer periods 391-392. The integration times of 0.05 s and 
0.1 s at laser powers of 0.1 mW, and 1 mW were used to record the LAS Raman spectra for 
RBCs, parasite and synthetic Fe(III)PPIX complexes respectively in an effort to minimize 
damage.  
First, the LAS Raman spectrum for each sample was corrected for cosmic rays (filter size 
4; dynamic factor 50), smoothed using a Savitzky-Golay algorithm (9 smoothing points; 
derivative 0), averaged (spectral 9; spatial 0) and subtracted for background correction (shape 
size 100; noise factor 4). Using a built-in true component analysis tool, the Raman spectra for 
individual components (e.g. haemozoin) were extracted from the LAS residual image using an 
auto-setting in order to determine the regions pertaining to the different Fe(III)PPIX complexes 
in a sample. This process was repeated for 10-15 cells to ensure that the extracted spectra from 
the respective regions for each Fe(III)PPIX complex were accurate. From here, the spectra for 
all components selected were averaged with an auto-setting, demixed and extracted. Demixing 
is important for this process as it is aimed at the removal of any contribution of one components 
spectrum to another for the selected components within a sample. The spectra were extracted 
and used as reference spectra for the individual Fe(III)PPIX complexes.  
Before recording the single scan Raman spectra, the oscillator was adjusted and 
calibrated to the aluminium foil covered glass microscope slide to correct for any background 
signals. This was also to reduce the cosmic ray effect which can cause false peaks in Raman 
spectra. For all Fe(III)PPIX complexes, experiments were carried out in triplicate. An average 
of 30 single scan Raman spectra for each Fe(III)PPIX complex, obtained from the previously 
determined areas of the cell, were recorded from 10 randomly selected cells for RBCs and 
parasite samples. For synthetic Fe(III)PPIX complexes, the same number of single scan Raman 
spectra were obtained, however, from 5 randomly selected regions for each slide pertaining to 
a specific Fe(III)PPIX complex. In addition, each single scan Raman spectrum was collected 
using a total of 100 accumulations at an integration time of 0.05 s. The spectra for parasite 
Fe(III) PPIX complexes, including RBCs, were obtained with an optimal laser power of 0.1 
mW for high signal-to-noise ratio spectra, at the same time avoiding haemolysis and photo-
damage of cells. Cells were also allowed to rest for intervals of 10 min before each scan. 
Synthetic Fe(III)PPIX complexes were analyzed using a laser power of 1 mW. All individual 
single scan Raman spectra were corrected for the cosmic ray effect, smoothed, averaged and 
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background subtracted using the same parameters described above, after which, were plotted 
in GraphPad Prism v8.2.1 (Figure 4-2). 
 
4.3.2 Confocal Raman true mapping images 
 
Similar to the sequential procedure described above for obtaining single scan Raman spectra, 
separate LAS image Raman spectra were also recorded in order to determine the true mapping 
images for RBCs, parasites and synthetic Fe(III)PPIX complexes at selected peak positions 
(754 cm-1, 1080 cm-1, 1090 cm-1 and 1642 cm-1).  
 First, the LAS Raman spectra were recorded and corrected for the cosmic ray effect, 
smoothed, averaged and background subtracted using the same parameters described above for 
single scan Raman spectra (see Section 4.3.1). The Raman spectra for individual components 
(e.g. haemozoin) in a sample were extracted manually from the specific regions pertaining to 
each Fe(III)PPIX complex that were previously determined for the single scan Raman spectra 
using the built-in true component analysis tool. Starting with a LAS residual image, each 
component was extracted, where after each component was extracted there was a remaining 
residual image and so forth until a residual image corresponding only to background noise is 
left (i.e. arising from the aluminium foil covered glass microscope slide). In more detail, this 
process extracts the spectra (in each pixel) pertaining to each component from the LAS residual 
image separately. From here, the spectra for all the components selected were averaged with 
an auto-setting, demixed and extracted. With emphasis on demixing, spectra were required to 
be demixed to ensure that when the signals at different peaks were analyzed no signal 
contributions from one Fe(III)PPIX was observed in the true mapping image of another 
Fe(III)PPIX complex. The demixed-component spectra were individually analyzed further 
with a built-in filter viewer. The filter viewer is a tool that produces images that map out the 
distribution of the spectra pertaining to an individual component. At specific peak positions 
that have been assigned to specific vibrations and stretches, a filter width of 1 cm-1 was used. 
This filter width was chosen to reduce the contribution of neighboring peaks, decrease the 
effect of broad peaks or inclusion of shoulder peaks when obtaining the true mapping images. 
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Figure 4-2: A multivariate analysis for confocal Raman true mapping images for individual Fe(III)PPIX complexes in untreated and treated  iRBCs 
393.
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4.3.3 PCA 
 
The peak positions of the recorded Raman spectra for the spectral range of 1700-500 cm-1 for 
all Fe(III)PPIX complexes were separated using PCA (Figure 4-3). In more detail, an average 
of 150-200 spectra were recorded from the relevant true mapping images for each Fe(III)PPIX 
complex. The obtained repeat spectra for all Fe(III)PPIX complexes were individually 
corrected for cosmic ray effect, smoothed, averaged and background subtracted as previously 
mentioned in Section 4.3.1. Thereafter, individual spectra for each Fe(III)PPIX complex were 
taken through various steps in order to extract the relevant peak positions necessary for this 
study. 
 
First, spectral intensity was normalized using a modified standard normal variate method which 
involves subtracting the mean (µ) from each data point ("#), divided by the standard deviation 
($%&') and subtracting the minima ("(#)) 394. The resulting normalized data points ("*) were 





− "(#)6                                                   Eq. 1 
 
Next, the normalized spectra were converted to their corresponding second derivative spectra, 
using GraphPad Prism v8.2.1, to easily define the relevant peak positions based on their 
curvature rather than their intensity. The relevant second derivative spectra were then 
transferred to another Excel document where the data points (± 7#) at each peak position for a 
second derivative spectra were refined to determine whether or not the resulting data points (± 
7#′) were above (Eq. 2) or below (Eq. 3) the positive (+:;.;=) or negative (−:;.;=) 95th-
percentile. 
 
+7#′ = 	7# > +:;.;=                                              Eq. 2 
 
and,                                                     −7#′ = 	−7# < −:;.;=                                             Eq. 3 
 
The resulting data points (± 7#′) were further refined to ensure that only the peak positions with 
data points (± 7#′′) showing maximum or minimum values in comparison to the neighboring 
data points would be selected (Eq. 4 and Eq. 5): 
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+7#





@ > +:;.;=)                            Eq. 4 
 
−7#





@ < −:;.;=)                            Eq. 5 
 
Finally, the peak positions (G#′′) of the refined data points (± 7#′′) were selected using Eq. 6: 
 
 G#′′′ = (+7#@@ > +:;.;=	); (−7#@@ < −:;.;=)                                 Eq. 6 
 
All resulting peak positions for pairs of Fe(III)PPIX complexes being analyzed (e.g. oxy-
haemoglobin versus haemozoin) were transferred to the Molegro Data Modeler Executive 
software. This software was used to generate the eigenvectors (PC1 and PC2) and 
corresponding eigenvalues. From here, all PCA plots were plotted using GraphPad Prism 
v8.2.1.  
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Figure 4-3: Analysis of repeat spectra for individual Fe(III)PPIX complexes for PCA analysis. 
 
4.3.4 Welch’s t-test analysis 
 
The statistical significance of the separation of clusters for each PCA plot for pairs of 
Fe(III)PPIX complexes was analyzed using a Welch’s t-test analysis that was performed in 
GraphPad Prism v8.2.1. In brief, the clusters were shifted so that the one centroid lay at the 
origin and then transformed so that both centroids lay on the H axis (Figure 4-4 a-d). This was 
done using the following equations; 
 
Repeat spectra were all 
corrected for cosmic ray 
effect, smoothed, averaged, 
background corrected and 
normalized (Eq. 1)
Second derivative spectra 
and 95th percentiles were 
calculated in GraphPad 
Prism v8.2.1
Repeat spectra were refined 
to determine the relevant 
maximum peak positions
(Eq. 2, Eq. 3, Eq. 4, Eq. 5 
and Eq. 6)
Compiled peak positions for 
repeat spectra were analyzed 
in Molegro Data Modeller
and PCA plots were 
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Centroids for cluster I and II are defined by Cartesian coordinates IJK  and ILK , 7 = I or II given 
















                                                           Eq. 8 
 
where RK is the number of points in cluster 7. Application of Eq. 9 and Eq. 10 shifts the centroid 










T                                                    Eq. 10 
 










T                                                    Eq. 12 
 
 
The new position of centroid II in polar coordinates is given by Eq. 13 to Eq. 16 (Figure 4-4 
d): 
IJ
TTS = VTT cos Z                                                 Eq. 13 
 
IL
TTS = VTT sin Z                                                  Eq. 14 
 







                                          Eq. 15 
 
and,                                                           Z = $`R.C ,'a
bbS
cbb
6                                               Eq. 16 
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Finally, rotation of the axes through angle Z results in a new set of axes H@@ and U@@ in which 
both centroids lie on H@@ axis with no separation of the clusters along the U@@ axis and maximum 




KS cosZ − U#
KS sin Z                                          Eq. 17 
 
The statistical significance of the separations of the means IJT
SS and IJTT
SS was evaluated using a 
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4.4 Results and discussion 
 
4.4.1 Evidence of co-localization of Fe(III)PPIX and test compound 1 in treated CQS P. 
falciparum parasites 
 
In chapter 3, it was shown that an apparent 1:1 relationship exists between the total intracellular 
test compound amount and the amount of exchangeable haem present in CQS NF54 parasites 
for the range of haemozoin inhibitors investigated in this study. From here, it was hypothesized 
that the cause of this observation was the formation of Fe(III)PPIX-inhibitor complexes 
forming within the parasite DV which would be characterized by co-localization of 
Fe(III)PPIX and the inhibitor.  
Therefore, to examine the possible co-localization of Fe(III)PPIX and a selected 
haemozoin inhibitor in both untreated and treated CQS parasites, TEM with ESI based on 
EELS was used (see Section 4.2.5). For this specific experiment, test compound 1 was selected 
from the series of test compounds investigated in this study because it contains a Br atom. 
Crucially, (i) it produced a moderate total intracellular test compound amount which coincided 
with a moderate amount of exchangeable haem present in parasites at its IC50 value and thus 
was more easily detected than CQ which is present in much smaller amounts and gives much 
lower amounts of exchangeable haem; and, (ii) for microscopy, the difference in L2 and M4,5 
excitation edges of Fe and Br respectively makes it possible to distinguish between the two 
elements in untreated and treated CQS parasites 395-396.  
In brief, CQS NF54 cultures were inoculated at the immature ring stage at the IC50 value 
of test compound 1 (616 nM) and incubated for 30-32 hrs. After incubation, cultures were taken 
through several preparation steps that included; enrichment by Percoll density gradient 
centrifugation, agarose-encapsulation for cryofixation (high-pressure freezing, freeze 
substitution and low temperature embedding) (see Section 4.2.5.1). A cryofixation method was 
chosen as opposed to chemical fixation methods (ethanol) to rule out the possibility of: (i) the 
test compound 1 leaching out of or being relocated in the parasite; (ii) the formation of artefacts 
(e.g. water crystals); (iii) improved preservation of ultrafine structures; and (iv) higher signal-
to-noise ratio within the parasite which is advantageous for imaging 397-398. For both untreated 
and treated iRBCs, the experiments were carried out in triplicate for which representative TEM 
and EELS images are discussed below. 
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Figure 4-5 a-f: TEM images for samples prepared by cryofixation were obtained for (a) 
untreated and (d) test compound 1-treated CQS NF54 parasites. ESI coupled with EELS was 
used to determine both the Fe (green) and Br (yellow) location and distribution in CQS NF54 
parasites for b) untreated parasites showing a strong signal (green) for haemozoin crystals in 
the parasites DV (red arrow), c) no Br signal for untreated parasites, e) Fe distribution image 
for test compound 1-treated iRBCs showing a strong signal for haemozoin crystals in the 
parasites DV (green) as well as a low Fe signal in the RBC cytoplasm (red arrows), and f) test 
compound 1-treated iRBCs showing a low Br signal distributed throughout the iRBC but a 
much stronger Br signal can be seen inside the parasites DV (yellow) which is indicated by the 
arrow (red). In a and d; the RBCs are delineated with a red dashed line, the parasite with a 
purple dashed line and the parasites DV with a yellow dotted line. Abbreviations in (a) and (d) 
were used and include; RBC = red blood cell, Pc = parasite cytoplasm, P = parasite, DV = 
digestive vacuole, Tv = transport vesicle and Hz = haemozoin crystals. 
 
For untreated iRBCs, Figure 4-5 a illustrates the TEM image of a parasite (purple dashed line) 
inside a RBC (red dashed line). Clearly defined lath-shaped haemozoin crystals localized inside 
the parasites DV (yellow dotted line) were observed. With this, additional features were also 
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observations published by Love et al who showed transport vesicles containing haemoglobin 
399. For the Fe distribution image, a stronger Fe signal (green) within the parasites DV in 
comparison to a negligible Fe signal in the RBC cytoplasm was observed. This strong Fe signal 
was attributed to the haemozoin crystals (red arrow) which were shown to be dispersed 
throughout the DV. It also indicated that in untreated iRBCs most of the Fe(III)PPIX associated 
Fe was in the form of haemozoin (Figure 4-5 b). This agreed with previous findings which 
showed that in untreated iRBCs about 70-100% of vacuole Fe(III)PPIX Fe is associated to 
haemozoin 286. Figure 4-5 c illustrated that for the Br distribution no signal was observed. This 
was expected for untreated iRBCs which are expected to contain negligible Br.  
Compared to untreated iRBCs, test compound 1-treated iRBCs resulted in similar 
observations where the parasite was located in the RBC showing features such as the parasites 
cytoplasm and transport vesicles. Artefacts as a result of sectioning in untreated iRBC were 
also observed for test compound 1-treated iRBC. This was shown by the elongated tube-like 
feature observed inside the iRBC which is a cutting artefact (Figure 4-5 d). This is a common 
error as previously suggested by Bleck et al 400. In contrast to untreated iRBCs, iRBCs in the 
presence of test compound 1 resulted in less defined haemozoin crystals within the parasites 
DV as a result of an electron dense halo around the crystals. This was consistent with the fact 
that the formation of haemozoin was disrupted and agreed with similar findings previously 
observed by Combrinck et al 242. Figure 4-5 e illustrates the Fe distribution image for test 
compound 1-treated iRBCs, where, a strong Fe signal (green) was observed from the 
haemozoin crystals. No Fe signal was observed in the Pc which indicated that no appreciable 
Fe associated Fe(III)PPIX was distributed out of the DV in the presence of test compound 1. 
These observations were different to the finding by Combrinck et al and colleagues who 
showed that Fe(III)PPIX associated Fe had diffused out of the DV into the parasites cytoplasm 
as a result of CQ treatment 242. An increased Fe signal was observed in the RBC cytoplasm 
compared to untreated iRBCs and is indicated by the red arrow. Figure 4-5 f showed a strong 
Br signal (yellow), attributed to the Br atom of test compound 1, for treated iRBCs compared 
to untreated iRBCs. From this, it was evident that majority of the signal was observed to be 
located within the DV of the parasite, coincident with the region of the Fe signal. It was, 
however, not apparent whether the Br signal observed in the parasite was as a result of a poor 
signal-to-noise ratio and therefore devoid of test compound 1 or test compound 1 was 
distributed throughout the entire iRBC.  
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Figure 4-6 a-c: Evidence of the co-localization of Fe(III)PPIX and test compound 1 in the DV 
of CQS NF54 parasites represented by the (a) overlaid image of the (b) Fe (green), and (c) Br 
(yellow) distribution images.  
 
To further establish whether Fe(III)PPIX and test compound 1 were in the same region within 
the parasites DV, the Fe and Br distribution images for test compound 1-treated parasites were 
overlaid (Figure 4-6 a). Upon overlaying Figure 4-6 b and c, it was immediately apparent that 
the Fe(III)PPIX associated Fe signal and Br signal attributed to test compound 1 were both 
located within the parasites DV in the same specific place. This definitively shows that co-
localization does occur between Fe(III)PPIX and test compound 1 which led to further 
investigations into the possibility that this co-localization is due to the formation of a 
Fe(III)PPIX-inhibitor complex. 
 
4.4.2 Evidence of a Fe(III)PPIX-inhibitor complex in treated CQS P. falciparum iRBCs. 
 
4.4.2.1 Confocal Raman microspectroscopy 
 
Based on the evidence, previously highlighted in Section 4.4.1, it was further proposed that the 
co-localization of Fe(III)PPIX and test compound 1 was as a direct result of the formation of a 
putative Fe(III)PPIX-test compound 1 complex in the DV of CQS NF54 parasites. A detailed 
investigation into this putative Fe(III)PPIX-test compound 1 complex was carried out using a 
non-destructive, fast and highly sensitive technique, Raman spectroscopy 311,401. This technique 
was utilized in order to determine the molecular variations in the vibrational modes in RBC, 
parasite- and synthetic-based Fe(III)PPIX complexes in an effort to identify the putative 
Fe(III)PPIX-test compound 1 complex. 
a b c 
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For observation of parasite-based Fe(III)PPIX complexes, CQS NF54 parasites (ring stage) 
were treated at 1 × IC50 of test compound 1 (616 nM) and incubated for 30-32 hrs. After 
incubation, cultures were centrifuged and aspirated. After 24 hrs, cultures were left to stand at 
rt. for 10-15 min. Cultures were then mixed and smeared (2 µl) onto an aluminium foil covered 
glass microscope slide. The same procedure was carried out for observing untreated iRBCs. 
Packed RBCs were prepared as previously described in Chapter 2 (see Section 2.4.2). The 
untreated and treated parasite Fe(III)PPIX complexes included: oxy-haemoglobin in RBCs; 
oxy- and deoxy-haemoglobin; haemozoin; and a putative Fe(III)PPIX-test compound 1 
complex. For synthetic Fe(III)PPIX complexes, various solutions of 1 mM concentration were 
prepared in DMSO, dried onto an aluminium foil covered glass microscope slide with an 
incandescent light before analysis. These included: haematin; haemin; β-haematin; test 
compound 1; and a haematin-test compound 1 mixture.  
The typical single scan Raman spectra were recorded with varying laser power at an 
excitation wavelength of 532 nm for the Fe(III)PPIX porphyrin dominated spectral region of 
1700-500 cm-1 for all Fe(III)PPIX complexes investigated in this chapter (see Section 4.3.1). 
This specific spectral range was chosen for the reason that it has been previously reported that 
haemozoin inhibitors, such as test compound 1, tend to bind to Fe(III)PPIX via π- π interactions 
with the porphyrin ring of Fe(III)PPIX and therefore would presumably affect this part of the 
spectrum most strongly 143,322,402-404. For comparison, all spectra were normalized using a 
modified standard normal variate method. This was to ensure that peaks of a specific 
Fe(III)PPIX complex were not excessively different  in scale as might occur by normalizing to 
one specific peak characteristic of another Fe(III)PPIX complex. The observed peak positions, 
local coordinate, assignments and symmetry terms for the Fe(III)PPIX complexes associated 
with RBCs and treated iRBCs are listed in Table 4-4. These were adapted from Abe et al, Hu 
et al, Szczerbowska-Boruchowska et al, Socrates, Dines et al, Webster et al, Marzec et al, 
Wood et al, Suwaiyan et al, Mohan et al, Weselucha-Birczynska et al, Frosch et al and Wood 
et al 294,320,322,401,405-414. The porphyrin symmetry terms of Fe(III)PPIX were designated 
according to idealized D4h symmetry; v1-v9 for A1g, v10-v18 for B1g, v19-v26 for A2g, v27-v35 for 
B2g and v36-v55 for Eu, where, Eu are IR and Raman active modes. δ, γ, w, m and s were 
designated to in-plane deformations, out-of-plane deformations, weak, medium and strong 
peaks relative to other peaks respectively 405-406. Normal modes are also given in local 
coordinates (see Figure 4-7). The results are discussed below. 
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Figure 4-8 a-e: Single scan Raman spectra for the Fe(III)PPIX complexes that are assigned to 
(a) oxy-haemoglobin in RBCs, and (b) oxy-haemoglobin, (c) deoxy-haemoglobin, (d) 
haemozoin, (e) putative Fe(III)PPIX-test compound 1 complex in test compound 1-treated 
CQS iRBCs. The red line represents the possible marker band for the putative Fe(III)PPIX-test 
compound 1 complex at 1080 cm-1.
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Table 4-4 a-e: The observed peak positions, local coordinates, assignments and symmetry terms for RBC and treated iRBCs Fe(III)PPIX complexes 
observed at 532 nm excitation 320,322,405-414. Labels a-e correspond to oxy-haemoglobin in RBCs, oxy-haemoglobin, deoxy-haemoglobin, 
haemozoin and the putative Fe(III)PPIX-test compound 1 complex in treated iRBCs respectively. 
a  b  c  d  e  Local coordinate Assignment Symmetry 
 w  m 1642 w, sh 1642 m, b -  v(CαCm)asym v10 B1g 
1632 w, sh 1632 w, sh -  -  1633 w, sh v(CαCm)asym v10 B1g 
-  1611 w, b -  -  -  v(Ca=Cb) v (Ca=Cb)  
-  -  1601 s,b -  -  v(CαCm)asym v19 A2g 
1594 s, b 1584 w, b 1574 w 1591 s 1591 s, b v(CαCm)asym v37 Eu 
1547 m 1545 m 1545 w -  1564 w, sh v(CβCβ) and, or δ(N-H) v11 or v20 B1g 
-  -  -  -  1456 w, b Aromatic ring vibration, v(C=C)sym v19 E2g 
1432 w 1442 w, b -  -  1437 w v(CαCm)sym v28 B2g 
1393 m 1399 w -  -  1399 m v(pyr quarter-ring) v20 A2g 
1377 m, sh 1379 w, b 1372 m, b -  -  v(pyr half-ring)sym v4 A1g 
-  1364 w, b -  -  1364 s, b v(pyr half-ring)sym v4 A1g 
1341 m, b -  1349 m, b 1349 m, b -  v(pyr half-ring)sym v41 Eu 
1305 m, b 1316 w 1317 m, b 1314 m, b 1312 s δ(CmH)asym v21 A2g 
-  -  1249 w, sh -  -  δ(CmH) v13 B1g 
1223 m, b 1231 m, b 1231 m, b 1228 w 1233 m, b δ(CmH) v13 or v42 B1g, Eu 
1172 m, b 1182 m, b 1182 s 1185 w 1177 m, b v(pyr half-ring)asym v30 B2g 
-  -  -  1160 m, sh -  v(pyr half-ring)asym v30 B2g 
1133 s, b -  1139  1134 s 1136 s v(CαN) and, or  v(pyr half-ring)asym v22 A2g 
1092 w, b 1090 w, b 1095 w, sh 1090 w, sh -  v(CβC1)asym and, or γ(=CbH2)sym v23 A2g 
-  -  -  -  1080 w, b v(CβC1)asym, possible marker band v23 A2g 
1009 w, b 1012 w, b 1012 m, b -  -  Phenylalanine   
-  -  -  1007 w, b 1001 m, b v(Cβ-methyl)asym v45 Eu 
-  -  -  965 w, b 967 w δ(pyr deform)asym v46 Eu 
-  -  -  -  832 w γ(CmH) γ10 B1u 
757 m 757 m,b 760 s 754 w, b 754 s, b v(pyr breathing)asym v15 B1g 
v , stretch; δ, in-plane deformation; γ, out-of-plane deformation; pyr, pyrrole; deform, deformation; asym, asymmetric; sym, symmetric; α, β, m, carbon positions on haem porphyrin; w, weak  peak relative to others; m, 
medium peak relative to others , and, s, strong peak relative to others. Local coordinates, assignments and symmetry terms for the haem labelling scheme were adopted from references 320,322,405-414.
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The spectrum of oxy-haemoglobin in RBCs was recorded from the microscope image in the 
region indicated by the red circle, presented in Figure 4-8 a, inset. Poor signal-to-noise ratio 
with weak broad peaks were observed in the region of the asymmetric stretches of the porphyrin 
ring which were assigned to v10 (v (CαCm)asym) and include peaks at 1650 cm-1 and 1632 cm-1 
(Table 4-4 a). A strong but broad peak in the core size region of the spectrum at 1594 cm-1 (v37 
(v (CαCm)asym)) relative to other peaks was observed compared to a weaker carbon-carbon (C-
C) stretch in the porphyrin ring at 1547 cm-1 (v11 (v (CβCβ)). Weak and medium peaks at 1432 
cm-1, 1393 cm-1, 1377 cm-1, 1341 cm-1 and 1305 cm-1 were observed in the symmetric and 
deformed pyrrole-ring stretching region which were assigned to v28 (v (CαCm)sym), v20 (v (pyr 
quarter-ring)), v4 (v (pyr half-ring)sym), v41 (v (pyr half-ring)sym) and a methine deformation 
mode, v21 (δasym (CmH) respectively. Broad peaks were observed in the spectral region of 1250-
1000 cm-1 and included peaks at 1233 cm-1, 1172 cm-1, 1133 cm-1, 1092 cm-1 and 1009 cm-1 
which were assigned to v13 or v42 (δ (CmH), v30 (v (pyr half-ring)asym), v22 (v (CαN)) and, or (v 
(pyr half-ring)asym), v23 (v (CβC1)asym) and, or γ(=CbH2)sym) and the amino acid phenylalanine, 
whilst the peak at 757 cm-1 was assigned to the pyrrole breathing mode v15 (v (pyr 
breathing)asym). The peak at 1009 cm-1 has been previously assigned to the amino acid 
phenylalanine in globin and has been known to be indicative of transitions between oxy- and 
deoxy-haemoglobin 313,316,415-416. Notably, the observed spectrum for oxy-haemoglobin in 
RBCs showed similarities in the peak positions previously published by Wood et al, but, 
differed in terms of relative peak intensities and definition in the region of 1700-1500 cm-1 316. 
This could be as a result of differences in the resolution of the microscope images as well as 
excitation wavelengths 320. 
In treated iRBCs, oxy- and deoxy-haemoglobin, haemozoin and a putative Fe(III)PPIX-
test compound 1 complex spectra are illustrated in Figure 4-8 b-e with proposed assignments 
listed in Table 4-4 b-e. All spectra are colour-coded and collected from the regions indicated 
by the same colour in the microscope image shown in Figure 4-8 b, inset. The spectrum 
obtained for oxy-haemoglobin (red circle), illustrated in Figure 4-8 b, showed peak positions 
that were very similar to oxy-haemoglobin in RBCs. This was in close agreement with findings 
previously reported by Dasgupta et al 417. However, some peaks were observed to have shifted 
to higher wavenumbers (2-10 cm-1) and there was broadening in the majority of the peaks 
ascribed to poorer signal-to-noise ratio. Specifically, in the core Fe(III)PPIX porphyrin region 
peaks at 1652 cm-1, 1632 cm-1, 1584 cm-1 and 1545 cm-1 were observed and assigned to v10 (v 
(CαCm)asym), v37 (v (CαCm)asym) and v11 (v (CβCβ)) respectively. The peak at 1584 cm-1 was 
observed to be the strongest peak relative to the other peaks. Additional peaks were observed 
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in the spectrum for oxy-haemoglobin in treated iRBCs compared to oxy-haemoglobin in RBCs, 
specifically for the spectral region from 1700-1500 cm-1. This was due to the fact that for oxy-
haemoglobin in treated iRBCs, a better resolution was achieved, however, the appearance of 
these additional peaks was in close agreement with the observations previous reported by 
Wood et al 416. In this region, similar weak peaks at 1642 cm-1, 1601 cm-1, 1574 cm-1 and 1545 
cm-1 with the exception of 1632 cm-1 were observed for deoxy-haemoglobin (Figure 4-8 c) 
which was obtained from the region shown by the orange circle in Figure 4-8 c, inset. These 
peaks were assigned to v10 (v (CαCm)asym), v19 (v (CαCm)asym), v37 (v (CαCm)asym) and v11 (v 
(CβCβ)) respectively. The absence of the peak at 1632 cm-1 agreed with the findings reported 
by Strekas et al, Brunner et al, Ozaki et al, Venkatesh et al and Ong et al 319,418-421. While it 
has also been reported in previous studies by Asghari-Khiavi et al, that the Raman spectrum of 
oxy- and deoxy-haemoglobin is very similar to the Raman spectrum of met-heamoglobin, this 
was as a result of the increased oxidation of oxy- and deoxy-haemogloin in RBCs that were 
fixed with glutaraldehyde which was not used in the present experiment 422. On the other hand, 
it has also been previously reported that deoxy-haemoglobin and met-haemoglobin is similar 
in terms of peaks but differ where met-haemoglobin shows a peak at 1636 cm-1. Therefore, 
since glutaraldehyde was not used as a fixative in this study the peak at 1636 cm-1 was not 
observed in the above spectrum for deoxy-haemoglobin proving that it was not met-
haemoglobin 416. Haemozoin, shown by the dark region (green circle) in the microscope image 
resulted in peaks at 1642 cm-1 (v10 (v (CαCm)asym)) and 1591 cm-1 (v37 (v (CαCm)asym)) which 
was similar to peaks observed for deoxy-haemoglobin (Figure 4-8 c). The latter peak position 
was the strongest in haemozoin and has been attributed to excitonic coupling as a result of the 
propionate linkage of the Fe(III)PPIX porphyrin units in haemozoin 322,423. The putative 
Fe(III)PPIX-test compound 1 complex (purple arrow in Figure 4-8 c, inset) showed peaks at 
1633 cm-1, 1591 cm-1 and 1564 cm-1, where the peak at 1564 cm-1 was shifted to a higher 
wavenumber (17-19 cm-1) compared to the other Fe(III)PPIX complexes (Figure 4-8 d). Peak 
assignments pertaining to v10 (v (CαCm)asym)), v37 (v (CαCm)asym)), v11 (v (CβCβ)) and, or v20 (δ(N-
H)) respectively, were made for these peaks.  
For the region pertaining to the pyrrole-ring stretches and carbon-hydrogen (C-H) 
deformations, oxy-haemoglobin resulted in peaks at 1442 cm-1, 1399 cm-1, 1379 cm-1, 1364 
cm-1, 1316 cm-1 which were assigned to v28 (v (CαCm)sym), v20 (v (pyr quarter-ring)), v4 (v (pyr 
half-ring)sym) and v21 (δ (CmH)asym) respectively. Deoxy-haemoglobin showed peaks at 1372 
cm-1 and 1317 cm-1 with the exclusion of 1349 cm-1 which was shifted to lower wavenumbers. 
These peaks were assigned to v4 (v (pyr half-ring)sym), v21 (δ (CmH)asym) and v41 (v (pyr half-
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ring)sym) respectively. Compared to the other Fe(III)PPIX complexes, deoxy-haemoglobin 
showed a peak at 1249 cm-1 which was assigned to v13 (δ (CmH)). This specific peak was 
observed to be shifted from 1259 cm-1 in oxy-haemoglobin, which has been previously 
observed to be a distinctive difference when comparing the spectra of oxy- and deoxy-
haemoglobin 415-416. The peaks in this region for deoxy-haemoglobin were also observed to be 
more pronounced than in oxy-haemoglobin. This has been observed in previous studies and 
was suggested to be as a result of peaks in this region specifically tending to be sensitive to the 
oxidation and spin state of the Fe atom 423-430. Similar to deoxy-haemoglobin, weak and broad 
peaks at 1349 cm-1 and 1314 cm-1, assigned to v41 (v (pyr half-ring)sym) and v21 (δ (CmH)asym) 
were observed for haemozoin. The putative Fe(III)PPIX-test compound 1 complex had peaks 
at 1456 cm-1, 1437 cm-1 (v28 (v (CαCm)sym)), 1399 cm-1 (v20 (v (pyr quarter-ring))), 1364 cm-1 
(v4 (v (pyr half-ring)sym)) and 1312 cm-1 (v21 (δ (CmH)asym)) which were similar to that observed 
for the other Fe(III)PPIX complexes with the exception of an additional peak observed at 1456 
cm-1. This peak was assigned to an aromatic ring vibration (v19 (v (C=C)sym)). 
Towards lower wavenumbers, oxy-haemoglobin showed peaks at 1090 cm-1, 1012 cm-1 
and 757 cm-1 that were assigned to v23 (v (CβC1)asym) and, or γ(=CbH2)sym), phenylalanine and 
v15 (v (pyr breathing)asym). Similarly, deoxy-haemoglobin and haemozoin showed peaks at 1133 
cm-1, 1095 cm-1, 1012 cm-1, 760 cm-1 and 1160 cm-1, 1134 cm-1, 1090 cm-1, 1007 cm-1, 965 cm-
1 and 754 cm-1 respectively. For deoxy-haemoglobin these peaks were assigned to v22 (v (CαN)) 
and, or  (v (pyr half-ring)asym)), v23 (v (CβC1)asym) and, or γ(=CbH2)sym), phenylalanine and v15 
(v (pyr breathing)asym), where, peaks for haemozoin were assigned to v22 (v (CαN)) and, or  (v 
(pyr half-ring)asym)), v23 (v (CβC1)asym) and, or γ(=CbH2)sym), v45 (v (Cβ-methyl)asym), v46 (δ(pyr 
deform)asym) and v15 (v (pyr breathing)asym). Notably, the peak at 1133 cm-1 for deoxy-
haemoglobin and 1134 cm-1 for haemozoin differed in relative intensity but coincided with 
similar observed peaks in oxy-haemoglobin in RBCs and the putative Fe(III)PPIX-test 
compound 1 complex. Reports by Hobro et al, reported similar findings where peaks in the 
region of the pyrrole half-ring stretches for haemoglobin and haemozoin were similar but 
tended to differ in their relative intensities 431.  In addition, the peak at 1160 cm-1 was observed 
to only appear in the spectrum for haemozoin. It has been suggested by Hobro et al that the 
appearance of this peak could be the reason for the differences in the relative intensities for the 
neighboring peaks (1185 cm-1 and 1134 cm-1) in the pyrrole half-ring stretching region compare 
to the strong peaks for oxy-haemoglobin, deoxy-haemoglobin and the putative Fe(III)PPIX-
test compound 1 complex between 1180-1130 cm-1 431. The putative Fe(III)PPIX-test 
compound 1 complex showed peaks at 1136 cm-1, 1080 cm-1, 1001 cm-1, 967 cm-1, 832 cm-1 
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and 754 cm-1. These peaks, excluding 1080 cm-1, were assigned to v22 (v (CαN)) and, or  (v (pyr 
half-ring)asym)), v45 (v (Cβ-methyl)asym), v46 (δ(pyr deform)asym), γ10 (γ(CmH)) and v15 (v (pyr 
breathing)asym) respectively. With regards to the peak at 1080 cm-1 (v23 (v (CβC1)asym), this was 
not observed in any of the spectra for the other Fe(III)PPIX complexes, shown by the red line 
in Figure 4-8 a-e. However, it could be that the peak at 1090 cm-1 is red shifted to 1080 cm-1 
which is indicative of a π- π interaction with the pyrrole and imidazole ring. This has been 
previously observed by Tempera et al with CQ where it was also suggested that a similar shift 
was as a result of the π- π interaction between the pyrrole and quinoline rings 376.  It is also 
worth noting that the peaks observed at 1349 cm-1, 1314 cm-1, 1228 cm-1, 1185 cm-1, 1090 cm-
1 and 1007 cm-1 in haemozoin appeared shifted in the spectrum of the putative Fe(III)PPIX-test 
compound 1 complex and included an absence of the peak at 1160 cm-1. In addition, an 
increased signal-to-noise ratio was observed for the peaks at 1134 cm-1 and 754 cm-1 in the 
spectrum of the putative Fe(III)PPIX-test compound 1 spectrum compared to haemozoin. 
Therefore, these observed changes in the peak position and shape of the spectrum for the 
putative Fe(III)PPIX-test compound 1 complex compared to haemozoin could also be 
indicative of changes in the molecular environment of Fe(III)PPIX as a result of a π- π 
interaction between test compound 1 and Fe(III)PPIX 322,376. It was, however, apparent that in 
the spectrum of the putative Fe(III)PPIX-test compound 1, no prominent peaks attributed to 
test compound 1 were observed. This is likely the result of haem resonance. Similar 
observations were reported by Webster et al for CQ-treated iRBCs 322.   
 
Next, single scan Raman spectra were recorded for synthetic Fe(III)PPIX complexes. This was 
in order to determine whether the spectrum of the putative Fe(III)PPIX-test compound 1 
complex was unique to test compound 1-treated iRBCs. The spectra along with the observed 
peak positions, local coordinate assignments and symmetry terms for all synthetic Fe(III)PPIX 
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Figure 4-9 a-e: Single scan Raman spectra for synthetic Fe(III)PPIX complexes represented 
by (a) haematin, (b) haemin, (c) β-haematin, (d) test compound 1 (inset), and, (e) haematin-
test compound 1 mixture precipitated from aqueous DMSO. The red line represents the 
possible marker band for the Fe(III)PPIX-test compound 1 complex at 1080 cm-1. 
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Table 4-5: The observed peak positions, local coordinate, assignments and symmetry terms for synthetic Fe(III)PPIX complexes observed at 532 
nm excitation 320,322,405-414. Labels a-e correspond to haematin, haemin, β-haematin, test compound 1 and the haematin-test compound 1 mixture in 
DMSO respectively. 
v , stretch; δ, in-plane deformation; γ, out-of-plane deformation; Bz, benzene; Im, imidazole; pyr, pyrrole; deform, deformation; asym, asymmetric; sym, symmetric; α, β, m, carbon positions on haem porphyrin; w, weak  
peak relative to others; m, medium peak relative to others , and, s, strong peak relative to others. Local coordinates, assignments and symmetry terms for the haem labelling scheme were adopted from references 
320,322,405-414. 
a  b  c  d  e  Local coordinate Assignment Symmetry 
-  -  1640 s, b -  -  v(CαCm)asym v10 B1g 
1627 s 1628 s -  -  1628 s, b v(Ca=Cb) v (Ca=Cb)  
-  -  -  1620 s -  v(C=C)Bz and, or  v(C=N) v11 E2g 
1581 s, b 1582 s 1585 s -  1586 s, sh v(CαCm)asym v37 Eu 
-  1564 s, sh -  -  -  v(CβCβ) v2 A1g 
-  -  -  1557 m, b -  v(CβCβ) and, or   δ(N-H) v20  
-  1538 m -  -  -  v(CβCβ) v11 B1g 
-  -  -  1486 w, sh -  v(C=C) v (C=C)  
-  -  -  1456 s 1464 w, b v(C=C)aromatic ring v19 E2g 
1435 w, b -  -  -  -  v(CαCm)sym v28 B2g 
1372 s, b 1378 s, b 1379 m, b -  1377 w v(pyr half-ring)sym v4 A1g 
-  -  1343 m, b -  1331 w, b v(C-N) and, or v(pyr half-ring)sym v41 Eu 
-  -  -  1339 s, b -  v(C-N) and, or  v(C=C)  A2g 
1310 m 1312 m, sh 1317 m -  -  δasym(CmH) v21 A2g 
-  -  -  1276 s, b 1271 w v(C-N) and  δ(Bz) a´  
1230 w, b 1233 w, b 1233 w,b -  -  δ(CmH) v13 or v42 B1g, Eu 
-  -  -  1195 m -  v(C-H)aromatic ring and δ(C-H)Bz   
1180 w 1175 w 1174 m -  1175 w, b v(pyr half-ring)asym v30 B2g 
1139 w, b 1126 w, b 1128 m -  -  v(CαN) and, or  v(pyr half-ring)asym v22 A2g 
-  -  1095 w,sh -  -  v(CβC1)asym and, or γ(=CbH2)sym v23 A2g 
-  -  -  -  1080 w, b v(CβC1)asym and, or possible marker band v23 A2g 
-  -  -  1027 w, b -  δ(Bz) and, or  v(CβC1)asym   
993 w, b -  1009 w, b -  -  v(CβC1)asym v45 Eu 
-  970 w, b 970 w, b -  975 m δ(pyr deform)asym and, or  γ(=CbH2)sym v46 Eu 
-  -  -  967 w, b -  δ(Im) and, or   δ(pyr breathing)sym v46 E2u 
765 m 765 m, b 760 m, b -  765 w, b v(pyr breathing)asym v15 B1g 
-  -  -  629 w, b -  γ(N-H) v30 Cs 
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First, haematin was observed to result in a spectrum with peaks showing better signal-to-noise 
ratio compared to haemin that showed a poor signal-to-noise ratio with broader featureless 
peaks (Figure 4-9 a-b). In particular, for the Fe(III)PPIX porphyrin core size region (Table 4-
5 a-b), haematin and haemin showed peaks at 1627 cm-1, 1581 cm-1, and, 1628 cm-1, 1582 cm-
1, 1564 cm-1 and 1538 cm-1 respectively. These peaks were assigned to v(Ca=Cb), v37 (v 
(CαCm)asym), and, v(Ca=Cb), v37 (v (CαCm)asym), v2 (v(CβCβ)) and v11 v(CβCβ) respectively. In the 
region of the pyrrole-ring stretches and C-H deformations (1500-1200 cm-1), haematin and 
haemin showed similar peaks with some peaks that were shifted slightly to higher 
wavenumbers in haemin. Haematin showed peaks at 1435 cm-1, 1372 cm-1, 1310 cm-1 and 1230 
cm-1, where haemin showed peaks at 1378 cm-1 (v4 (v (pyr half-ring)sym)), 1312 cm-1 (v21 (δ 
(CmH)asym)) and 1233 cm-1 (v13 or v42 (δ (CmH))). The peaks for haematin were assigned to v28 
(v (CαCm)sym), v4 (v (pyr half-ring)sym), v21 (δ (CmH)asym) and v13 or v42 (δ (CmH)). On the lower 
end of the spectra, haematin showed peaks at 1180 cm-1, 1139 cm-1, 993 cm-1 and 765 cm-1, 
where, haemin showed peaks at 1175 cm-1, 1126 cm-1, 970 cm-1 and 765 cm-1. These peaks 
were assigned to pyrrole half-ring stretches and breathing modes which were designated as; v30 
(v (pyr half-ring)asym), v22 (v (CαN)) and, or  (v (pyr half-ring)asym)), v45 (v (Cβ-methyl)asym) and 
v15 (v (pyr breathing)asym). Haemin was observed to have an additional peak at 970 cm-1, which 
could correspond to v46 (δ(pyr deform)asym) and, or (γ(=CbH2)). Both spectra were similar to 
that obtained by Wood et al, who identified haematin to be in the monomeric Fe3+ high spin 
state and haemin in the Fe3+ high spin state 416.  
The spectrum of β-haematin exhibited peaks at 1640 cm-1, 1585 cm-1, 1379 cm-1, 1343 
cm-1, 1317 cm-1, 1233 cm-1, 1174 cm-1, 1128 cm-1, 1095 cm-1, 1009 cm-1, 970 cm-1 and 760 cm-
1 which coincided with the observed peaks for haemozoin (Table 4-5 c). These peaks were 
assigned to v10 (v (CαCm)asym), v37 (v (CαCm)asym), v4 (v (pyr half-ring)sym), v41 (v (pyr half-
ring)sym) and, or (v (C-N)), v21 (δ (CmH)asym)), v13 or v42 (δ (CmH)), v30 (v (pyr half-ring)asym), 
v22 (v (CαN)) and, or  (v (pyr half-ring)asym)), v23 (v (CβC1)asym) and, or γ(=CbH2)sym), v45 (v (Cβ-
methyl)asym), v46 (δ(pyr deform)asym) and, or (γ(=CbH2)) and v15 (v (pyr breathing)asym) 
respectively. In β-haematin, a commonly observed peak at 1375 cm-1 has been previously 
reported to be an indication that β-haematin is a high spin Fe(III) species 414. This appeared to 
be shifted to 1379 cm-1 in this study (Figure 4-9 c). Overlay demonstrates how similar the 
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Figure 4-10: Overlay of the single scan Raman spectra for haemozoin in situ in a parasite 
(green) in test compound 1-treated iRBCs and synthetically prepared β-haematin in DMSO 
(black). 
 
Figure 4-9 d illustrates the spectrum for test compound 1 in DMSO that showed very good 
signal-to-noise ratio which coincided with clearly defined peaks, specifically for the spectral 
range of 1700-1100 cm-1 (Figure 4-9 d, inset). Peaks at 1620 cm-1, 1557 cm-1, 1486 cm-1 and 
1456 cm-1 were observed, with the strongest peaks being 1620 cm-1 and 1456 cm-1.  These 
peaks were assigned to v11 (v(C=C)Bz) and, or  (v(C=N)), v20 (v(CβCβ) and, or (δ(N-H)), 
(v(C=C)) and the aromatic ring stretch v19 (v(C=C). In the region of 1400-1000 cm-1, test 
compound 1 showed peaks at 1339 cm-1, 1276 cm-1, 1195 cm-1 and 1027 cm-1 which were 
assigned to the vibrational and stretching modes of the benzimidazole which included; v(C-N) 
and, or v(C=C), a´ (v(C-N) and δ(Bz)), v(C-H)aromatic ring and δ(C-H)Bz, δ(Bz) and, or  
v(CβC1)asym. Towards the lower end of the spectrum, peaks at 967 cm-1 and 629 cm-1, assigned 
to v46 (δ(Im) and, or δ(pyr breathing)sym) and v30 (γ(N-H)), were observed to be much broader 
and weaker compared to the other peaks (Table 4-5 d).  
The haematin-test compound 1 mixture showed peaks that were related to both haematin 
and test compound 1 which was suggested to be as a result of the presence of unbound haematin 
and test compound 1 with bound haematin and test compound 1 in the mixture (Figure 4-9 e). 
Moreover, the peaks that were observed for this haematin-test compound 1 mixture included; 
1628 cm-1, 1586 cm-1, 1464 cm-1, 1377 cm-1, 1331 cm-1, 1271 cm-1, 1175 cm-1, 1080 cm-1, 975 
cm-1 and 765 cm-1. These peaks were designated to v(Ca=Cb), v37 (v (CαCm)asym), aromatic ring 
stretch v19 (v(C=C), v4 (v (pyr half-ring)sym), v41 (v (pyr half-ring)sym), a´ (v(C-N) and  δ(Bz)), 
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v30 (v (pyr half-ring)asym), v23 (v (CβC1)asym), v46 (δ(pyr deform)asym) and v15 (v (pyr 
breathing)asym) respectively, which are listed in Table 4-5 e. The solution contained a large 
excess of test compound 1 relative to the amount of haematin. This was in order to drive the 
equilibrium towards complex formation and to reduce the domination of test compound 1 
signals by the signals associated with unbound haematin, which would dominate the spectrum 
owing to the haem resonance effect.  Again, the peak at 1080 cm-1 that was observed in the 
spectrum for the putative Fe(III)PPIX-test compound 1 complex in treated iRBCs was observed 
in the spectrum for the haematin-test compound 1 mixture, but in none of the other Fe(III)PPIX 
complexes (red line). From here, it was inferred that this specific peak could indeed be a marker 
band for the Fe(III)PPIX-test compound 1 complex. However, as presented the spectra differed 
visibly, where the haematin-test compound 1 mixture showed a much lower signal-to-noise 
ratio in comparison to the putative Fe(III)PPIX-test compound 1 complex. This was 
unsurprising given the drastic differences in haematin to test compound 1 ratio. 
To reduce this problem, the spectra of these Fe(III)PPIX complexes were overlaid as 
illustrated in Figure 4-11. For comparison, the spectra for the putative Fe(III)PPIX-test 
compound 1 complex and test compound 1 in DMSO (black) were added together in the same 
ratio before overlaying the averaged spectrum with the spectrum of the haematin-test 
compound 1 mixture (peach). The resulting overlaid spectra showed similarities in most parts 
of the spectrum, but, this was more apparent in the spectral range of 1700-1400 cm-1. However, 
the spectra differed in parts of the spectrum that were attributed to the pyrrole-ring stretching 
region (1400-1000 cm-1) with a poor signal-to-noise ratio.  
A disadvantage with the haematin-test compound 1 mixture was that solubility 
difficulties were encountered with test compound 1 which made it difficult to precipitate the 
synthetically prepared complex. Multiple experiments were required before it was concluded 
that the mixture would have to be analyzed in solution rather, which could explain the poor 
signal-to-noise ratio. Nonetheless, it was inferred that the proposed Fe(III)PPIX-test compound 
1 complex observed in treated iRBCs was in fact a complex that formed between Fe(III)PPIX 
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Figure 4-11: Overlay of the Raman spectra for the putative Fe(III)PPIX-test compound 1 
complex averaged with the spectrum of test compound 1 in DMSO (black) with the haematin-
test compound 1 mixture (peach). 
 
4.4.2.2 Confocal Raman true mapping images 
 
A fast, efficient and non-invasive imaging technique that is rapidly advancing the way in which 
the variations in chemical and molecular vibrations observed in a Raman spectrum are imaged 
is, confocal Raman imaging 432. The images that are obtained are often recorded for a specific 
region which is defined by the number of lines per image and points per line, where each pixel 
pertains to a specific spectrum within the image.  Here, this allows for the sample to be analyzed 
for one Fe(III)PPIX complex at a time 433. Thus, this technique was used to gain further insights 
into the contribution of a specific Raman peak to the signal distribution for a specific 
Fe(III)PPIX complex, and thus being able to identify the location of the specific spectra 
pertaining to each Fe(III)PPIX complex in untreated and treated iRBCs.  
 In brief, CQS NF54 parasites were treated with test compound 1 (1 × IC50) and incubated 
at physiological temperature for 30-32 hrs. Cultures were removed after the incubation period, 
aspirated, then fixed with 25% glutaraldehyde in filtered PBS and stored at 4 °C. An advantage 
of using an aldehyde as a fixative (e.g. glutaraldehyde), for imaging purposes is that aldehyde 
fixatives are known to preserve the native composition and components of the cell without the 
formation of artefacts 435-436. After 24 hrs, cultures were then left to stand for 15 min at rt. 
before smearing (2 µl) the samples onto the aluminium foil covered glass microscope slide. 
The same was applied to untreated iRBCs.  
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Thus, confocal Raman true mapping images were obtained for the Fe(III)PPIX complexes: 
oxy-haemoglobin; deoxy-haemoglobin; haemozoin; and the Fe(III)PPIX-test compound 1 
complex from LAS image Raman spectra (see Section 4.3.2, Figure 4-2). Briefly, the LAS 
image Raman spectra were taken through a number of analysis steps using the WITec Project 
FIVE software. The spectra were analyzed using a built-in true component analysis tool, where, 
the spectra of each Fe(III)PPIX complex were individually extracted from the residual LAS 
image. The individually extracted component spectra were averaged and demixed. From here, 
the spectrum for each Fe(III)PPIX complex was analyzed separately by using the filter tool 
(width 1 cm-1). This filter viewer was used to generate true mapping images at specific peak 
positions, including: 754 cm-1; 1080 cm-1; 1090 cm-1; and 1642 cm-1 which were color-coded 
accordingly (red, green, yellow and orange respectively). These specific Raman peaks were 
chosen based on the observations discussed previously in Section 4.4.2.1, where changes in 
peak intensities and positions were observed to be apparent in the presence of test compound 
1, as well as investigations into the distribution of the possible marker peak at 1080 cm-1 for 
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Figure 4-12 I-III: Confocal Raman true mapping images, obtained using true component 
analysis and filter viewer tools, for untreated iRBCs containing three distinct Fe(III)PPIX 
complexes which are represented by (I) oxy-haemoglobin, (II) deoxy-haemoglobin and (III) 
haemozoin which were imaged at specific Raman peaks represented by a, e and i) 754 cm-1 
(red); b, f and j) 1080 cm-1 (green); c, g and k) 1090 cm-1 (yellow) and; d, h and l) 1642 cm-1 
(orange) that were previously assigned to v15 (v (pyr breathing)asym), v23 (v (CβC1)asym), v23 
(v(CβC1)asym and, or γ(=CbH2)sym) and  v10 (v (CaCm)asym). (15 × 15 points per image and points 
per line and 0.05 s intergration time with a run time =35 min). 
 
The confocal Raman true mapping images for untreated iRBCs are shown in Figure 4-12 I-III 
for three distinct Fe(III)PPIX complexes namely: oxy-haemoglobin; deoxy-haemoglobin; and 
haemozoin. The images for these Fe(III)PPIX complexes were determined at four specific 
Raman peaks: 754 cm-1 (red); 1080 cm-1 (green); 1090 cm-1 (yellow); and 1642 cm-1 (orange) 
that were previously assigned to v15 (v (pyr breathing)asym), v23 (v (CβC1)asym) and, or possible 
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It was observed from the images at the Raman peak of 754 cm-1 represented the signal 
distribution of oxy- and deoxy-haemoglobin in the RBC of the iRBC, where, the image for 
deoxy-haemoglobin was observed to be more pronounce (Figure 4-12 a and e). For the image 
pertaining to haemozoin, the signal distribution of haemozoin was observed to be localized in 
the parasite DV with some haemozoin outside of the RBC (Figure 4-12 i, white arrow). This 
has been observed recently by Kapishnikov et al who revealed with X-ray fluorescence 
microscopy that several isolated haemozoin crystals were observed outside RBCs 291. At the 
Raman peak of 1080 cm-1, no signal distribution was observed in the images for all Fe(III)PPIX 
complexes which was expected, since none showed a peak at this position (Figure 4-12 b, f 
and j). On the other hand, oxy-haemoglobin, deoxy-haemoglobin and haemozoin produced 
images at the Raman peak of 1090 cm-1, which, all showed similar signal distributions to that 
observed for the Raman peak at 754 cm-1 (Figure 4-12 c, g and k), although, compared to the 
images at the Raman peak of 754 cm-1, a more intense signal for oxy-haemoglobin was 
observed than that for deoxy-haemoglobin. Haemozoin showed a much less intense signal 
distribution but was consistent with the observations for the Raman peak at 754 cm-1. 
Additionally, the Raman peak at 1642 cm-1 resulted in images illustrated in Figure 4-12 d, h 
and l which showed clear signal distributions for deoxy-haemoglobin and haemozoin, but not 
oxy-haemoglobin. This was expected since oxy-haemoglobin did not show a peak at this 
position. The images for deoxy-haemoglobin and haemozoin showed intense signals 
distributed in the RBC and parasite DV respectively. 
To compare, confocal Raman true mapping images for test compound 1-treated iRBCs 
were also investigated at the same Raman peaks for untreated iRBCs. Figure 4-13 I-IV 
illustrates the true mapping images for four distinct Fe(III)PPIX complexes, including the 
Fe(III)PPIX-test compound 1 complex, that were observed to result in signal distributions that 
were similar to untreated parasites. 
In more detail, the images for the Raman peak at 754 cm-1 showed a strong signal 
distribution in the RBC of the treated iRBC for oxy- and deoxy-haemolgobin, whereas, 
haemozoin and the Fe(III)PPIX-test compound 1 complex showed signal distributions within 
the DV (Figure 4-13 a, e, i and m). Interestingly, the signal distribution for haemozoin and the 
Fe(III)PPIX-test compound 1 complex were observed to result in similar signal distribution 
images at this Raman peak, with a less intense signal distribution observed for the Fe(III)PPIX-
test compound 1 complex. Similar to the observations for untreated iRBCs, the image for 
haemozoin revealed haemozoin crystals outside of the RBC of the treated iRBC which may 
represent material from previous cycles (Figure 4-13 i, white arrows). However, for the 
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Fe(III)PPIX-test compound 1 complex at this particular Raman peak, it was suggested that this 
vibrational stretch (v15 (v (pyr breathing)asym)) could be associated to both unbound Fe(III)PPIX 
itself or Fe(III)PPIX attributed to by the Fe(III)PPIX-test compound 1 complex. In addition, 
part of the signal was observed in the same region as the haemozoin seen outside of the RBC 
of the treated iRBC (Figure 4-13 m, white arrow). 
For the Raman peak at 1080 cm-1, none of the Fe(III)PPIX complexes resulted in a signal 
distribution except the Fe(III)PPIX-test compound 1 complex which was expected (Figure 4-
13 b, f, j and n). From this, it was clear from the image illustrated in Figure 4-13 n that this 
particular Raman peak was unique for this particular Fe(III)PPIX-test compound 1 complex 
and could be considered to be marker band.  
Images for the Raman peak at 1090 cm-1 were observed to result in signal distributions  
from the RBC for oxy-haemoglobin and deoxy-haemoglobin and the DV for haemozoin, 
except no signal was observed for the Fe(III)PPIX-test compound 1 complex (Figure 4-13 c, 
g, k and o). Additionally, oxy-haemoglobin showed a more intense signal than deoxy-
haemoglobin, but, both showed a poorer signal-to-noise ratio in comparison to haemozoin. 
The images for the Raman peak at 1642 cm-1 revealed no signal for oxy-haemoglobin 
and the Fe(III)PPIX-test compound 1 complex (Figure 4-13 d and p). On the other hand, 
deoxy-haemoglobin and haemozoin resulted in signal distributions that was localized to the 
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Figure 4-13 I-IV: Confocal Raman true mapping images obtained, using true component 
analysis and filter viewer tools, for test compound 1-treated iRBCs containing four distinct 
Fe(III)PPIX complexes which are represented by (I) oxy-haemoglobin, (II) deoxy-
haemoglobin, (III) haemozoin, and, (IV) Fe(III)PPIX-test compound 1 complex which were 
imaged at specific Raman peaks represented by a, e, i and m) 754 cm-1 (red); b, f, j and h)1080 
cm-1 (green); c, g, k and o) 1090 cm-1 (yellow) and; d, h, l and p) 1642 cm-1 (orange) that have 
been previously assigned to v15 (v (pyr breathing)asym), v23 (v (CβC1)asym), v23 (v(CβC1)asym and, 
or γ(=CbH2)sym) and  v10 (v (CaCm)asym). (15 × 15 points per image and points per line and 0.05 
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To better visualize whether the signal distribution of the spectra for haemozoin imaged at the 
peak position of 754 cm-1 and the Fe(III)PPIX-test compound 1 complex at the peak position 
of 1080 cm-1 were localized within the same region of the parasites DV, the true mapping 
images were overlaid (Figure 4-10 a-c). From this observation, it was apparent that the signal 
distribution of the spectra for haemozoin and the Fe(III)PPIX-test compound 1 complex are 









Figure 4-14 a-c: Evidence of the Fe(III)PPIX-test compound 1 complex in the DV of CQS 
NF54 test compound 1-treated iRBCs represented by (b) overlaid image of (a) haemozoin at 




PCA, a common multidimensional analysis often used in combination with Raman 
spectroscopy to identify correlations and variability in the Raman spectra, was used in this 
study 417,431,437-439. This analysis was used to statistically distinguish between the spectra for 
the different Fe(III)PPIX complexes based on their peak positions in view of the close 
similarity of the spectra. In essence, each repeat spectrum can be considered as a point in 
multidimensional space with a dimension equal to the number of peaks under consideration. 
These peak positions are then reduced to two dimensions on a set of orthogonal axes (PC1 and 
PC2). The variance within the spectra of each of the pair of Fe(III)PPIX complexes being 
considered is represented by a cluster of points on the plot. The replicate spectra for each 
Fe(III)PPIX complex were obtained from the true mapping images of treated iRBCs (Figure 
4-15 a-d). The same process as described in Section 4.4.2.2, was used to obtain true mapping 
images for synthetic Fe(III)PPIX complexes, specifically for performing PCA. Briefly, 150-
200 spectra for each Fe(III)PPIX complex investigated in this study for the spectral range of 
1700-500 cm-1 were collected individually prior to performing a number of analysis steps, 
a b c 
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previously described in Section 4.3.3. The eigenvectors with the corresponding eigenvalues 
were calculated for each Fe(III)PPIX complex being compared using Molegro data analysis 
tool after which individual PCA plots were constructed in GraphPad Prism v8.2.1. The results 



























Figure 4-15 a-d: PCA plots for PC1 versus PC2 of Fe(III)PPIX complexes that were compared 
and are represented by (a) oxy- (red) and deoxy-haemoglobin (orange), (b) oxy-haemoglobin 
(red) and haemozoin (green), (c) test compound 1 (blue) and Fe(III)PPIX-test compound 1 
complex (purple), and, (d) Fe(III)PPIX-test compound 1 complex (purple) and haematin-test 
compound 1 mixture (peach).
a b 
c d 
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In Figure 4-15 a, the PCA plot for oxy-haemoglobin (red) versus deoxy-haemoglobin (orange) 
in treated iRBCs showed a significant separation along PC1, where, 86% of the variance was 
accounted for by PC1 and 8% by PC2. In addition, the cluster for deoxy-haemoglobin was less 
scattered compared to the cluster for oxy-haemoglobin. A smaller separation between the 
clusters of oxy-haemoglobin (red) and haemozoin (green) was observed (Figure 4-15 b) along 
PC1. For this plot, 71% of the variance was accounted for by PC1 and 17% for PC2.  This was 
expected as very similar peak positions for oxy-haemoglobin and haemozoin with slight shifts 
(2-5 cm-1) were observed previously (see Section 4.4.2.1). However, the haemozoin cluster 
showed a higher degree of scatter compared to that of oxy-haemoglobin which could be as a 
result of the quality of the replicated spectra for haemozoin. With that said, it was very difficult 
to obtain high quality spectra for haemozoin as after 30-32 hrs of incubation in the presence of 
test compound 1, the haemozoin crystals were observed to be less well-defined (Figure 4-5 d) 
as a result of inhibition of haemozoin formation as well as being intimately mixed with the 
Fe(III)PPIX-test compound 1 complex thus decreasing the signal-to-noise ratio in the spectra 
as seen in Figure 4-8 e. 
 Interestingly, for the PCA plot of test compound 1 (blue) and the Fe(III)PPIX-test 
compound 1 complex (purple) there was no sign of any overlap in the clusters but rather they 
were slightly separated along PC1 (Figure 4-15 c). About 71% variance was accounted for by 
PC1 and 16% for PC2 for this specific plot. One possible reason, was that the peaks relating to 
test compound 1 are dominated by the Fe(III)PPIX peaks as a result of haem resonance, 
therefore resulting in a separation between the two clusters. In addition, much less scatter was 
observed for the test compound 1 cluster compared to the Fe(III)PPIX-test compound 1 
complex. Again, this could be as a result of the quality of the spectra obtained as well as the 
signal-to-noise ratio being too low for some of the replicates.  
 On the other hand, Figure 4-15 d shows the PC1 (63%) versus PC2 (21%) plot for the 
Fe(III)PPIX-test compound 1 complex versus the haematin-test compound 1 mixture where no 
significant separation was observed on either PC1 or PC2. From this, it was inferred that despite 
the difficulties in visually comparing these spectra, seen in Figure 4-11, PCA confirms that the 
Fe(III)PPIX-test compound 1 complex is in fact the same as the haematin-test compound 1 
mixture, at least with respect to peak positions, confirming that the spectra obtained from the 
cell almost certainly represent a complex, particularly given the appearance of the unique peak 
at 1080 cm-1 mentioned previously.
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4.4.2.4 Welch’s t-test analysis 
 
To better establish the significance of the cluster separations observed in the PCA plots for the 
Fe(III)PPIX complexes, a Welch’s t-test analysis was conducted (Figure 4-16 a-d). A similar 
approach called the Mahalanobis distance has been previously reported by Goodpaster et al, 
however, with the clusters being so close to the " axis this more complicated approach was not 
necessary 440. The equations previously described in Section 4.3.4 were used instead. This 
involved shifting the centroids of each cluster and transforming the clusters about the angle 
between the centroids in order to obtain a new shifted and transformed PCA plot of " versus # 
such that the centroids of both clusters lay on the " axis with one at the origin. From here, the 
new data points for the plot of #$$ versus "$$ were used to perform a Welch’s t-test analysis of 
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Figure 4-16 a-d: Welch’s t-test plots for the PCA plots represented for; (a) oxy-haemoglobin 
versus deoxy-haemoglobin, (b) oxy-haemoglobin versus haemozoin, (c) test compound 1 
versus the Fe(III)PPIX-test compound 1 complex, and, (d) the haematin-test compound 1 
mixture versus the Fe(III)PPIX-test compound 1 complex. Using GraphPad Prism v8.2.1, 
correlation coefficients were calculated to be; R2 = 0.9736, R2 = 0.8771, R2 = 0.8889 and R2 = 
0.0000022 respectively. 
 
Figure 4-16 a-d presents the Welch’s t-test analysis plots for the PCA plots shown in Figure 
4-15 a-d. From the Welch’s t-test plots, it was observed that the separation between oxy-
haemoglobin and deoxy-haemoglobin was significant at the 99.99% confidence level (p = 
<0.0001) and resulted in a correlation coefficient of R2 = 0.9736. The same was observed for 
oxy-haemoglobin versus haemozoin (p = <0.0001; R2 = 0.8771), and test compound 1 versus 
the Fe(III)PPIX-test compound 1 complex (p = <0.0001; R2 = 0.8889). However, the separation 
between the Fe(III)PPIX-test compound 1 complex and the haematin-test compound 1 mixture 
was observed to be not significant (p = 0.9869; R2 = 0.0000022). This further verifies that there 
a b 
c d 
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is in fact no separation between the clusters of the Fe(III)PPIX-test compound 1 complex and 
the Fe(III)PPIX-test compound 1 mixture in the PCA plot observed in Figure 4-15 d. 
 
Table 4-6: Statistical comparison of the Fe(III)PPIX-test compound 1 complex in treated 
iRBCs to all other Fe(III)PPIX complexes analyzed 
Fe(III)PPIX complexes compared to 
Fe(III)PPIX-test compound 1 complex 
p value R2 value 
 
a. oxy-haemoglobin in RBCs <0.0001 0.7059 
b. oxy-haemoglobin in treated iRBCs  <0.0001 0.6082 
c. deoxy-haemoglobin in treated iRBCs <0.0001 0.7523 
d. haemozoin in treated iRBCs <0.0001 0.7729 
e. β-haematin <0.0001 0.8371 
f. haematin <0.0001 0.8267 
g. haemin <0.0001 0.6017 
 
In addition, PCA plots for the Fe(III)PPIX-test compound 1 complex versus all the remaining 
Fe(III)PPIX complexes were analyzed. From Table 4-6, it was observed that there is a 
statistically significant separation in the cluster for the Fe(III)PPIX-test compound 1 complex 
versus all the other Fe(III)PPIX complexes, resulting in correlation coefficients above 0.6 (p = 
<0.0001). However,  haemin was observed to result in the lowest correlation coefficient of 
R2=0.6017 (p = <0.0001), but the difference was still highly significant and hence it was 
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Table 4-7: Comparison of oxy-haemoglobin in treated iRBCs to all other Fe(III)PPIX 
complexes analyzed 
Fe(III)PPIX complexes compared to oxy-
haemoglobin in treated iRBCs 
p value R2 value 
 
a. oxy-haemoglobin in RBCs 0.0026 0.03082 
b. deoxy-haemoglobin in treated iRBCs <0.0001 0.8771 
c. haemozoin in treated iRBCs <0.0001 0.6501 
d. β-haematin <0.0001 0.7411 
e. haematin <0.0001 0.3467 
f. haemin <0.0001 0.3933 
g. haematin-test compound 1 mixture <0.0001 0.8793 
 
In order to further explore whether this method was reliable, oxy-haemoglobin in treated iRBCs 
was compared to all other Fe(III)PPIX complexes analyzed. In Table 4-7, it was observed that 
there is a statistically significant separation between the cluster for oxy-haemoglobin in treated 
iRBCs and the clusters of the other Fe(III)PPIX complexes at the 99.99% confidence level (p  
= <0.0001), with the exception of oxy-haemoglobin in RBCs (p = 0.0026; R2 = 0.03082). These 
were, however, still not significantly different at the 99.99% confidence level. Interestingly, 
haematin and haemin resulted in the lowest correlation coefficients of R2 = 0.3467 and R2 = 
0.3933 respectively. This indicated that the separation between the clusters of oxy-
haemoglobin in treated iRBCs  and haematin or haemin was smaller compared to the other 
Fe(III)PPIX complexes. This could be as a result of overlapping peak positions for oxy-
haemoglobin in treated iRBCs, haematin and haemin, which agrees with reports by Wood et al 
who showed that Fe(III)PPIX associated peaks are similar in the spectra for these Fe(III)PPIX 
complexes 416. 
The same was investigated for haemozoin and the other Fe(III)PPIX complexes. From 
Table 4-8, it was observed that there is a statistically significant separation between the cluster 
for haemozoin and the other Fe(III)PPIX complexes, except β-haematin. This further 
confirmed the observations discussed in Section 4.4.2.1 where the spectra for haemozoin and 
β-haematin were observed to be very similar as expected (Figure 4-10). 
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Table 4-8: Comparison of haemozoin in treated iRBCs to all other Fe(III)PPIX complexes 
analyzed 
Fe(III)PPIX complexes compared to 
haemozoin in treated iRBCs 
p value R2 value 
 
a. oxy-haemoglobin in RBCs <0.0001 0.8377 
b. oxy-haemoglobin in treated iRBCs  <0.0001 0.8364 
c. deoxy-haemoglobin in treated iRBCs <0.0001 0.8887 
d. β-haematin 0.8528 0.0001228 
e. haematin <0.0001 0.8104 
f. haemin <0.0001 0.8349 
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4.5 Summary and Conclusions 
 
In summary, evidence for the colocalization of Fe(III)PPIX and test compound 1 as a result of 
the formation of a Fe(III)PPIX complex in the DV of CQS NF54 iRBCs was successfully 
obtained in this chapter. 
First, the colocalization of Fe(III)PPIX and test compound 1, a benzimidazole haemozoin 
inhibitor containing a Br atom, was investigated with TEM and EELS. TEM images of 
untreated and treated iRBCs, prepared by cryofixation, illustrated intact parasites in RBCs with 
clear visualization of haemozoin crystals dispersed throughout the parasite DV. For treated 
iRBCs, less well-defined haemozoin crystals were observed indicating that the formation of 
haemozoin was inhibited in the presence of test compound 1. Untreated iRBCs resulted in 
strong Fe signals attributed to haemozoin consistent with most of the Fe(III)PPIX being 
haemozoin. Compared to untreated iRBCs, treated iRBCs showed a strong Fe signal for the 
haemozoin crystals with an increased Fe signal in the RBC cytoplasm. The fact that a 
significant proportion of the parasite Fe(III)PPIX is in the form of exchangeable haem, this 
implies that it must be located around the haemozoin. In addition, a strong Br signal was 
observed in the parasite DV for treated iRBCs. From the overlaid image of the Fe and Br 
distribution maps, it was clear that co-localization of Fe(III)PPIX and test compound 1 occurs 
in CQS NF54 parasites, suggestive of complexation.  
 Second, confocal Raman microspectroscopy was used to investigate the vibrational 
modes of RBCs, parasite- and synthetic-Fe(III)PPIX complexes. This provided evidence of a 
putative Fe(III)PPIX-test compound 1 complex. High quality Raman spectra for the 
Fe(III)PPIX porphyrin dominated region of 1700-500 cm-1 at an excitation of 532 nm were 
obtained for all Fe(III)PPIX complexes including the putative Fe(III)PPIX-test compound 1 
complex. From the recorded spectra, it was observed that the spectrum for the putative 
Fe(III)PPIX-test compound 1 complex was similar to that of the spectrum for the haematin-
test compound 1 mixture that showed a unique peak at 1080 cm-1. This was indicative of π- π 
interactions between the pyrrole-imidazole ring which was expected for a Fe(III)PPIX-test 
compound 1 complex. It was also observed that the putative Fe(III)PPIX-test compound 1 
complex showed peaks that appeared shifted in comparison to the peaks for haemozoin. 
However, with the absence of the peak at 1160 cm-1 in the spectrum for the putative 
Fe(III)PPIX-test compound 1 complex it was apparent that there was no contribution from the 
haemozoin spectrum. Additionally, no strong peaks attributed to test compound 1 itself were 
observed probably as a result of much stronger haem peaks arising from resonance. Spectra for 
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synthetic Fe(III)PPIX complexes were also investigated for comparison with the spectrum for 
the putative Fe(III)PPIX-test compound 1 complex, including a haematin-test compound 1 
mixture. From this, it was shown that the spectra for haematin (monomer), haemin, β-haematin 
and test compound 1 were visibly different from the putative Fe(III)PPIX-test compound 1 
complex. With respect to β-haematin, the spectrum was observed to be very similar to the 
spectrum of haemozoin. On the other hand, the spectrum of the haematin-test compound 1 
mixture had peak positions similar to the spectrum of the putative Fe(III)PPIX-test compound 
1 complex, which was most evident when this spectrum was overlaid with the average spectra 
of the putative Fe(III)PPIX-test compound 1 complex and test compound 1. It was similar even 
with noticeable reductions in the peaks pertaining to the pyrrole half-ring stretching and 
deformation region. This was concluded to be as a result of the drastic difference in the 
Fe(III)PPIX and test compound 1 ratio. Interestingly, the same peak at 1080 cm-1 was observed 
in the spectrum of the haematin-test compound 1 mixture and confirmed the possibility that 
this particular peak could be a marker band for the formation of this putative Fe(III)PPIX-test 
compound 1 complex. 
 Confocal Raman true mapping images were obtained to determine the signal distribution 
of selected Raman peaks in untreated and treated iRBCs. For untreated iRBCs, it was observed 
that the Raman peak at 754 cm-1 was useful for imaging the signal distribution of haemozoin 
localized in the parasite DV, whilst oxy- and deoxy-haemoglobin were localized to the RBC at 
the Raman peaks at 754 cm-1, 1090 cm-1 and 1642 cm-1. No signal distribution was observed 
for the images obtained at the Raman peak of 1080 cm-1 in untreated iRBCs. For treated iRBCs, 
similar observations were made, except that, the Fe(III)PPIX-test compound 1 complex was 
located in the parasite DV. In addition, overlaid true mapping images highlighted that the signal 
distribution for haemozoin and the Fe(III)PPIX-test compound 1 complex were located in the 
same region of the parasite DV. This further confirmed the findings obtained with TEM and 
EELS, and, the uniqueness of the Raman peak at 1080 cm-1 for observing the Fe(III)PPIX-test 
compound 1 complex.  
 The results obtained from PCA confirmed that there were differences in the peak 
positions of the spectra for all the Fe(III)PPIX complexes including the Fe(III)PPIX-test 
compound 1 complex. From the resulting PCA plots, it was observed that the Fe(III)PPIX-test 
compound 1 complex was different to the spectrum of test compound 1 itself with clusters 
separated along PC1 rather than PC2. It was also observed that there was no difference in the 
peak positions of the spectra for the Fe(III)PPIX-test compound 1 complex and the haematin-
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test compound 1 mixture. This confirmed the existence of a Fe(III)PPIX-test compound 1 
complex in CQS NF54 parasites.  
 Using a Welch’s t-test analysis, the separations of clusters observed in the PCA plots 
were shown to be statistically significantly for all Fe(III)PPIX complexes being compared to 
the Fe(III)PPIX-test compound 1 complex with the exception of the haematin-test compound 
1 mixture on the one hand and haemozoin versus β-haematin on the other. This method was 
applied to oxy-haemoglobin and haemozoin in treated iRBCs which showed that this method 
was very reliable and could be used for future investigations. 
 In conclusion, this chapter has provided definitive evidence that test compound 1 co-
localizes with Fe(III)PPIX, forming a complex in the DV. Most importantly, it was clear from 
the observations in this chapter that the hypothesis that haemozoin inhibitors, like test 
compound 1, act by forming a Fe(III)PPIX-inhibitor complex is true at least in the case of this 
compound. Presumably, this explains the accumulation of the compound with Fe(III)PPIX 
which then goes on to cause parasite death.
Chapter 5: Haemoglobin digestion by aspartic and cysteine proteases 
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5.1 Introduction 
 
A complete understanding of haemozoin inhibition would require a model of the haem pathway 
from haemoglobin digestion to haemozoin formation. The formation of haemozoin has been 
the focal point for understanding the mechanism of action of various antimalarials for many 
years. This has not only provided a better understanding into the behavior of antimalarials like 
CQ but also the discovery of new antimalarially active compounds. The first key step in the 
formation of haemozoin is the degradation of haemoglobin. Haemoglobin degradation occurs 
in the DV of P. falciparum parasites and is vital for its growth, and, is known to be a complex 
process 79,441-444.  As mentioned in Chapter 1, the RBC content consists of 95% haemoglobin 
and this is ingested during the blood stage of the parasite via the parasite cytostome and 
transported into the DV by double-membrane bound transport vesicles 73,123. Once inside the 
DV, haemoglobin is digested by a series of known proteases (aspartic and cysteine) which 
account for 60-80% and 20-40% of haemoglobin digestion respectively 76-78,84,445-449. In a partly 
ordered manner, aspartic proteases (Plm I and Plm II, including HAP) have been reported to 
initially cleave haemoglobin at selected sites which causes the unfolding of native haemoglobin 
76,80,445-446. Plm II is most active thereafter in digesting large globin fragments with the resulting 
smaller fragments subject to falcipains which result in smaller peptides and amino acids 444,450. 
This results in a very large number of amino acids that are to an extent utilized for self-
generation of new proteins, but primarily to maintain osmotic stability within the DV by most 
of the amino acids being exported from the parasite 74,451. 
Kinetics have been previously reported by Luker et al for aspartic proteases which 
included the Michealis-Menten (Km) and turnover constants (kcat). They were able to show that 
HAP resulted in a much lower Km (0.29 µM) with a much slower kcat (0.05 s-1) compared to 
PLM I (0.49 µM; 2.3 s-1) and PLM II (2.6 µM; 11 s-1). With this they inferred that HAP would 
be 20 times less efficient at digesting haemoglobin than Plm I and II 85. It has also been 
previously determined that haemoglobin is digested at a rate of 0.06 fmol/hr per DV in the 
trophozoite stage 84. Studies with SDS-PAGE have previously shown that upon addition of 
inhibitors like pepstatins and E-64, haemoglobin degradation is inhibited in an ordered manner. 
The reason for this is that pepstatins are specific inhibitors of aspartic proteases where E-64 is 
specific to cysteine proteases 452-454. Banjeree et al has used indirect immunofluorescence 
microscopy to analyse which aspartic proteases are present in the blood stage of the parasite 
and their location within the DV. From this, they were able to show the presence of these 
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aspartic proteases at different parasite stages, where specifically Plm II and HAP localize with 
haemozoin. This was similar to the reports by Francis et al 80-81.  
Estimation of concentrations of these proteases require knowledge of the amount of 
protein and organelle volume. Various protein quantification assays such as Bradford, 
bicinchoninic acid (BCA) and Nanodrop, have also been used to quantify the unfolding of 
falcipain-2, recombinant ookinete micronemal protein chitinase (PgCHT1) and purified 
mitochondrial dihydroorotate dehydrogenase 455-457. In 2012, Hanssen et al used previously 
published methods by Rabiner et al and Snell et al to determine the cell volume and 
concentration of haemoglobin in iRBCs. They showed that for iRBCs, the volume remained 
relatively constant from the ring (84 ± 16 fL) to late schizonts stage (68 ± 9 fL) 458-460, while, 
the haemoglobin concentration decreased slowly during the ring stage and sharply from the 
trophozoite stage. Additionally, Gligorijevic et al was the first to quantitatively determine the 
rate of haemozoin formation using spinning disk confocal microscopy. They showed that 
haemozoin first appears at the early trophozoite stage which coincided with the point at which 
haemoglobin was digested. Also, the rate of haemozoin formation was observed to reach a 
maximum at the point when haemoglobin digestion stopped which coincided with the late 
trophozoite stage 205. 
In this chapter the prerequisites required for a haem pathway model include the 
concentrations of aspartic proteases, rate constants for each step and a description of the rate 
of haemoglobin uptake. In addition, to validate the model, the amount of haemoglobin, 
exchangeable haem and haemozoin throughout the blood stage of the CQS NF54 parasite is 
required. To this end, the concentration of proteases was estimated by compiling bioinformatics 
data for both CQS (NF54) and CQR (Dd2) strain parasites using the protein abundance 
database, PAXdb. This included collecting the relative abundances for all proteins, and 
determining their individual molecular weights with the SIB bioinformatics resource portal, 
ExPASY. From this, the averaged abundance-weighted molecular weight for the entire 
proteome of Dd2 parasites could be calculated. Next, the mass of the proteins in RBCs, CQS 
and CQR parasites were analysed using three independent protein quantification methods 
namely, the Bradford, BCA and NanoDrop spectrophotometric assays With the protein masses 
and the average abundance-weighted molecular weight for Dd2 parasite proteins, the total 
number of protein molecules per cell in Dd2 parasites was estimated. Estimates were also made 
for RBCs and NF54 parasites. Dd2 parasites were found to have a higher number of protein 
molecules per cell than NF54 parasites. Using the total protein count and PAXdb data, together 
with estimated volumes of the DV, the concentrations of Plm I, II, HAP and falcipain-2 were 
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calculated based on their relative abundances. The highest average protease concentration in 
the Dd2 strain was that of HAP (0.12 µM).  
As a basis for future validation, a time point quantification experiment of the 
haemoglobin amounts present in CQS NF54 parasites throughout the blood stage was 
performed. This was carried out by first performing an observation experiment to determine 
the time point 0 in which merozoites invade RBCs so as to accurately determine the time points 
for the specific parasite stages for the quantification of haemoglobin, exchangeable haem and 
haemozoin (mass of haem Fe in fg per cell) using a modified pyridine-based parasite haem 
fractionation plate method. The amount of haemoglobin, exchangeable haem and haemozoin 
were successfully determined. The results showed a rapid sigmoidal decrease in haemoglobin, 
while exchangeable haem remained relatively constant and haemozoin increased linearly. 
Specifically, haemoglobin was observed to decrease in a sigmoidal manner, where, large 
amounts were observed for early time points than the later stages where it reached a steady 
state. This sigmoidal decrease suggested that the initial uptake of haemoglobin was larger and 
could be as a result of an observed increasing concentration of aspartic proteases. This large 
initial uptake of haemoglobin was further investigated by performing haemoglobin 
contamination experiments which proved that the method that was used was reliable and 
efficient for quantifying the amount of haemoglobin, exchangeable haem and haemozoin 
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5.2 Materials, instrumentation and methods 
 
5.2.1 Materials  
 
General materials, used throughout this study, are detailed in Chapter 2 (see Section 2.1). The 
commercially purchased materials, used only in this chapter, were all of AR grade or higher 
and used without further purification unless specified below. Protein quantification kits for 
Bradford and BCA assays were purchased from Bio-Rad Laboratories and Sigma-
Aldrich/Merck respectively. The materials that were specific to this chapter are listed below in 
Table 5-1 to Table 5-2. 
 
Table 5-1: Materials used for Bradford protein quantification kit 
Bradford protein quantification kit 
Material Supplier 
Bovine serum albumin Bio-Rad Laboratories 
Coomassie® Brilliant Blue G-250 dye 








General instrumentation used throughout this study is discussed in detail in Chapter 2 (see 
Section 2.2), with the inclusion of one instrument pertaining to this chapter; 
 
 
BCA protein quantification kit 
Material Supplier 
Bovine serum albumin Sigma Life Science 
Reagent A (sodium bicinchoninate, sodium 
carbonate, sodium tartrate, sodium 
hydroxide and sodium bicarbonate) 
Sigma Life Science 
Reagent B (copper(II)sulphate and d.H2O) Sigma Life Science 
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NanoDrop Spectrophotometer 
Microliter protein samples were measured using a Thermo Scientific NanoDropTM ND-1000 
spectrophotometer, in the Microbiology department at the UCT. It has a Xenon flash lamp 




The general software used to analyse data and construct graphs is described in detail in Chapter 
2 (see Section 2.3). Software pertaining to this chapter included the protein abundance 
database, PAXdb4.1, and, the SIB bioinformatics resource portal, ExPASy, were used to obtain 
P. falciparum protein abundances and molecular weights 461-462. The Nanodrop Protein A280 
v3.5.1 was used to quantify protein samples of micro-litre volumes 463.  
 
5.2.4 Preparation of samples and solutions  
 
The preparation of samples and solutions for RBCs, cell culturing of P. falciparum cultures, 
isolation, fixation, counting and the pyridine-based parasite haem fractionation plate method 
have been previously described in Chapter 2 (see Section 2.4.2 and 2.4.4.1). Sample and 
solution preparation that were specific to this study are described below; 
 
Coomassie® Brilliant Blue dye (Bradford reagent) 
The Coomassie® Brilliant Blue dye was diluted 1:4 (v/v) by adding 10 ml of Coomassie® 
Brilliant Blue dye concentrate to 40 ml of d.H2O. The diluted solution was stored at 4 ºC until 
further use with a storage life of a maximum of 2 weeks. 
 
BCA working reagent 
The working reagent was prepared by adding 1 ml of reagent B (Copper (KK) sulfate 





The general experimental method for cell culturing of P. falciparum parasites, isolation, 
fixation and counting used in this chapter are discussed in detail in Chapter 2 (see Section 2.5.1 
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and Section 2.5.3.2). Throughout this study RBCs, CQS (NF54) and CQR (Dd2) parasite 
strains were used. The experimental methods used in this chapter are described below.  
 
5.2.5.1 Lysis of RBCs 
 
RBCs were lysed using a modified method previously described by Reed et al 464. Packed 
RBCs were washed in complete medium and aspirated as described in Chapter 2 (see Section 
2.4.2). RBCs were lysed by adding 250 µl of 1% saponin to 1 ml of packed RBCs in 30 ml of 
filtered PBS. The solution was centrifuged at 750 rpm for 5 min before aspirating the 
supernatant. The remaining lysed RBCs were divided into Eppendorf tubes of 300 µl in 100 µl 
of filtered PBS and frozen at -80 °C until further use.  
 
5.2.5.2 P. falciparum parasite lysis 
 
CQS and CQR cultures were lysed using methods previously described by Ambele et al 372. 
Before lysis, the trophozoite pellet was checked by Giemsa smears using a light microscope. 
From here, the trophozoites were harvested by lysing the iRBCs using 1% saponin (250 µl) in 
filtered PBS (30 ml) and incubated for 2 min in a water bath. The lysed iRBCs were then 
centrifuged at 750 rpm for 10 min. The supernatant was aspirated, leaving behind the isolated 
trophozoite pellet. This pellet was then washed 3 times with filtered PBS (10 ml) by 
centrifuging at 750 rpm for 10 min. A final volume of 100 µl of filtered PBS was added to the 
isolated pellet in a 1.5 ml Eppendorf tube. The suspended pellet was counted using a 
haemocytometer before freezing at -80 °C. After 1 hr, the isolates were thawed at rt. before the 
isolated DVs were viewed by Giemsa smears. This freeze-thaw process facilitates the rupturing 
process of the membranes of the isolated trophozoites and was repeated until all trophozoite 
membranes were lysed. After this, pooled trophozoite lysate and DVs were triturated multiple 
times using a 26.5 Gauge needle to break open the DVs releasing the proteins and other 
membrane materials into solution. This process was repeated 4 times to ensure all DVs were 
completely ruptured, after which, the samples were frozen at -80 °C until further analysis. 
 
5.2.5.3 Protein Quantification methods 
 
The protein quantification for RBCs, CQS and CQR parasites was performed using three well 
established methods namely, the Bradford, BCA and NanoDrop assay. The Bradford method, 
In vitro modelling of cellular haemozoin and inhibition by β-haematin inhibitors and their derivatives 
Roxanne Openshaw-January 2020 172 
originally determined by Bradford et al, is a well-known, time efficient and accurate 
spectroscopic method for quantitatively determining the concentration of proteins in a sample 
465-472. This method uses a Coomassie® Brilliant Blue G-250 dye that binds to proteins and 
forms a complex. Upon the formation of a dye-protein complex, the dye shows a red shift in 
its absorbance from 465 nm to 595 nm which produces a noticeable colour change from reddish 
brown to blue 466.  
Similar to the Bradford method, Smith et al developed another spectroscopic assay for 
quantifying the concentration of proteins in a sample, namely the BCA method 473. This method 
utilizes a copper(II) sulphate solution which is reduced to copper (I) in the presence of proteins, 
however, it is temperature dependent. With this, an observed colour change from blue to purple 
is observed when two BCA molecules bind to one Cu+ cation in the presence of proteins. The 
amount of complex that is formed is proportional to the concentration of protein which can be 
spectroscopically assayed at 562 nm 473.  
The NanoDrop microvolume spectrophotometer records the absorbance of protein 
containing samples as small as 0.5 µl. This fast and efficient technique makes use of the 
principle of surface tension where the sample is analysed between two optical fibres. Light is 
then passed through the sample from which absorbances at 280 nm are recorded. The 
spectrophotometer converts the absorbance into a concentration of total protein in a sample 
based on an average extinction coefficient 474-475. The methods are described in detail below. 
 
Bradford protein quantification method 
 
The microplate method, described in the Bio-Rad protein quantification kit, was modified for 
this experiment (Table 5-1) 476. First a bovine serum albumin (BSA) standard curve was 
established. Briefly, the 30 µM stock solutions (1 ml), provided in the kit, of BSA was used as 
the control which was diluted to known concentrations in Eppendorf tubes in the ratio of 1:1 
(v/v) in filtered PBS by adding 500 µl of the control to 500 µl of filtered PBS. The resulting 
concentrations for the control stock solutions ranged from 30-0.4 µM. In column 1 of the 96-
well plate, 5 µl of filtered PBS was added as a blank. To columns 2-7, 5 µl of the serial diluted 
control stock solutions were added. All control stock solutions were measured in triplicate. To 
the plate, 250 µl of Bradford reagent was titrated into all the BSA-containing wells using a 
micro-multichannel pipette before adding to the blank well (1:20 dilution). This was to ensure 
that the absorbance of the blank was lower than the control-containing wells. Each well was 
then gently resuspended using a micro-multichannel pipette and the bubbles were removed 
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with a 26.5 Gauge needle before leaving the plate to incubate at rt. for 30 min. After the 
incubation period the plate was spectroscopically assayed at 595 nm using a SpectraMax 












Figure 5-1: A standard curve based on the absorbance of BSA determined using the Bradford 
method at 595 nm for increasing concentrations of BSA, analysed as a protein-dye complex. 
The standard curve represents a fit to the mean ± SD for data points obtained from four different 
experiments. A linear regression analysis was performed using GraphPad Prism v8.2.1 to yield 
a correlation coefficient, R2 = 0.9940 with an average molar adsorption coefficient (ε) of 57,696 
± 3,604 M-1 cm-1 (ε was calculated for three separate BSA standard curves and averaged). 
 
Next, to quantify the protein concentration for CQS and CQR parasites and RBCs, the same 
modified microplate method was used. The samples obtained from the lysed cells (see Section 
5.2.5.1), were thawed at 37 °C in an incubator before further use. In the same 96-well plate as 
the BSA standard in column 1, 5 µl of filtered PBS was added as a blank and column 2-6 
contained 5 µl of the samples (Figure 5-2). All samples were measured in quadruplet for each 
experiment to ensure reproducibility of results (biological repeats = 3). To the plate, 250 µl of 
Bradford reagent was titrated into all the sample-containing wells using a micro-multichannel 
pipette before adding to the blank (1:20 dilution). Each well was gently resuspended with a 
micro-multichannel pipette, bubbles were removed with a 26.5 Gauge needle before the plate 
was left to incubate at rt. for 30 min. After 30 minutes, the absorbance was recorded at 595 nm 
using a SpectraMax 340PC plate reader. 
 
% = '. ')*+', + '. '.+/0 
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Figure 5-2: Microplate method used for the Bradford protein quantification. 
 
BCA Protein Quantification method 
 
As described in the Sigma-Aldrich protein assay kit, the microplate method was used to 
determine a BSA standard curve and the protein concentrations for RBCs, CQS and CQR 
parasites (Table 5-2) 477. Similar to the Bradford protein quantification kit, 30 µM solutions (1 
ml) of BSA were provided and used as a control of which further dilutions in Eppendorf tubes 
were prepared, 15-0.4 µM. Using a 96-well plate, 25 µl of filtered PBS was added to column 
1 which was used as a blank. To column 2-7, 25 µl of each diluted control sample was added. 
All BSA-diluted samples were carried out in triplicate. The BCA working reagent (200 µl) was 
Saponin lysis of CQS 
NF54 culture 
Wash 3 times with 
filtered PBS 
Whole trophozoite pellets 
diluted in 100 µl of filtered 
PBS 
(Freeze-thaw and triturate) 
Transfer 5 µl of 
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titrated into the wells containing the diluted control samples using a micro-multichannel pipette 
before adding to the blank (1:8 dilution). Each well was gently resuspended with a micro-
multichannel pipetted. Before incubating the plates at 37 °C for 15 min, the bubbles were 
removed using a 26.5 Gauge needle. The absorbance (562 nm) was recorded on a SpectraMax 












Figure 5-3: A standard curve for the absorbance of BSA at 562 nm at increasing concentrations 
of BSA, analysed as a protein-dye complex. The standard curve represents a fit to the mean ± 
SD for data points obtained from four different experiments. A linear regression analysis was 
performed using GraphPad Prism v8.2.1 to yield a correlation coefficient, R2 = 0.9982 with an 
average molar adsorption coefficient (ε) of 36,901 ± 2,965 M-1 cm-1 (ε was calculated for three 
separate BSA standard curves and averaged). 
 
This microplate method was also used to quantify the protein concentration for CQS and CQR 
iRBCs, including RBCs. Briefly, the samples obtained from the cell lysis method (see Section 
5.2.5.1), were thawed at 37 °C in an incubator before further analysis. In the same 96-well 
plate, 25 µl of filtered PBS (blank) and 25 µl of the samples were added to column 1 and 
column 2-6 respectively (Figure 5-4). All samples were conducted in triplicate (biological 
repeats = 3). In the plate, 200 µl of working reagent was titrated into all the sample-containing 
wells using a micro-multichannel pipette before adding to the blank. Each well was gently 
resuspended using a micro-multichannel pipette, bubbles were removed using a 26.5 Gauge 
needle and placed in an incubator to incubate at 37 °C for 15 min. After the incubation period, 
the plate was spectroscopically assayed at 562 nm using a SpectraMax 340PC plate reader. 
% = '. '12++, + '. ''.'/. 
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The samples (CQS and CQR iRBCs, including RBCs) obtained after cell lysis (see Section 
5.2.5.1) were thawed at 37 °C in an incubator. All samples were analysed (2 µl of each sample) 
using a NanoDropTM ND-1000 spectrophotometer. The samples were run using the protein 
A280 module that measures an ultraviolet spectrum, determines the protein absorbance at 280 
nm and automatically calculates the protein concentration 474-475. Samples were tested in 
triplicate for each experiment (biological repeats = 3). 
 
5.2.5.4 Time point quantification in CQS NF54 cultures 
 
A time point quantification plate method was carried out using a modified method previously 
described by Combrinck et al 263. In more detail, CQS NF54 strain parasites were cultured 
according to methods described previously in Chapter 2 (see Section 2.5.1). At the start, highly 
synchronous ring stage cultures (CQS NF54) were confirmed by Giemsa stained smears in 
order to determine the parasitaemia. From there, the calculated parasitaemia (average of 1000 
cells counted) was used to dilute the ring cultures (5% parasitaemia; 2% haematocrit) in 49 ml 
of complete medium and washed O+ RBCs. In a 6-well plate (Greiner Bio-One), 5 ml of the 
diluted ring culture was pipetted into each well where each time point (20-50 hrs) was tested 
in triplicate. All plates were gassed with 3% O2, 4% CO2 and N2 for 1 min in a sterile gassing 
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chamber and incubated at 37 °C for the relevant time points. Before removing the plates from 
the incubator at their respective time points, Giemsa smears were made to confirm the stage of 
the trophozoite culture. After the confirmation of the different stages, supernatants were 
aspirated and parasites isolated by saponin lysis of RBCs by adding 250 µl of 1% saponin in 2 
ml of filtered PBS (pH 7.5). The iRBC pellets were resuspended to promote lysis and 
centrifuged at 750 rpm for 10 min. After centrifugation, supernatants were aspirated before 
washing the isolated pellets with 2 ml of PBS. This process was repeated until a clear 
supernatant was observed in order to remove excess traces of haemoglobin from RBCs, cell 
debris and haemozoin from previous cycles 263. The washed pellets were transferred to a 96-
well plate in a 100 µl of filtered PBS. For cell counting, 10 µl of the resuspended mixture was 
aliquoted into a separate 96-well plate prior to freezing the remaining pellets at -80 °C (stock 
plate). Isolated trophozoites were glutaraldehyde-fixed, prepared for cell counting and taken 
through a solvent-mediated plate method for the fractionation of haem species as previously 
described in Chapter 2 (see Section 2.5.5.3 to Section 2.5.5.4). 
 
5.2.5.5 Haemoglobin contamination experiment 
 
The haemoglobin contamination experiment for the early time points was carried out in 6-well 
plates (Greiner Bio-One). Briefly, synchronous CQS NF54 cultures (ring stage) were viewed 
by Giemsa smears to confirm the parasitaemia of the culture. From here, the percentage 
parasitaemia was used to dilute the culture to 5% parasitaemia and 2% haematocrit in 49 ml of 
complete medium and packed RBCs. Cultures were incubated at 37 °C for 24 hrs and 27 hrs 
in a sterile gas chamber (3% O2, 4% CO2 and N2), before, the plates were removed. The plates 
were removed at their respective time point and Giemsa smears were made in order to confirm 
the stage of the parasite. After confirmation from the Giemsa smears, the supernatant was 
removed via aspiration. The remaining pellet was then spiked with 250 µl of packed RBCs and 
left to stand for 5 min. After 5 min, 250 µl of saponin (1%) was added to the pellet with 2 ml 
of filtered PBS and left to incubate at rt. for 15 min. Using a pipette, the lysed pellet was 
transferred to a 2.5 ml deep well plate and centrifuged at 750 rpm for 10 min. The remaining 
isolated trophozoite pellet was then continuously washed (3 times) until a clear supernatant 
was observed to remove excess undigested haemoglobin 263. A 100 µl aliquot of filtered PBS 
was added to the washed pellet, mixed to ensure a homogenous mixture and transferred to a 
96-well plate. For cell counting, 10 µl of the resuspended mixture was aliquoted into a separate 
96-well plate prior to freezing the remaining pellet at -80 °C (stock plate). Isolated trophozoites 
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were glutaraldehyde-fixed, prepared for cell counting and taken through a solvent-mediated 
plate method for the fractionation of haem species as previously described in Chapter 2 (see 
Section 2.5.5.3 to Section 2.5.5.4). 
 
5.3 Data analysis 
 
5.3.1 Average abundance-weighted molecular weight of all proteins in the P. falciparum 
proteome 
 
The average abundance-weighted molecular weight (34567 ) for Dd2 parasites was calculated 
from the sum of the product of the protein abundance (89:) and protein molecular weight (856) 






HID JG                                       Eq. 1 
 
where K is the total number of proteins in the proteome 
 
5.3.2 Protein concentration 
 
BSA standard curves were constructed for the concentration range of 15-0.4 µM as described 
in Section 5.2.5.3 using both the Bradford and BCA methods. Considering that the standard 
curve for BSA is linear for this concentration range, the Beer-Lambert law was applied. This 
states that the absorbance (A) at any wavelength is equal to the product of the absorptivity in 
g-1cm-1 (ε), mass concentration (c) of the sample and path length (l) equation (Eq. 2) 478-479:  
 
3 = LMN                                                             Eq. 2 
 
Therefore, the protein concentration could be calculated from the respective linear equations 
of the BSA standard curves where the concentration of protein (M) is equal to the absorbance(3) 
minus the y-intercept (3E) and divided by the slope of the standard curve (L) (Eq. 3):  
 
															3 = LM + 3E 
Which was rearranged to; 
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M = ;9P9Q
R
J                                                           Eq. 3 
 
The protein mass per cell (S$) was calculated by dividing the mass concentration (M) by the 
total number of trophozoites (TU) counted using the haemocytometer, and multiplying by the 




                                                                Eq. 4 
 
5.3.3 Total number of proteins 
 
Based on the average abundance-weighted molecular weight (34567 ) obtained for the proteins 
in Dd2 parasites, the protein mass per cell (S$) and Avogadro’s’ constant (Z[ =
6.022 × 10`a), the total number of proteins per cell (8U/Wcdd) for RBCs, CQS (NF54) and CQR 





×	Z[h                                          Eq. 5 
 
5.3.4 Aspartic and cysteine protease concentrations 
 
The concentrations for both aspartic and cysteine proteases (8ij) were calculated based on 
their individual relative abundances (34kkf), the volume of the DV (lmn = 3.5	 ×	10PDq	r) 
205, the total number of proteins per trophozoite (8U/Wcdd) for Dd2 parasites and Avogadro’s 
constant (Z[) using Eq. 6: 
 
[8ij] = 	 ;
9:uuv×=7/wxyy
z{×DEF
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5.4 Results and Discussion 
 
To determine the concentration of the four major aspartic (Plm I, II and HAP) and cysteine 
(falcipain-2) proteases involved in haemoglobin digestion in the DV of P. falciparum parasites, 
the variables discussed below were determined 76,81,444,450,480. 
 
5.4.1 Average abundance-weighted molecular weight of Dd2 parasites 
 
The average abundance-weighted molecular weight of the proteins that are present in NF54 
and Dd2 strain parasites was determined by compiling a list of the known relative abundances 
and molecular weights for the individual proteins. The relative protein abundance and their 
individual molecular weights are available in the protein abundance database (PAXdb) and SIB 
bioinformatics resource portal (ExPASy) respectively. However, with the limited 
bioinformatics data available for NF54 proteins, the average abundance-weighted molecular 
weight could not be determined. On the other hand, 1337 proteins obtained from the list of Dd2 
proteins expressed in the trophozoite stage and previously reported by Tao et al consisted of 
226 proteins (17%) which were attributed to conserved Plasmodium proteins of unknown 
function and 1111 (83%) of known proteins 481. From this, the relative abundances and their 
individually determined molecular weights were used to calculate the average abundance-
weighted molecular weight for Dd2 proteins (see Section 5.3.1, Eq. 1) which was calculated 
to be 40,483 ± 77 g/mol. 
 
5.4.2 Protein concentration and total number of proteins 
 
The protein concentration for NF54 and Dd2 parasites, including RBCs as a control, was 
determined using the Bradford microplate method that has been previously described in 
Section 5.2.5.3. In brief, NF54 and Dd2 trophozoites were isolated by saponin lysis and 
centrifugation before the isolated trophozoites were freeze-thawed. From this, pooled 
trophozoite lysate and DVs were triturated with a 2.6 Gauge needled multiple times, diluted in 
1 ml of filtered PBS and frozen at -80 °C. In a 96-well plate; 5 µl of filtered PBS was added as 
a blank and 5 µl of the thawed samples were added to the respective columns. A 1:20 dilution 
was done by titrating 250 µl of Bradford reagent into all the sample-containing wells before 
adding to the blank. Before recording the absorbance at 595 nm, using a SpectraMax 340PC 
plate reader, each well resuspended, the bubbles were removed and the plate was left to 
Chapter 5: Haemoglobin digestion by aspartic and cysteine proteases 
Roxanne Openshaw-January 2020 181 
incubate at rt. for 30 min. Similar protein quantification methods which included the BCA 
assay and NanoDrop, previously discussed in Section 5.2.5.3, were included in this study for 
comparison. 
 
Table 5-3: Total protein mass (pg/cell) determined for RBCs, NF54 and Dd2 parasites 
determined by; (a) Bradford, (b) BCA, and, (c) NanoDrop. 
 a b c Mean ± SD 
RBC 30.92 32.48 30.65 31.35 ± 0.99 
NF54 8.02 8.46 8.01 8.16 ± 0.26 
Dd2 12.50 12.72 13.18 12.80 ± 0.35 
 
The protein mass per cell, listed in Table 5-3, were calculated from the BSA standard curves 
using Eq. 3 and Eq. 4 that have been previously described in Section 5.3.2. From these results, 
it was observed that the protein masses were relatively constant across all protein quantification 
methods for RBCs, NF54 and Dd2 parasites. It was, however, observed that that BCA method 
resulted in slightly higher protein masses compared to the other methods. This could be due to 
the sensitivity difference between methods, where, the BCA method is known to have much 
improved sensitivity relative to the Bradford method 482-483. Looking at the mean protein 
masses, the protein mass for RBCs was 31 ± 1 pg per cell which was in the accepted range 
previously reported in the literature 484-485. For NF54 and Dd2 parasites, the protein mass for 
Dd2 was observed to be considerably higher than that for NF54 parasites. These data were 
similar to those previously reported by Wang et al, where HB3 strain parasites had a total 
protein content similar to that of Dd2 strain parasites 486. 
 
Next, the total number of protein molecules per cell was calculated using Eq. 5 (see Section 
5.3.3). From these data, listed in Table 5-4, it was observed that the total number of protein 
molecules per cell was higher for RBCs than NF54 and Dd2 parasites which was expected. On 
the other hand, the total number of protein molecules per cell for Dd2 parasites resulted in a 
larger number of protein molecules per cell than for NF54. This was as expected given the 
observations in Table 5-3. Specifically, Dd2 parasites had 70 million more protein molecules 
than NF54 parasites which had 121 million per cell. 
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Table 5-4: Total number of protein molecules per cell for RBCs, NF54 and Dd2 based on (a) 
the Bradford, (b) BCA, and (c) NanoDrop assays. 
 Bradford BCA NanoDrop Mean (SD) 
RBC 4.60 × 108 4.83 × 108 4.56 × 108 4.66 (15) × 108 
NF54 1.19 × 108 1.26 × 108 1.19 × 108 1.21 (4) × 108 
Dd2 1.86 × 108 1.89 × 108 1.96 × 108 1.90 (5) × 108 
 
Based on the average abundance-weighted molecular weight of Dd2 proteins (40,483 ± 77 
g/mol) and the relative abundances of Plm I, II, HAP and falcipain-2, the concentration of these 
proteases was determined using Eq. 6 (see Section 5.3.4). Figure 5-5 illustrates the 
concentrations of Plm I, II, HAP and falcipain-2 in Dd2 parasites. It can be seen that HAP had 
the highest concentration at 0.12 µM, Plm I at 0.061 µM, Plm II at 0.051 µM and falcipain-2 at 
0.0018 µM. HAP is known to be 60% similar to, but less efficient than Plm I and II, but, its 
abundance is 2-fold higher than Plm I and II, and 7-fold higher than falcipain-2. This could 












Figure 5-5: Bar graph of the four main protease concentrations in Dd2 parasites which is 
represented by; (a) Plm I (red), (b) Plm II (purple), (c) HAP (blue), and, (d) falcipain-2 (green). 
 
5.4.3 Time point quantification in CQS NF54 parasites 
 
For future validation of models of the whole haemozoin pathway, the amount of haemoglobin, 
exchangeable haem and haemozoin was determined throughout the life cycle of CQS P. 
falciparum parasites in the blood stage.  
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First, a microscopic observation experiment was conducted. This was carried out to determine 
the relevant time points of the different stages of the parasites and thus the time point at which 
merozoites invade RBCs, corresponding to time point 0 hrs. Briefly, CQS NF54 cultures were 
kept in continuous culture and synchronized to the early ring stage as previously described in 
Chapter 2 (see Section 2.5.1). Cultures were then observed for 48 hrs, where, at 3 hr intervals 
Giemsa smears were made in order to confirm the stage of the parasites. Throughout the 
experiment cultures were gassed under sterile conditions (3% O2, 4% CO2 and N2) and 
incubated at 37 °C in a CO2 incubator.  
Next, using a modified method previously described by Combrinck et al, a time point 
quantification assay was carried out. This was to quantify the haem species (haemoglobin, 
exchangeable haem and haemozoin) present in CQS NF54 parasites at different time points 
which can be spectroscopically assayed as low-spin Fe(III)PPIX-pyridine complexes (see 
Section 5.2.5.4) 263. Highly synchronous CQS NF54 ring stage cultures were confirmed by 
viewing Giemsa stained smears. From here, the calculated parasitaemia was used to dilute the 
ring cultures (5% parasitaemia; 2% haematocrit) in 49 ml of complete medium and washed O+ 
RBCs. Diluted Cultures (5 ml) were then transferred to a 6-well plate (Greiner Bio-One), with 
each time point (20-50 hrs) tested in triplicate. Before incubation at 37 °C for the relevant 
times, all plates were gassed with 3% O2, 4% CO2 and N2 for a minute in a sterile gassing 
















In vitro modelling of cellular haemozoin and inhibition by β-haematin inhibitors and their derivatives 






















Figure 5-6 a-d: Time point quantification in CQS NF54 parasites represented by, (a) panel of 
microscope images of Giemsa smears for different time points representing different parasite 
stages during the intraerythrocytic stage, and (b) the amount of haemoglobin (red) and 
exchangeable haem (green), and (c) haemozoin expressed as mass of haem Fe in fg per cell at 
different time points (20-50 h) throughout the life cycle of the parasite. TP = time-point; M = 
merozoites; ER = early rings; LR = late rings; ET = early trophozoites; MT = mid-trophozoites; 
LT = late trophozoites; S = schizonts; LS = late schizonts. 
 
Figure 5-6 a illustrates a panel of microscope Giemsa smear images obtained from observing 
the CQS NF54 cultures over 48 hrs, starting at the merozoite stage (TP 1) to the late schizont 
stage (TP 8). It was observed from these images that between 0-14 hrs  merozoites to early 
rings were present; 14-20 hrs early rings to early trophozoite were seen; 20-28 hrs early 
trophozoites to late trophozoites occurred; 28-36 hrs late trophozoites to schizonts were 
b 
ET LR S MT ER LT M LS 
TP 1 TP 2 TP 3 TP 4 TP 5 
0-14 hrs 14-20 hrs 20-28 hrs 28-36 hrs 
c 
TP 6 TP 7 TP 8 
36-42 hrs 
a 
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observed; and 36-42 hrs schizonts to late schizonts were observed. These observations were in 
close agreement with the observations previously reported by Gligorijevic et al whom showed 
similar Giemsa smear microscope images confirming that at 19 hrs, for example, cultures were 
in the early trophozoite stage 205. 
Figure 5-6 b-d illustrates the quantified time points for the amount of haemoglobin, 
exchangeable haem and haemozoin throughout the life cycle of CQS NF54 parasites. From 
this, it was observed that the amount of haem attributed to haemoglobin (Figure 5-6 b) 
decreased in a sigmoidal manner from an initially high value. Compared to the amount of 
haemoglobin, the amount of exchangeable haem was observed to remain relatively constant 
throughout the life cycle albeit, with a small sigmoidal increase (Figure 5-6 c). Haemozoin 
amounts, on the other hand, were observed to increase linearly from early to late time points 
(Figure 5-6 d).  
In more detail, it was observed that the amount of haemoglobin started to decrease at 20 
hrs (TP 4) which corresponded to the early trophozoite stage when the haemozoin was first 
observed. For the earlier time points (20-28 hrs), corresponding to the early to late trophozoite 
stage (TP 4-TP 6), a sharp initial decrease in the amount of haemoglobin was observed and 
corresponded to a steady increase in haemozoin from 10 fg to 30 fg Fe per cell as well as a 
slight increase in the amount of exchangeable haem. This sharp initial decrease in the amount 
of haemoglobin agreed with recent reports by Elliott et al, who showed that between 6-30 hrs 
a large volume of haemoglobin is taken up by the parasite 487-490. A reason could be for this 
could be as a result of the appearance of Plm I and II, which although from the same group of 
proteases, have different periods at which they appear in the intraerythrocytic stage of the 
malaria parasite 491. During the early stages, (ring stage), Plm I is found to be first synthesized 
by the parasite and is then continuous throughout the trophozoite stage, which according to 
Francis et al is an indication that Plm I activity in the haemoglobin degradation process is 
minimal. Plm II, on the other hand, is at its highest concentration only in the trophozoite stage 
suggesting that its main activity begins after 24 hrs, post invasion 7. With regards to the amount 
of haemozoin, these observations agreed with the findings previously reported by Gligorijevic 
et al and Mauritz et al, where at the mid to late trophozoite stage the amount of haemozoin was 
observed to peak 205,491.  
After 30 hrs, the amount of haemoglobin remained constant and the amount of 
exchangeable haem increased by 4 fg Fe per cell whereas the amount of haemozoin continued 
to increase linearly to 70 fg Fe per cell at 48 hrs. This corresponded to the schizont to late 
schizont stage (TP 7-TP 8).  
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With regards to the amount of haemoglobin observed at early time points, between 20-27 hrs 
specifically, the large error bars that were observed raised some concern. Bearing in mind the 
limitation of this method which make early time points, especially for the late rings to early 
trophozoite stage, difficult to measure, there is a difficulty in obtaining reliable results at this 
stage. This leads to the risk of contamination from the excess haemoglobin of RBCs in the 
culture. Therefore, a haemoglobin contamination experiment was performed for the early time 











Figure 5-7: Bar graph for haemoglobin contamination experiment for early time points of 24 
and 27 hrs expressed as mass of haem Fe per cell (fg) for haemoglobin in non-spiked samples 
(red) and samples spiked with RBCs (orange). 
 
Figure 5-7 illustrates the haemoglobin contamination experiment that was conducted for non-
spiked (red) and RBC-spiked samples (orange) at the early time-points of 24 hrs and 27 hrs 
post-invasion. From the bar graph, it was inferred that there was no significant haemoglobin 
contamination from lysed cells at these time points. It also confirmed that the time point 
quantification method proved to be a reliable and efficient method for quantifying the haem 
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5.6 Summary and conclusions 
 
In summary, the concentration of the aspartic and cysteine proteases (Plm I, II, HAP and 
falcipain-2) as well as the amount of haemoglobin throughout the life cycle of CQS NF54 
parasites was successfully determined for future use in a haem pathway model.  
Using the protein abundance database (PAXdb) and SIB bioinformatics resource portal 
(ExPASy), the average abundance-weighted molecular weight of 1337 proteins in Dd2 strain 
parasites was calculated to be 40,483 ± 77 g/mol.  
Three protein quantification methods, Bradford, BCA and NanoDrop assays, were used 
to determine the protein mass of NF54 and Dd2 strain parasites with RBCs as a control. The 
resulting data was observed to be relatively consistent across all three methods. It was observed 
that Dd2 strain parasites had a higher average protein mass than NF54 strain parasites with 
RBCs having a similar average protein mass to that reported in the literature. From this, the 
total number of protein molecules per cell was calculated.  
These data combined with the reported volume of the DV and the relative abundances of 
Plm I, II, HAP and falcipain-2 from PAXdb were used to calculate the concentration of these 
proteases. From this, it was observed that HAP had a higher concentration than Plm I and II 
(2-fold) and falcipain-2 (7-fold).  
Lastly, a time point quantification assay was successfully performed in order to 
determine the amount of haemoglobin, exchangeable haem and haemozoin throughout the life 
cycle of CQS NF54 parasites. It was observed from these data that there was a sigmoidal 
decrease in the haemoglobin amounts that corresponded to a linear increase in the haemozoin 
amount and relatively constant exchangeable haem amounts. With this it was noticed that there 
was a large initial decrease in haemoglobin which was confirmed to not be caused by 
haemoglobin contamination.  
In conclusion, the prerequisites required for the development of a haem pathway model 
were successfully determined in this study. It was apparent that the protein quantification and 
time point quantification methods proved to be efficient and reliable in determining the protein 
masses, total number of protein molecules per cell, protease concentrations as well as the 
haemoglobin amounts throughout the life cycle of CQS NF54 parasites. From this, it was 
apparent that Dd2 parasites had a higher protein mass that coincided with a higher number of 
protein molecules per cell, compared to NF54 parasites. It was also inferred that the 
concentration of aspartic proteases (Plm I, II and HAP) were 4-fold higher than cysteine 
proteases (falcipain-2) which was a direct reflection of their relative abundances within Dd2 
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parasites. Time point quantifications showed significantly high amounts of haemoglobin at 
early time points (early trophozoite stage) which suggested that the initial intake of 
haemoglobin by parasites is larger than at later time points (schizont stage) where it is relatively 
constant. It was, however, not apparent why exchangeable haem amounts remained relatively 
constant at early time points with the large amounts of haem being releases as a result of 
haemoglobin being digested. On the contrary, a reason for this could be as a result of the 
formation of neutral lipids in the parasite DV. These neutral lipids have been previously 
identified by Jackson et al, who showed 100 nm sized particles containing neutral lipids inside 
the parasite DV using a Nile Red probe and fluorescent imaging 159. 
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6.1 Overall Conclusions 
 
One strategy to deal with drug resistance in P. falciparum parasites is the discovery of new 
inhibitors that are equivalent to or more potent than well-known β-haematin inhibitors like CQ 
in both CQR and CQS parasites. With the low cost and reliability of CQ, investigations into 
CQ analogues have proven to show activity against CQ-resistant P. falciparum parasites and 
thus increasing the interest into the discovery of new haemozoin inhibitors 10-12. An approach 
has been developed for the discovery of new haemozoin inhibitors that uses a high through-put 
screening method. This high through-put screening method has proven to select β-haematin 
inhibitors that are active against the formation of the synthetic counterpart of haemozoin, β-
haematin. Ncokazi and Egan developed a cheap and fast β-haematin inhibition assay which has 
been successful when combined with detergent mediated β-haematin formation in the 
identification of new β-haematin inhibitors 262. Like CQ, these β-haematin inhibitors have also 
been shown to have the ability to disrupt the formation of haemozoin in malaria parasites by 
increasing exchangeable haem percentages and causing parasite death 144,263,492. The proposed 
mechanism in which these β-haematin inhibitors achieve this is through accumulation within 
the DV of parasites, which is influenced by the phenomenon of pH trapping 269,283,493-495. 
Although, the exact mechanism of how these β-haematin inhibitors cross the DV membrane 
and accumulate is still in question. With this, it has also been proposed that accumulating β-
haematin inhibitors have the ability to bind to the µ-oxo dimer of haematin or absorb onto the 
fastest growing face of haemozoin within the parasite 121,144,251. Quinoline-derived β-haematin 
inhibitors have also been claimed to have other mechanisms of action which includes 
interfering with the process of haemoglobin digestion, reducing the availability of amino acids 
for protein synthesis by the parasite therefore inhibiting its growth. However, the exact 
mechanism by which these β-haematin inhibitors inhibit the formation of haemozoin has 
remained in question.  
In this study, investigations into the inhibition of haemozoin formation were carried out 
in P. falciparum parasites using ten selected β-haematin inhibitors and their derivatives. These 
β-haematin inhibitors (test compounds 1-10) were chosen across different scaffolds, namely: 
benzimidazoles (1-4), quinazolines (5-7), benzothiazoles (8), benzoxazoles (9), and 
triarylimidazoles (10) including CQ and AQ for comparison. First, the parasite growth 
inhibition activities of these β-haematin inhibitors in CQS NF54 strain parasites were measured 
using a p-LDH method. From the sigmoidal dose response curves, micromolar IC50 values were 
determined for these β-haematin inhibitors which were all less active than CQ. Second, a 
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pyridine-based parasite haem fractionation method was used to measure the effects of these β-
haematin inhibitors at increasing inhibitory concentrations (0.5, 1.0, 2.0, 2.5 and 3.0×IC50) on 
undigested haemoglobin, exchangeable haem and haemozoin present in CQS parasites. 
Initially, test compound 1 exhibited increasing amounts of exchangeable haem with decreasing 
amounts of haemozoin, 4- and 3-fold respectively larger than CQ. Similarly, the remaining test 
compounds (2-9) exhibited similar trends at increasing dosage, where, one of the least active 
test compound (9) resulted in the largest increase in the amount of exchangeable haem at the 
IC50 value which coincided with empty parasite DVs containing no visible haemozoin crystals. 
From these data, it was apparent that the mechanism of action of these β-haematin inhibitors 
was the inhibition of haemozoin formation, although given the very small change, the 
quinazoline-containing β-haematin inhibitors could have more than one mechanism of action. 
This was further confirmed from the observations of the inversely proportional relationship 
between the decreasing percentage parasite growth and increasing exchangeable haem amounts 
as a function of increasing dosage of these β-haematin inhibitors. Moreover, a bar plot 
exhibited a clear but counterintuitive trend between parasite growth inhibition activity and the 
amount of exchangeable haem at the IC50 value of each β-haematin inhibitor, where decreased 
parasite growth inhibition activity often corresponded to increased exchangeable haem. While 
it was not apparent as how parasite growth inhibition activities arise, these β-haematin 
inhibitors could nonetheless be classified as haemozoin inhibitors from this point on.  
With suggestions that these haemozoin inhibitors are capable of inhibiting the formation 
of haemozoin by accumulating in the parasites DV, further investigations to determine their 
experimental CAR values were carried out. Using an inoculum effect analysis,  IC50 values 
were measured at varying parasitaemia. The resulting data showed a linear increase in IC50 
values as a function of inoculum size, from which the experimental CAR values were 
calculated. The experimental CAR values for these haemozoin inhibitors were observed to be 
much lower than the comparative test compounds 11, CQ and AQ. From this, it was inferred 
that pH trapping may contribute but not primarily be the cause for the accumulation of these 
haemozoin inhibitors. For further analysis, the experimental CAR values were converted to 
intracellular test compound amounts for all haemozoin inhibitors which was based on their 
experimental CAR values, volume of an iRBC and their IC50 values under standard test 
conditions. This facilitated direct comparison with exchangeable haem amounts produced by 
these haemozoin inhibitors which was expressed as femtomoles of exchangeable haem per cell. 
Remarkably, a plot of femtomoles of exchangeable haem versus the total intracellular test 
compound amount showed a 1:1 relationship between them. This provided further evidence 
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that in order for these haemozoin inhibitors to inhibit parasite growth, increase exchangeable 
haem amounts and inhibit haemozoin formation, they need to accumulate within the parasite’s 
DV.  
 The suggested rationale for the ability of these haemozoin inhibitors to accumulate in 
this way was the formation of a 1:1 Fe(III)PPIX-inhibitor complex within the DV of the 
parasite implying co-localization of Fe(III)PPIX and the inhibitor. Thus, the co-localization  of 
Fe(III)PPIX and a benzimidazole haemozoin inhibitor which incorporated a Br atom (test 
compound 1) was investigated using TEM with ESI coupled with EELS for untreated and 
treated iRBCs. Following cryofixation, TEM images showed parasites within the RBCs with 
observable structures that included the DV and transport vesicles. For untreated parasites, 
clearly formed elongated haemozoin crystals were observed. Similar observations were seen 
for treated iRBCs, however, the haemozoin crystals were less well defined as a result of 
inhibition by test compound 1 which was observed to be surrounded by what was suggested to 
be exchangeable haem. Fe distribution maps revealed a strong Fe signal that was attributed to 
the haemozoin crystals with very little in the RBC cytoplasm for untreated iRBCs. Compared 
to untreated iRBCs, a slightly less concentrated but still strong Fe signal associated with 
haemozoin was observed with an increased signal observed in the cytoplasm of the RBC. No 
Br distribution map was obtained for untreated iRBCs but a strong Br signal attributed to test 
compound 1 was observed for treated iRBCs in the parasite DV in the same region as the 
haemozoin crystals. From this, both the Fe and Br distribution maps were overlaid and revealed 
that Fe(III)PPIX and test compound 1 co-localize in the parasite DV. While this co-localization 
supported the hypothesis of a Fe(III)PPIX-inhibitor complex forming in the DV, further 
evidence was obtained using a 532 nm confocal Raman microspectrometer in order to observe 
changes in the vibrational modes of Fe(III)PPIX complexes in RBCs, untreated and treated 
parasites. The resulting single scan Raman spectra for the spectral region of 1700-500 cm-1 
showed subtle shifts in peak positions and increased intensities of certain Fe(III)PPIX peaks 
for the different Fe(III)PPIX complexes, including the putative Fe(III)PPIX-test compound 1 
complex. From the recorded spectrum for the putative Fe(III)PPIX-test compound 1 complex, 
a unique peak at 1080 cm-1 was identified and was observed in the spectrum of its synthetic 
counterpart in a haematin-test compound 1 mixture. This unique peak was consistent with 
Fe(III)PPIX pyrrole binding to the imidazole ring via π- π interactions. Upon further inspection, 
shifted peaks observed in the spectrum for the putative Fe(III)PPIX-test compound 1 complex 
were seen to be similar to peaks observed in haemozoin. It was, however, inferred from the 
absence of the peak at 1160 cm-1 in the putative Fe(III)PPIX-test compound 1 complex that 
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there was no contribution from the haemozoin spectrum. In addition, no peaks associated with 
test compound 1 itself were prominent, probably as a result of haem resonance. On the contrary, 
the spectrum for β-haematin was observed to be the same as the observed spectrum of 
haemozoin. Moreover, the spectra for all other Fe(III)PPIX complexes were visually different 
to that of the putative Fe(III)PPIX-test compound 1 complex which upon overlaying with the 
haematin-test compound 1 mixture was very similar in peak positions. These data confirmed 
the possibility that the formation of a Fe(III)PPIX-test compound 1 complex occurs in the DV 
of CQS parasites and that the peak at 1080 cm-1 could be a marker band for this complex. With 
the observed increased intensities of certain peaks and the possible marker band for the 
Fe(III)PPIX-test compound 1 complex, confocal Raman true mapping images were obtained 
for untreated and treated iRBCs at the Raman peaks at 754 cm-1, 1080 cm-1, 1090 cm-1 and 
1642 cm-1. It was observed that the Raman peak at 754 cm-1 was reliable for imaging the signal 
distribution of haemozoin in the parasite DV, whilst oxy- and deoxy-haemoglobin was 
localized in the RBC for the remaining Raman peaks for both untreated and treated iRBCs. 
Interestingly, no signal distribution at the Raman peak at 1080 cm-1 was observed for oxy-
haemoglobin, deoxy-haemoglobin or haemozoin, but only for the Fe(III)PPIX-test compound 
1 complex. Overlaid true mapping images confirmed that the signal distributions of haemozoin 
and the Fe(III)PPIX-test compound 1 complex co-localized in the parasite DV, consistent with 
the previous observations for TEM and EELS, highlighting that 1080 cm-1 is a marker band for 
the complex. These spectra were further analysed to identify spectroscopic variations in the 
spectra of all Fe(III)PPIX complexes using PCA, based on the peak positions. PCA plots 
exhibited evidence that the Fe(III)PPIX-test compound 1 complex was different to all the other 
Fe(III)PPIX complexes with cluster separations along PC1, with the exception of the product 
of the haematin-test compound 1 mixture for which no cluster separation was observed. 
Given the central role of haemoglobin degradation within the parasite DV in the 
mechanism of action of these haemozoin inhibitors, an effort was made to generate 
experimental input and validation data for the development of a haem pathway model. This 
included information to determine the concentration of the four main proteases responsible for 
60-80% of haemoglobin degradation. To tackle this problem, an abundance-weighted average 
molecular weight of all P. falciparum proteins, calculated from PaxDB, was used to calculate 
the total number of protein molecules per parasite from a measurement of the total protein mass 
per parasite. This was then used to determine the cellular concentrations of these haemoglobin-
digesting proteases. The abundance-weighted average molecular weights of all P. falciparum 
proteins determined for the CQR Dd2 strain parasite (1337 proteins) was found to be 40,483 ± 
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77 g/mol. Average total protein mass per cell (Dd2) obtained from three protein quantification 
assays namely Bradford, BCA and Nanodrop was found to be 12.80 ± 0.35 pg/cell, 
corresponding to a total of 1.90 × 108 protein molecules per parasite. Intriguingly, Dd2 strain 
parasites had a higher number of protein molecules per parasite than NF54 strain parasites. 
From this, the cellular concentration of the haemoglobin-digesting proteases in Dd2 parasites 
was calculated based on their relative PaxDB abundances, the total number of protein 
molecules in Dd2 parasites and the estimated DV volume. It was observed that aspartic 
proteases had a higher average concentration than the cysteine protease, falcipain-2, with HAP 
having the highest concentration. For future validation purposes, the amount of haemoglobin, 
exchangeable haem and haemozoin was determined with a time point quantification assay for 
20-50 hrs during the blood stage of CQS NF54 parasites. From these data, the amount of 
trophozoite haemoglobin was observed to decrease in a sigmoidal manner, whilst, haemozoin 
increased linearly and exchangeable haem remained relatively constant. In early time points 
the amount of haemoglobin decreased dramatically, and was confirmed to be not as a result of 
contamination through spiking with excess haemoglobin. These data were also consistent with 
the early trophozoite to late trophozoite stages that was observed by Giemsa smears. 
Therefore in this study, direct evidence of the behaviour of β-haematin inhibitors proved 
that their mechanism of action is to inhibit the formation of haemozoin and parasite growth by 
accumulating in the parasite DV, causing a build-up of exchangeable haem involving co-
localization of Fe(III)PPIX and the inhibitor (at least for test compound 1) which forms a 
Fe(III)PPIX-inhibitor complex. In addition, large initial amounts of haemoglobin were also 
observed at early time points in the blood stage pertaining to the early trophozoite stage which 
coincided with 4-fold higher concentrations for aspartic proteases that are known to be 
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6.2 Future Work 
 
To fully understand the inhibition of haemozoin formation in the presence of various 
haemozoin inhibitors for the development of a complete haem pathway model, certain aspects 
in this study require further investigations. 
An initial parameter that has, for a long time, been a reliable indicator of the efficacy of 
new antimalarials is parasite growth inhibition activity. The widely known p-LDH assay has 
shown to be consistent and sensitive in determining the parasite growth inhibition activities of 
new antimalarials, including potential inhibitors that target the formation of haemozoin 496. 
However, it is not apparent from this p-LDH assay as to how parasite growth inhibition activity 
arises. In the case of haemozoin inhibition, it was also unclear how parasite growth inhibition 
activity is related to the observed variable amounts of exchangeable haem present in parasites, 
where less active haemozoin inhibitors were observed to often result in larger amounts of 
exchangeable haem than more active haemozoin inhibitors. Firstly, Wein et al showed that the 
determination of parasite growth inhibition activity by various clinical drug sensitivity assays 
is dependent on the mechanism of action of these haemozoin inhibitors. Therefore, inoculating 
parasites at the trophozoite stage and using a SYBR green assay, which is based on DNA levels 
and independent of the mechanism of action of parasite growth inhibitors, may be more useful 
in understanding how parasite growth inhibition activity arises 497. Specifically, this method 
may be effective for the quinazolines investigated in this study which were suggested to have 
more than one mode of action. Secondly, the relationship between parasite growth inhibition 
activity and exchangeable haem amounts could be understood by determining the rate of 
parasite growth in the presence of these haemozoin inhibitors. In addition, it would also be 
useful in exploring whether the activities of these inhibitors are stage specificity. A reason for 
the latter is that Ignatushchenko et al used light microscopy to monitor the changes in the stage 
of parasites at varying times in the presence of xanthone derivatives which are known to inhibit 
haemozoin formation 307. From this, the data showed that these derivatives were only toxic at 
the trophozoite stage, where maximum exchangeable haem levels were observed.  
It was observed from cryo-EM studies that a benzimidazole inhibitor containing a Br 
atom (test compound 1) co-localized with Fe(III)PPIX in the DV of CQS parasites. TEM 
images for untreated and test compound 1 treated iRBCs provided clear visualization of 
parasite structures, which included less well defined haemozoin crystals indicating inhibition. 
With the EELS distribution images, a clear distinction was made between both the Fe signal 
associated to exchangeable haem and Br signal corresponding to the haemozoin inhibitor test 
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compound 1. However, the Br signal distribution image in comparison to the Fe signal 
distribution image had a lower signal-to-noise ratio bringing about some concern as to whether 
the signal observed in the parasite cytoplasm corresponds to test compound 1. A further 
limitation to using EELS is that not all haemozoin inhibitors investigated in this study could 
be analyzed due to the atoms they contain, for example fluorine. It was difficult to distinguish 
between the elemental distribution of a fluorine-containing haemozoin inhibitor from the Fe 
signals associated to exchangeable haem as the excitation edges overlapped with that of Fe. 
Furthermore, the remaining haemozoin inhibitors (test compounds 2-10) had no suitable 
elements for distinguishing them from cellular material. To solve this problem and to determine 
whether the remaining haemozoin inhibitors co-localize with exchangeable haem in the 
parasites DV, the versatile, fast and efficient confocal Raman true mapping technique that was 
used in this study would be useful. This would also provide a further understanding of various 
haemozoin inhibitors and their association with exchangeable haem. At the same time, this 
technique combined with PCA could be used to determine the changes in the vibrational modes 
and possible identification of whether or not the remaining haemozoin inhibitors form 
complexes with Fe(III)PPIX; similar to that observed for the Fe(III)PPIX-test compound 1 
complex. With that said, it is still unclear if the formation of these complexes is responsible for 
parasite death or the unbound exchangeable haem that has been previously reported to be rather 
insoluble 285. It could be useful to determine the binding affinities and solubility of these 
complexes. Although, it may be challenging to determine the binding affinities of these 
complexes especially with the problems encountered with precipitation of the haematin-test 
compound 1 mixture as well as low solubility in various solvents of these haemozoin inhibitors. 
Finally, haemoglobin digestion is important for the survival of the parasite and it has 
been shown in this study that large initial amounts of haemoglobin are digested in the early 
trophozoite stage where as at 30 hrs post-invasion, it is constant. This also corresponded to a 
relatively constant exchangeable haem amount and linear increase in the amount of haemozoin 
throughout the blood stage of the parasite. No definite conclusion could be drawn as to why a 
large amount of haemoglobin is present early in the life cycle which decreases rapidly for early 
time points while a steady 3-fold increase in exchangeable haem by 30 hrs post-invasion was 
seen. While the volumes of haemoglobin uptake during the blood stage of the parasite has been 
previously reported by Elliot et al, the rate at which haemoglobin is taken up by the parasite is 
yet to be determined 490. Thus, further investigation into the determination of the rate of 
haemoglobin uptake and digestion could possibly provide reasons for the previously mentioned 
observed trends. Additionally, a similar assay could be performed from the time of merozoite 
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invasion to measure the rate of haemoglobin uptake, where Esposito et al used Förster 
resonance energy transfer (FRET) with a calcein fluorophore to determine the concentration of 
haemoglobin throughout the blood stage of the parasite 498.  
Therefore, further investigations will not only be useful in developing a future haem 
pathway model, but also provide a better understanding of these processes for the development 
of new antimalarials to aid in the eradication of malaria in the future. 
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